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The recovery of the selected biological material in affinity-based separations relies on 
reversing the biological interaction responsible for the binding. General elution methods 
which are independent of the bioaffinity interaction have attracted increasing attention. The 
first three chapters of this thesis describe the development of a novel “click” functionalised 
azobenzene-based linker for affinity-independent elution protocols and the preliminary 
affinity studies using this linker. Ligands functionalised with a bioorthogonal propargyl 
label were readily attached to the terminal azide of the linker using the copper(I) catalysed 
Huisgen cycloaddition (or "click" reaction). Following separation, the linker was cleaved 
under mild non-denaturing conditions using Na2S2O4.  
 
In the last three chapters a novel approach towards the synthesis of the 4-methyl proline 
fragment of the cytotoxic natural product bisebromoamide (a potential affinity target) is 
proposed.  
 
For the pyrrolidine ring construction an enamide-olefin ring-closing metathesis (RCM) 
approach has been attempted. The installation of the required absolute stereochemistry has 
been achieved using a phase-transfer catalyst for the enantioselective alkylation of Schiff 
bases derived from glycine esters. 
 
 1 
1 Affinity Chromatography 
 
1.1 Theoretical aspects 
 
The term affinity chromatography is used to describe a procedure aimed at the purification 
of one or more components of a biochemical mixture, based on the reversible adsorption of 
biomolecules using highly specific biological interactions.
1
 The technique is ideal for a 
capture or intermediate step in a purification protocol and can be used whenever a suitable 
ligand is available for the biomolecule of interest.
2
 Biological interactions between a ligand 
and a target molecule can be a result of electrostatic or hydrophobic interactions, van der 
Waals‟ forces and/or hydrogen bonding. To elute the target molecule from the affinity 
medium the interaction has to be reversed, either specifically using a competitive ligand, or 
non-specifically, by changing the pH, ionic strength or polarity of the mobile phase. 
Successful affinity separation requires a biospecific ligand that can be covalently attached 
to a chromatography matrix. The coupled ligand must retain its specific binding affinity for 
the target molecule(s) and, after washing away unbound material, the binding between the 
ligand and target molecule(s) must be reversible to allow the target molecule(s) to be 
removed in an active form (Fig. 1). Enzyme/substrate or inhibitor; antibody/antigen or 
virus; lectin/polysaccharide or glycoprotein; nucleic acid/ complementary base sequence or 
histones; hormone or vitamin/receptor or carrier protein are among the most frequently 
used biological interactions in affinity chromatography. Although most of the ligands are of 
biological origin, the term “affinity chromatography” has also been used over the years to 
describe some chromatography matrices that contain selective ligands of non-biological 
origin. Terms such as “bioaffinity chromatography” and “biospecific adsorption” are 
occasionally used to specify that the affinity ligand is biological in nature.
3
 The type of 
ligand can be used to divide affinity techniques into various subcategories, for example 
lectin, immunoaffinity,
4






Figure 1: A classical affinity chromatography separation. (a) Sample is applied under conditions 
that favour specific binding of the target biomolecule(s). (b) Target substances bind specifically, but 
reversibly, to the ligand while unbound material washes through the column. (c) Target protein is 
recovered by changing conditions to favour elution of the bound molecules. Elution is performed 
specifically, using a competitive ligand, or non-specifically, by changing the pH, ionic strength or 
polarity. Target protein is collected in a purified, concentrated form. (d) The affinity medium is re-
equilibrated with the binding buffer. 
 
1.2 Biomolecular interactions and affinity chromatography 
 
The chemistry of biological interactions involves a variety of mostly non-convalent 
interactions between reactive groups in the receptor and the ligand. The sum total of the 
energy contribution of the various forces to the overall stability of the complex receptor-
ligand determines the dissociation constant (Kd), or affinity of the binding. The dissociation 






Kd = [A] [B] 
       [AB] 
In which Kd is the dissociation constant and A is for instance an antibody, B an antigen and 
AB the complex formed between them. Binding affinity is also influenced by solid support 
characteristics as well as the activity and functional availability of the solid phase-bound 







 Both the chemical and mechanical properties of the solid phase are important in this 
regard. Non-specific interactions between the solid phase and the ligand are inconsistent 
and unpredictable, hence complicating the elution profiles. On the other hand, the physical 
structure of the solid phase polymer may sterically hinder effective interaction between free 
proteins and the immobilised ligand even at high Kd values. Both of these problems can be 
significantly reduced by the prudent use of inert spacer arms. 
 
1.3 Components of an affinity medium 
 
An affinity-based separation system typically consists of a matrix (stationary phase), a 





Figure 2: Physical components of an affinity medium. (a) The matrix is designed for ligand 
attachment. A matrix should be chemically and physically inert. (b) The spacer arm is used to 
improve the binding between the ligand and the target molecule by overcoming any effects of steric 
hindrance. (c) The ligand is a molecule that binds reversibly to a specific target molecule (Figure 




1.3.1 The matrix  
 
The matrix is an inert support to which a ligand can be directly or indirectly coupled.
2
 
Since the success of affinity chromatography relies on specific interactions, extremely low 
non-specific adsorption to the solid support is required. A suitable matrix for affinity 
chromatography will offer an open pore structure for high capacity binding even for large 
biomolecules, stability under a range of experimental conditions (e.g. pH, detergents) and 
good flow properties for rapid separation. Sepharose, a cross-linked sugar polymer of 
agarose, possesses many of these properties (Fig. 3).
6
 Hydroxyl groups on the sugar 
residues are easily derivatised for covalent attachment of a ligand, providing an ideal 






Figure 3: Structure of agarose gel (Figure from ref. 2). 
 
 
In affinity chromatography the particle size and porosity are designed to maximize the 
surface area available for ligand coupling and binding of the target molecule. A small mean 
particle size with high porosity increases the surface area. Increasing the degree of cross-
linking of the matrix improves its chemical stability. In this way, a more rigid matrix is 




1.3.2 The ligand 
 
The ligand is the molecule that binds reversibly to a specific molecule or group of 
molecules, enabling purification by affinity chromatography.
2
 The selection of the ligand 
for affinity chromatography is influenced by two factors: the ligand must exhibit specific 
and reversible binding affinity for the target substance and have chemically modifiable 
groups that allow attachment to the matrix without destroying the binding activity.
7
 It is 
important to consider the region of the ligand that will be used for attachment to the matrix. 
For example, many proteins have several equally reactive groups through which coupling 
can take place resulting in a random orientation of the ligand on the matrix. This 
phenomenon may result in a reduction of the number of ligand molecules that are available 
in the correct orientation.  
 
1.3.3 Spacer arm 
 
The binding site of a target protein is often located deep within the molecule and an affinity 
medium prepared by coupling small ligands, such as enzyme cofactors, directly to the 
matrix may exhibit low binding capacity due to steric interference i.e. the ligand is unable 
to access the binding site of the target molecule (Fig. 4, a).
2
 In order to facilitate an 
effective binding an inert “spacer arm” is interposed between the matrix and the ligand. 
Spacer arms must be designed to maximize binding, but to avoid non-specific binding 






Figure 4: The importance of the attachment of the ligand molecule via an inert spacer arm (Figure 
from ref. 2).  
 
 6 
The length of the spacer arm is critical. If it is too short, the arm is ineffective and the 
ligand fails to bind substances in the sample. On the other hand, too long a spacer could 




1.4 Main applications 
 
Over the last 20 years, over 40,000 published articles have described or discussed affinity 
chromatography techniques. The affinity separation technique has registered an 
extraordinary development making it no longer only a research tool but also an interesting 
method from an industrial perspective.
9
 From the wide variety of applications of this 
technique a classical immunoaffinity separation will be briefly described, and some 
examples of the ever increasing number of applications of affinity chromatography in the 
field of proteomics and target identification will be given. 
 
1.4.1 Immunoaffinity chromatography 
 
Immunoaffinity chromatography adds the selectivity and specificity of an immunological 
reaction to affinity separation.
4
 This specialised form of affinity chromatography uses an 
immobilised antibody or antigen as the ligand and the selective separation comes about 
through immunological reactions (Fig. 5). One of the interacting partners is typically 
attached to a matrix (e.g. polyacrylamide, dextran, rigid plastic beads). Immunoaffinity was 
first described by Campbell et al.,
10
 who used diazotised aminobenzyl cellulose to 
immobilise an antigen for subsequent isolation of specific antibodies. Although most 
immunoaffinity separations are performed using a low pressure system, the development of 
suitable support media has allowed the principles of high performance liquid 
chromatography (HPLC), to be applied to immunoaffinity chromatography. This technique 










Figure 5: An immunoaffinity chromatography separation. 
 
The introduction of monoclonal antibodies has greatly advanced the application of IAC 
techniques especially in the area of membrane biochemistry.
4
 Many monoclonal antibodies 
have been raised against intact receptors, their subunits, and a wide variety of membrane 
proteins and glycoproteins. An antibody-coated matrix is packed into a column and a 
solution containing the specific antigen is passed over the matrix, the antigen is captured 
and retained while the unreactive material passes through the column in the mobile phase. 
The antigen is released and recovered by changing the nature of the mobile phase in such a 
way that dissociation of the immobilised antibody-antigen complex is achieved. Once the 
complex is fully dissociated, the antigen is released into the mobile phase and passes 





Since the mid-1990s proteomics (the complete analysis of the protein complement of a cell 
or an organism, the proteome) has rapidly grown in importance as a discipline in the life 
sciences.
12
 Mass spectrometry (MS), plays a central role in proteomics research, especially 
since the introduction of techniques such as electrospray ionisation (whose discovery was 
awarded by the Nobel prize in 2002) and laser desorption/ionisation (LDI). These so called 
“soft ionisation techniques” have laid the foundations for the modern MS analysis of 
proteins and peptides.
12
 Proteomics has two well recognised branches, namely compound-
centric chemical (CCCP) and activity-based probe profiling (ABPP) proteomics (Scheme 
1).
13
 CCCP focuses on gaining a better understanding of the molecular mechanism of a 
biologically active small molecule. Careful choice of the matrix for the preparation of 
molecular probes for CCCP is required (Scheme 1). Such a matrix should not interfere with 
the bioactivity of the target compound in order to successfully investigate the molecular 
mechanism of action of a certain biomolecule (with a known binding partner). The solid-
supported target is then incubated with the appropriate biological extract. Captured proteins 
are eluted and processed by either SDS-PAGE or by a “gel-free” approach. Following 
trypsin digestion, the peptides obtained are subjected to MS analysis and identification 
(bioinformatics). ABPP proteomics is usually focused on the investigation of classes of 
proteins (enzymes) which are related by their role in a specific condition (e.g. a disease). In 
scheme 1 the two methodologies are directly compared.
13
 An ABP typically consists of a 
reactive warhead, a spacer (linker) and a reporter tag (e.g. biotin), which is necessary for 
the subsequent affinity chromatography step. Upon incubation of this activity-based probe 
with the cell lysate of interest, targeted proteins are captured on an affinity matrix and 
digested with trypsin for MS analysis. At this stage, protein database screening and 






Scheme 1: Comparison of activity based probe profiling (ABPP) and compound-centric chemical 
proteomics (CCCP, scheme from ref. 13).  
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1.4.2.1 Compound-centric chemical (CCCP) proteomics 
 
Generally, CCCP proteomics makes use of the same principle of the classical drug 
affinity chromatography techniques, but can benefit from high-resolution mass 
spectrometry (MS) for analysis and bioinformatics for identification;
13
 both forms of 
analysis have advanced dramatically in recent years.
13
 Together with electrospray and 
nano-electrospray ionisation methods in MS, breakthroughs certainly have included 
isotope labelling (for quantification) and the ever increasing availability of databases of 
proteins. In the description of the CCCP approach, it was anticipated that the analysis of 
the molecules takes place straight after trypsin digestion, which generates a series of 
peptides. Three pieces of information are required for each peptide: its mass and the list 
of its fragments (for identification) and the ion intensity (for quantification).
14
 
Among several types of mass spectrometers, the most common apparatuses used 
in proteomics are quadrupole time-of-flight (TOF) and hybrid linear ion trap-orbitrap 
instruments.
15
 In TOF based instruments, separation of the peptide ions occurs 
depending on their arrival at the detector. In the orbitrap mass analyser, Fourier 
transformation of the measurement of the frequency of peptide ions oscillating in the 
trap generates the mass spectrum. For both configurations, MS resolution is fundamental 
as many peptide ions elute from the chromatographic column at the same time.
15
 
A plethora of methodologies is also available for the fragmentation of the 
peptides. Usually, they are collided with an inert gas, (collision-induced dissociation, 
CID).
16
 In ion trap mass spectrometers peptide ions are excited by an electric field which 
leads to fragmentation mainly through peptide bond cleavage. In quadrupole TOF 
instruments, the quadrupole serves as a mass filter allowing through only ions with a 
specific mass-to-charge (m/z) ratio. A TOF spectrum of the ions is obtained straight after 
fragmentation in the collision chamber. 
Isotope labelling has allowed highly accurate quantitative analyses for thousands 
of proteins as well as post-translational modifications (PTMs), which were previously 
impossible relying only on MS techniques.
17
 To ensure accuracy of the analysis of a 
proteome, two proteomes of the same type need to be differentially isotopically labelled. 
 
 11 
Among the amino acid-specific tagging strategies, the majority are directed towards 
cysteine residues.
12
 Cysteine is widely used because of the presence of a thiol group that 
can be easily modified and its relatively low abundance (only 1.1%) across several 
species.
12
 In 1999 Aebersold et al. reported the first isotope-coded affinity tag (ICAT).
18
 
The protocol had an enormous impact as this molecule became commercially available 
soon after its introduction. The tag consisted of a cysteine-reactive iodoacetyl group that 
allowed the specific attachment of the label to the thiol group of the Cys side chain and a 




Figure 6: Structure of the first ICAT reagent. (a) The biotin moiety which allows enrichment by 
biotin-avidin affinity chromatography. (b) An isotope-coded linker region, using hydrogen (X = H) 
or deuterium (X = D). (c) A thiol-reactive iodoacetamide group that allows alkylation of cysteine 
residues. 
 
The reagent is available in two forms, the light form (normal) containing eight hydrogen 
atoms and the heavy form (labelled) containing eight deuterium atoms. The polyether 
linker is directly connected to a biotin moiety, allowing affinity separation.
18
 
Stable isotope labelling by amino acids in cell culture (SILAC) is one example 
of a modern labelling strategy which generally uses Arg and Lys labelled with the stable 
13




 In this type of metabolic labelling the cells incorporate 
the isotopic label as part of their biosynthesis. The value of the known molecular weight 
difference between the „light‟ (normal) and „heavy‟ (labelled) amino acid that is used 
during the growth of the two cell populations is fundamental for recognising the two 
proteomes. The ease of use and the accuracy achieved has rendered SILAC the method 
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of choice in MS-based signalling research and its use has recently been extended to 
small mammals and human tumour tissues.
20
 
The most popular chemical labelling technique uses an isobaric tag for relative 
and absolute quantification (iTRAQ). In this approach the N-terminus and the Lys 
residues are enriched with a chemical group (Fig. 7, a).
21
 The chemical differentiation is 




Figure 7: Isobaric tag for relative and absolute quantification (iTRAQ). (a) iTRAQ reagent; (b) 
Identification and quantification of iTRAQ-labelled peptides. 
 
1.4.2.2 Applications of CCCP 
 
Among the wide variety of applications of chemical proteomics, two recent examples of 
successful investigations targeting kinase inhibitors and natural products deserve 
particular mention.
13
 Protein kinases are currently receiving much consideration, as drug 
targets, because of their role in a wide range of pathologies (e.g. oncology, autoimmune 
disorders).
22,23
 Indeed, various kinase inhibitors have entered clinical trials in recent 
years.
13
 Several protocols for the investigation of their activity are currently available 
(e.g. kinase activity assays). All these large-scale approaches provide important 
information but they need to be completed with parallel proteomics studies. Importantly, 
chemical proteomics can be performed in disease-relevant cells; hence the underlying 
 
 13 
mechanism of action of a particular kinase inhibitor can be more intimately investigated. 
Recently the complete target profiling of BCR-ABL tyrosine kinase inhibitor imatinib 
(Gleevec®) and the second-generation drugs nilotinib (Tasigna®), dasatinib (Sprycel®) 
and bosutinib (SKI-606), which are in clinical use or in late-stage clinical trials for 
chronic myeloid leukemia, have been reported.
24
 In this study, Bantscheff et al. made 
use of a new technology which consisted of using a solid-supported non-specific kinase 
inhibitor (“kinobeads”) together with a specific kinase inhibitor in the solution phase for 
a crossed investigation of their targets.
24
 These investigations led to a greater 
understanding of the molecular mechanism of these compounds and to the discovery of 
new targets for these drugs (e.g. for imatinib and nilotinib: the receptor tyrosine kinase 




The second application of note is the role of chemical proteomics in the 
investigation of biologically active natural products. Despite great efforts of the 
synthetic community, the structural diversity and complexity of natural products is still 
unmatched by their synthetic counterparts.
13
 Furthermore, most newly-isolated natural 
products are often tested mainly for their potential antibiotic and anticancer activity. 
Chemical proteomics has remarkably underlined the importance of a greater 
understanding of the molecular mechanism of such natural products as drugs or as 
specific tools for the alteration of biological pathways. This concept was nicely 






Figure 8: The natural product diazonamide A. 
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The use of chemical proteomics for the study of this antimitotic compound led to an 
important discovery about its target, ornithine δ-amino transferase. Interestingly, this 
enzyme was found to play an important role in mitotic spindle assembly and cell 
division.
26
 The key to the successful target identification was the comparison of the 




1.4.2.3 Activity-based probe profiling (ABPP) proteomics 
 
ABPP proteomics is a discipline that makes use of small molecules to tag and monitor a 
specific class of proteins within a complex proteome.
27
 At the heart of the activity-based 
proteomics technologies are the small molecules which are designed to interact with 
active sites within proteins (usually enzymes).
13
 In particular, in the so called 
mechanism-based ABPs (mainly based on irreversible enzyme inhibitors), the „warhead‟ 
is electrophilic in nature and specifically reacts with catalytic residues in the enzyme 
active site. An alternative strategy consists of the use of photocross-linkers which can be 
conjugated to molecules that bind within an active site, resulting in the modification of 
potentially non-catalytic residues upon irradiation with UV light. In both approaches, the 
probe binds to the target enzyme in its active form. In the last few years, the strategies 
for tagging and detection in ABPP have rapidly flourished.
27
 Among the tagging 
methodologies, the use of small molecule fluorophores have seen the greatest advances. 
The wide variety of commercially available fluorophores and their broad range of 
absorbance and emission spectra dramatically increased the scope of the application of 
this field of proteomics. 
The most interesting aspect of this technology is, perhaps, the use of 
fluorescently labelled ABPs for direct imaging of labelled targets (using fluorescence 
microscopy) and the simplicity of detection in gel based read-outs. A plethora of 
fluorophores has been used for the preparation of ABPs. The most commonly employed 









 (dipyrromethene boron difluoride) and the cyanine (Cy)-dyes
32
 
(Fig. 9). Fluorophores such as fluorescein and rhodamine are relatively cheap, but suffer 
 
 15 
from rapid photobleaching (permanent loss of fluorescence), making them less suitable 
for imaging applications. 
 
 
Figure 9: Structures of commonly used fluorophores for activity-based proteomics. 
 
BODIPY and Cy-dyes generally guarantee better performances due to their intrinsic 
properties (e.g. high absorption coefficient, narrow absorption peaks) and, being 
hydrophobic in nature, freely penetrate cell membranes. However, the cost of this class 
of fluorophores limits their use to small-scale production of ABPs. Molecular probes 
featuring BODIPY as a fluorophore have been successfully employed for in vivo 
labelling of cysteine cathepsins in whole animals.
31
 The encouraging advances of in vivo 
applications of this technology could be translated into new therapeutic imaging agents 
for use in human patients.
27
  
Radio-isotopes have also been shown to be useful in activity-based proteomics. 
In particular, 
125
I has been incorporated into many classes of ABPs as it can be readily 
introduced following standard iodination methodologies for proteins and peptides.
31
 The 
minimum structural requirement for the preparation of a radio-labelled ABP is the 
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presence of a phenol moiety (Scheme 2). One of the most common iodination strategies 
is the introduction of 
125











Alternatively, the hydroxyl group can be converted into a trimethylstannyl functionality 
to facilitate the displacement by radioactive iodine in the presence of chloroamine-T 
(Scheme 2). Tritium (
3
H) is also employed, although its use is limited by its overall low 
specific activity (long exposure times required). The main advantages of this kind of 
probe are certainly the ease of preparation and detection together with the production of 
a high ratio of signal to background noise.
31
 Furthermore, the size of these probes is 
quite small (compared to a fluorescent or an affinity tag), resulting in only minimal 
modification of the lead compound. However, the short half-life of 
125
I does not allow 
the storage of these probes for long periods and, unlike affinity tags, the radiolabels do 
not provide a direct means for isolation. The main application of radio-labeled probes is 
monitoring changes in enzyme activity by analysis of labeled samples by 1D or 2D gel 
electrophoresis. Examples of in vitro applications of radio-labeled probes for profiling 







 In addition to radio-isotopes, stable 
isotopes (although designed for quantitative proteomics applications, e.g. ICAT, 
SILAC) potentially can be used for activity-based proteomics.  
Affinity tags have found widespread application as they provide a practical 
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handle for isolation of the target protein. Biotin is the most common affinity tag due to 
its exceptional binding affinity with the protein streptavidin. The properties of these 
biomolecules will be discussed in connection with the preparation of the solid-supported 
biotin probes in chapter 2. While providing a reliable tool for the purification of isolated 
targets using a streptavidin-coated matrix, the biotin-labelled probes present a few 
problems, namely the low cell permeability and the need for harsh conditions for 
dissociation of the streptavidin/biotin complex. Short peptide sequences (recognised by 
specific antibodies) can also be employed as affinity tags. The first example of this type 
of tag was reported for probes that target deubiquitinating (DUB) enzymes.
35
 
 Important advances have been made in designing new strategies for “tandem 
labelling”.
27
 In this approach a chemical handle with orthogonal functionalities is 
inserted into the ABP. After binding with the target, a second “reporter” tag (e.g. a 
fluorophore tag for visualisation or an affinity tag for isolation) is covalently attached to 
the probe using highly specific bioorthogonal ligation chemistry. An example of an 






Scheme 3: A modified Staudinger reaction that produces the stable covalent adduct 8, in the 





A modified Staudinger reaction was employed to tag carbohydrates on the cell surface. 
In this approach, a probe containing an azide functionality is reduced forming the 
unstable intermediate aza-ylide 7. The aza-ylide intermediate rearranges, in aqueous 
media, to produce an amide linkage and the phosphine oxide (Scheme 3).A second 
strategy for bioorthogonal ligation makes use of the most commonly employed reaction 
in bioconjugated systems, the copper(I)-catalysed Huisgen 1,3-dipolar cycloaddition 
reaction, also known as the “click” reaction.
37,38
 The scope and the advantages of this 
reaction will be discussed in connection to the synthesis of solid-supported molecular 
probes in chapter 2.  
 
1.4.2.4 Applications of ABPP 
 
As outlined in section 1.4.2.3, the class of proteins (enzymes) targeted by ABPP 
proteomics are intimately related by their role in a disease. The most valuable 
application of this field of proteomics is in cancer research. There are currently ABPs 
for a multitude of enzyme classes, including many that have central roles in cancer.
39
 
Besides their use for the discovery of enzymes involved in cancerogenesis, they can be 
employed to image tumour development in living animals. Integrated with other 
proteomics methods, ABPs can lead to the mapping of entire proteolitic pathways. A 
series of fluorophosphonate probes that target the serine hydrolase superfamily have 
been successfully employed to discover several deregulated enzymes in cancer (Fig. 10, 
10).
39
 Indeed, thanks to these probes two uncharacterised serine hydrolases 
(KIAA1363
40,41,42
 and monoacylglycerol lipase,
43
 MAGL) have been found as enzymes 
highly expressed in aggressive human cancer cells and primary tumours. Using epoxide 
electrophile probes for cysteine proteases (Fig. 10, 12), Joyce and colleagues discovered 
that cathepsin activity is higher in angiogenic vasculature in carcinomas.
44,45
 This 
finding was also confirmed by the fact that pharmacological inhibition of a wide range 
of cathepsins limited the tumour growth, vascularity and invasiveness. They also found 
that cysteine cathepsins are increased in cervical carcinomas induced by human 
papilloma virus (HPV).
45
 ABPs have also been used for imaging enzyme activities 
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thanks to quenched near-infrared fluorescent activity based probes (qNIRFABPs) which 
can image cysteine protease activities in tumour xenografts in vivo and ex vivo.
46
 These 
probes emit the fluorescent signal only after covalently modifying a specific protease 
target. Caspase-directed ABPs 11 can also be used to monitor small molecule inhibitors 
of protease targets both biochemically and by direct imaging methods. A variant of 
probe 11 has been used to detect apoptosis induced by the monoclonal antibody 








Figure 10: Representative ABPs and their classes of target enzymes. The regions within the 
probes which interact with the binding site of the enzymes are highlighted.  
 
The notable advances of ABPP and other proteomics disciplines are providing precious 
insights into the role of certain classes of enzymes involved in cancer. These enzymes 
could represent the next generation of cancer therapeutics. 
1.4.3 Affinity chromatography & target identification 
 
Perhaps one of the most notable early examples of the use of affinity chromatography 
for the identification of the binding partner of small molecules is furnished by the 
groundbreaking work of Schreiber et al.
48
 The target of their investigations was to 
identify the binding proteins (immunophillins) within the signalling pathway in T 
lymphocytes, responsible for the biological activity of the immunosuppressant 
rapamycin and the structurally related macrolide FK506. The synthesis of agarose-based 
affinity matrices featuring either rapamycin or FK506 was performed and such 
molecular probes were incubated with an extract from the human T cell line Jurkat. The 
profiles of the captured proteins from both affinity matrices were remarkably similar, as 
confirmed by subsequent analyses (e.g. densitometry, SDS/PAGE mobility) while 
certain proteins seemed to belong to a previously unknown family of immunophillins, 
which included the novel immunophillin FK506 binding protein (FKBP).
48
 The main 
accomplishment of this investigation was to ascertain that the predominant rapamycin 
binding protein in Jurkat T lymphocytes is FKBP, thus outlining the prominent role of 
this immunophillin in mediating the biological activity of this drug and the mutual 
inhibition of the two related compounds. Furthermore, the newly discovered 




More recently, a photoaffinity probe has been successfully employed to 
investigate the mechanism of the inducible resistance of the glycopeptide antibiotic 
vancomycin.
49
 The mechanism of action of this antibiotic consists of binding the side 
 
 21 
chains of the virtually ubiquitous D-Ala D-Ala terminus in bacterial peptidoglycan, thus 
interfering with cell wall biosynthesis.
 
Since the discovery of vancomycin resistance in 
1998, numerous efforts have been made in order to elucidate the resistance mechanism 
in pathogens.
50
 The expression of genes vanH, vanA, vanX is associated with high 
resistance to the molecule. Inducible expression of these genes is controlled by a two-
component regulatory system, which consists of a transmembrane receptor histidine 






Figure 11: The regulatory system VanR and VanS responsible for vancomycin resistance 
(Figure from ref. 49). 
 
Intriguingly, activation of this regulatory system could be either the result of direct 
binding of vancomycin to VanS or mediated by cell wall proteins accumulated as a 
result of antibiotic action. As there was little agreement about the nature of such 
activation, Wright's team decided to resolve this longstanding controversy by 
synthesising a vancomycin photoaffinity probe (VPP, Fig. 12).
49
 Molecular probe 15 
consists of a benzophenone photoaffinity unit for covalent labelling of protein-probe 
complexes and a biotin tether for subsequent isolation (Fig. 12). A series of preliminary 
screening experiments of the activity of VPP were carried out using VanS proteins from 
the actinomycetes Streptomyces coelicor (VanSsC), which are pathogens resistant to 
vancomycin. These investigations confirmed that the vancomycin derivative has a 
resistance profile comparable to the lead compound.
49
 Incubation of membranes 
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expressing VanSsC isolated from E. coli with VPP, followed by irradiation, labelled a 
membrane protein whose molecular weight corresponds to the mass of VPP bound to 




Figure 12: Vancomycin photoaffinity probe (VPP) consists of the vancomycin backbone (black) 
linked to a benzophenone photoaffinity label (red) and a biotin tether (blue). 
 
1.4.4 Other applications 
 
Although it is clear that affinity chromatography can be used in a variety of ways within 
biological, pharmaceutical and clinical chemistry, there remains plenty of room for 
further growth and development. Among contemporary applications and recent trends, 
affinity-based chiral separations, the so-called “metal chelate affinity chromatography” 
and dye-ligand affinity chromatography will be briefly discussed. 
 Because of the increasing interest in the pharmaceutical field for methods 
capable of discriminating between the individual chiral forms of drugs, the ability to 





 HPLC methods that include chiral stationary phases have 
been shown to be particularly valuable in the quantification and separation of chiral 
compounds.
53
 As many of the ligands used in affinity chromatography are inherently 
chiral, these make them ideal stationary phases for these separations.  
“Immobilised metal ion affinity chromatography”, also known as “metal chelate 
affinity chromatography”, is a widely employed purification methodology. In this 
purification protocol, the affinity ligand is a metal ion that is complexed with an 
immobilised chelating agent. Iminodiacetic acid is the most common chelating agent 
used, but carboxymethylaspartic acid, triscarboxymethylethylenediamine, tris(2-
aminoethyl)amine, and dipicolylamine are also used.
52
 The metal ions placed within 










. This method separates 
proteins and peptides on the basis of interactions between certain amino acid residues 
(e.g. histidine, tryptophan, and cysteine) and the metal ions within the immobilised 
metal chelate (Fig. 13). Since its discovery, several peptides, proteins, and amino acids 





Figure 13: Schematic representation of the IMAC system. The affinity ligand (a metal ion 
complexed with an immobilised chelating agent) interacts with histidine residues within a protein 
in its native form. 
 
“Dye-ligand affinity chromatography” makes use of synthetic dyes as ligands. 
Specific ligands used in this method include Cibacron Blue F3G-A, Procion Blue MX-
3G or MX-R, Procion Red HE-3B, and Thymol Blue or Phenol Red.
3
 Although these 
compounds are all synthetic in nature, they are still classified as affinity ligands because 
they interact with the active sites of many proteins and enzymes by mimicking the 
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structure of the substrates, cofactors, or binding agents for these biomolecules. For 
example, Cibacron Blue F3G-A (Fig. 14, 16) consists of a chlorotriazine ring that has 
several side groups attached; one of them is an anthraquinone moiety that specifically 




 or ATP. Some 
advantages of these dye ligands include their selectivity, the reproducibility of the 




Figure 14: A common dye employed in affinity-based separation, Cibacron Blue F3G-A. 
 
1.5 A linker-based approach to enhance elution conditions  
 
Since the introduction of affinity chromatography as a practical laboratory tool in the 
1960s, chromatographers have been faced with the question of how to retrieve the bound 
protein in maximum yield and (usually) in an active form. The subsequent years have 
seen many developments for solid phase matrices and also the introduction of a wide 




1.5.1 An overview of potential elution buffers  
 
The role of the elution buffer is to disrupt the interactions between receptors and ligands 
pushing the ligand back into the mobile phase in order to be collected. In selecting an 
elution strategy it is important to take into account the chemical effects of different 
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solutions. Buffers of extreme pH, such us glycine-HCl (pH 2.8) or high pH buffers, 
employing amines or ethanolamine for instance, disrupt ionic bonds.
57
 With these 
solutions it is often recommended the use of a neutralizing buffer to prevent excessive 
denaturation of the proteins (Fig. 15). 
 
 
Figure 15: The use of harsh condition for the elution steps can cause denaturation of the 
isolated proteins. 
 
Changes in ionic strength induced by high salt solutions also disrupt ionic bonds 
but can favour hydrophobic interactions.
5
 Solutions of NaCl, MgCl2, or LiCl (3-5 M, 
also saturated) are effective non-denaturing eluants that allow easy column regeneration 
with lower concentration salt. 
Chaotropic ions (ions that favour interactions of non-polar groups with water) 
both disrupt the stability of the ligand in water and interfere with hydrophobic 
interactions (e.g. potassium isocyanate in a neutral buffer).
5
 Denaturing agents and 
detergents such as urea, and guanidine-HCl dissociate hydrogen bonds.
5
 Sodium 
dodecyl sulphate contains both hydrophobic and strong ionogenic groups. This 
compound binds to hydrophobic regions of a protein results in a layering of negative 
charges on the protein‟s surface, hence causing irreversible unfolding of the structure. 
The denaturing effect of these solutions limits their suitability to the most stable 
proteins. Other applications are the removal of “sticky” proteins during column 
regeneration or when functional eluate is not required. Ideally, an elution buffer should 
aim to disrupt the various bonds that make up protein-protein interactions. The elution 





1.5.2 Competitive elution 
 
The isolated proteins can be alternatively eluted by washing the column with an excess 




Figure 16: The addition of a competitive ligand in solution causes the release of the bound 
molecule (Figure from ref. 2).  
 
This strategy has several advantages including the retention of column-binding capacity 
due to the mild elution conditions and the specificity of elution, especially when there is 
suspicion of non-specific binding of mobile phase components on the solid matrix.
5
 
However, it may not always be possible to work with a large excess of ligand for 
practical or economical reasons.  
 
1.6 “Affinity-independent” elution of isolated biomolecules 
 
Despite the great advancements in elution techniques in affinity chromatography, the 
prediction of their efficiency remains complex.
58
 Therefore, general elution methods that 
are independent of the bioaffinity interaction would be desirable. A few examples of 
affinity-independent retrieval of the separated biological material are discussed below.  
A protocol set up by Santala et al. describes a novel elution method for the efficient 
recovery of antibody-displaying phages (viruses able to infect only bacteria) that have 
been captured with a biotinylated antigen on streptavidin-coated magnetic particles.
58
 
Using paramagnetic streptavidin beads featuring a nuclease-cleavable DNA linker 
between streptavidin and the bead surface, a high total recovery and a very low non-
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specific background have been achieved (Fig. 17). It has been shown that this system is 
suitable for any pre-existing phage display library with no need to adjust the vector 
construct.
58
 The universal (same conditions for all binders) affinity-independent elution 
should enable the automation of this method for high throughput isolation of binders in 






Figure 17: Schematic illustration of the elution in a phage display. To elute phages after 
bioaffinity selection from conventionally coated streptavidin (SA) paramagnetic particles (A), the 
detachment can be achieved by (dotted arrows): breaking the biotin-antigen bond (Ag) or 
cleaving the specific linker between Fab (the region of the antibody that binds the antigen) and 
phage coat protein. Using streptavidin beads containing a DNA linker (B), affinity-independent 
elution can be achieved by cleaving the DNA linker (solid arrow, figure from ref. 58). 
 
Another elegant example of an affinity-independent elution strategy has been 
described by Cho et al. in their study of the hepatitis C virus (HCV) RNA polymerase 
protein.
59
 A microbead-based affinity chromatography chip (µ-BACC) was developed to 
separate and purify these proteins by immobilisation of an RNA aptamer (nucleic acid 
species that have been engineered to bind various molecular targets) on beads (Scheme 
5). A photocleavable linker was conjugated between the beads and the aptamer to allow 
the elution of the bound RNA polymerase from the RNA aptamer in one step by UV 
irradiation (Scheme 4).
59
 This linker showed a cleavage activity over 70% upon UV 
irradiation at 1050 mW cm
-2





Scheme 4: Photocleavable linker used for photoelution of captured proteins. The end of the 
spacer features a reactive N-hydroxysuccinimide ester for covalent binding of aptamer having an 
amine group in position 3.
54 
 
In the approach reported by Cho et al., an o-nitrobenzyl photocleavable linker with an 
activated ester moiety was connected to PEG-modified beads, and was used for the 
immobilisation of aminated RNA (Scheme 5).
59
 The recovery of the eluted target, upon 
exposure to near-UV light, was shown to be possible without protein denaturation. The 
eluted biomolecules were subsequently subjected to tryptic digestion and the peptide 
ions analysed using matrix assisted laser desorption/ionisation-time of flight (MALDI-
TOF, Scheme 5).
59
 Cleavage conditions depend only on the U.V. wavelength and 
irradiation time, not on the affinity between ligands and captured molecules, thus 







Scheme 5: Schematic diagram of protein analysis by the µ-BACC process. Magnetic beads 
were immobilised in the center of the bead chamber by a permanent magnet. Target protein was 
captured by the aptamer immobilised on these beads by covalent bonding. Captured proteins 
eluted following UV irradiation were analysed by MALDI-TOF after tryptic digestion (Scheme 
from ref. 59). 
 
More recently, Leitner et al. synthesised a molecular probe featuring a cleavable 
unit represented by a malondialdehyde-indole derivative aimed at the investigation of 
the tyrosine kinase inhibitor bosutinib (Scheme 6, 24).
60,61
 The indole linker 20 was 
designed with orthogonal functionalities; a free aldehyde for condensation to the solid 
support bearing a hydrazine moiety and a carboxylic acid group for coupling to an 
amino group of the ligand of interest. Incubation with 50 mM pyrrolidine solution 
causes release of the affinity probe from the solid support. Bosutinib is an ATP-
competitive third generation kinase inhibitor which is currently in phase III clinical trials 
for the treatment of chronic myeloid leukemia (CML).
62,63
 An amino functionalised 
sample of bosutinib was employed for the preparation of molecular probe 24 for pull-
down experiments with K562 cell lysate followed by elution of the isolated protein by 
incubation with pyrrolidine.
61
 Immunoblot analysis confirmed the presence of BTK (a 
known binding partner of the drug of interest) and revealed the presence of new binding 
partners. LC/MS allowed the identification of 32 binding partners; known binding 
partners of bosutinib including SRC, ABL, BTK or TEC, together with newly isolated 
targets such as CAMK2G.
64
 However, a high degree of non-specific interactions was 





Scheme 6: Preparation of c-Bosutinib molecular probe 24; (a) MeCN/C2H7NO2(aq), 1/1, pH 4.5, 
10 mM aniline, 2 h; (b) DMT-MM, c-bosutinib, MeOH, 3 h, RT. 
 
The work discussed in this section presents three different elution strategies in 
which the recovery of the isolated biomolecules does not rely on reversing the 
interaction between the ligand and the target molecule. The successful design and 
applications of molecular probes featuring a cleavable unit has been shown in affinity-
based separations. 
 
1.7 Hulme group strategy  
 
The initial aim of this project was to gain further insight into the biological activity of 
the natural product anisomycin using a novel affinity probe. This molecular probe has 
been designed to capture anisomycin binding partner(s) and release the isolated 
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biomolecule(s) following an affinity-independent elution protocol. For this reason, it 
was planned to insert a cleavable azobenzene unit (linker) between the solid matrix and 
the active compound, thus simplifying the elution procedure and avoiding all the 




The pyrrolidine antibiotic anisomycin 25 was first isolated from Streptomyces 






Figure 18: The natural product anisomycin. 
 
Over subsequent years anisomycin has been found to display many interesting 
biological responses including anti-fungal activity,
65
 protein synthesis inhibition
66
 and 
anti-tumour activity in the nanomolar region.
67
 The most interesting activity
68
 is perhaps 
its role in the stress activated protein kinase (SAPK) pathways. The SAPK pathways are 
distinct signalling branches within the mitogen activated protein kinase (MAPK) 
superfamily and play a vital role in the intracellular signalling triggered by a range of 








Scheme 7: General scheme of the mitogen-activated protein kinase (MAPK) pathways; the 
SAPK pathways (yellow, light blue and pink) incorporate the target of the natural product 
anisomycin (Scheme from ref. 70). 
 
Mammalian cells possess four well-characterised MAPK pathways (Scheme 7).
70
 The 
core unit of these MAPK pathways is a three-membered protein kinase cascade whose 
components are highly conserved in structure and organisation. In this cascade, the 
MAPK pathways are phosphorylated and activated by a MAPK kinase 
(MAPKK/MKK). The MAPKK are “dual-specific” kinases that catalyze the 
phosphorylation of MAPKs at Thr and Tyr sites, specifically targeting a Thr-X-Tyr 
motif on MAPK (where X is proline and glycine for the JNK/SAPK1 and p38/SAPK2 
modules, respectively).
71
 Regulation of these pathways results in controlled activation of 
downstream kinases and transcription factors including c-Jun, ATF-2, and MAPKAP-
K2. This downstream effect is thought to play a role in a range of pathological 







 Although the downstream effects on the SAPK pathway have 
been well documented, the cellular target of anisomycin and its precise mode of 




1.7.2 Previous work carried out in the Hulme group 
 
Selective biotinylation is one of the most common practises in affinity-based 
separations.
75
 Biotinylated binders such as membranes, nucleic acids, antibodies and 
other proteins can be detected once an appropriate streptavidin-conjugated probe is 
available.
75
 Biotinylation may be readily achieved through the copper(I) catalysed 
Huisgen 1,3-dipolar cycloaddition reaction. The high purity and high yields of 
conjugation that are possible using “click” methodology, together with mild coupling 
conditions, and excellent regioselectivity render it the method of choice in conjugative 
routes to biotinylated molecular probes. In the Hulme group, propargyl derivatives of 
anisomycin 26 and 27 have been prepared and tested for SAPK activity.
76
 Gratifyingly, 
derivative 27 (Fig. 19) retained the biological activity of the lead compound and has 




Figure 19: Two representatives of the propargyl derivatives prepared in the Hulme group from 
the phenol and pyrrolidine series. 
 
Biotinylated anisomycin (Fig. 20, 28) was screened using an immunoblot assay for 









Figure 20: Biotinylated probe 28 (and its cartoon representation) synthesised in the Hulme 
group for affinity capture of the binding partner of anisomycin within SAPK pathways. 
 
The newly synthesised molecular probe was incubated with a HEK 293 cell extract for 
affinity capture of anisomycin‟s binding partner (Scheme 8). The mixture was next 
immobilised onto a streptavidin-coated matrix. The excess lysate was removed by 
extensive washing and the matrix treated with SDS at high temperature to remove the 
isolated biomolecules from the streptavidin-coated matrix. The isolated proteins were 
separated by gel electrophoresis.
77
 Upon screening of different conditions for the pull-
down experiments (e.g. different incubation time, staining etc.) only a large background 
response was obtained.
77
 When a smaller number of proteins were isolated by SDS-
PAGE, they were identified (after MS analysis) as proteins present in the cell extract 






Scheme 8: Pull-down experiment with molecular probe 28. 
 
Having successfully synthesised a series of biotin derived molecular probes based on 
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coupling anisomycin through its pyrrolidine nitrogen; the synthesis of a solid-supported 
anisomycin was envisaged. Compound 29 was readily achieved from commercially 
available Affi-gel. The molecular probes synthesised have been used for pull-down 





Figure 21: Solid-supported anisomycin. 
 
1.7.3 A smart cleavable linker for affinity-based separations 
 
In order to use affinity-based separation for the elucidation of the mechanism of action 
of anisomycin, an alternative approach to biotinylation and the use of standard 
biotin/streptavidin affinity interactions was envisaged. As discussed in section 1.6, 
affinity-independent elution methods present considerable advantages for the retrieval of 
the separated biomolecules. In the Hulme group, the introduction of a “click”-













It was hypothesised that this molecular probe would be able to capture anisomycin 
binding partner(s) from within a cell extract. Once the biological material was separated, 
the linker would be readily cleaved, minimising risk of contamination, protein 




Scheme 9: Pull-down experiment with the proposed novel affinity probe. 
 
Azobenzenes were chosen for the linker strategy as they can be cleaved under mild 
reducing conditions by using sodium dithionite (Na2S2O4).
79
 Importantly, the cleavage 
reaction conditions are compatible with biochemical systems, as exemplified by the use 
of azobenzenes as cleavable cross-linking reagents for proteins
80
 and in the 
functionalisation of a tyrosine residue on the surface of viral capsids.
81
 The primary 
amino group present on the linker would be available for coupling to a solid support. 
The matrix of choice was commercially available Affi-gel 10 31 (Bio-Rad), an agarose 
based affinity media that contains a neutral 10-atom spacer arm and a reactive N-




Figure 23: Affi-gel-10. 
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This solid support is designed to couple selectively to primary amino groups in both 
aqueous and non-aqueous systems. The azide functionality in the linker 30 would be 
subsequently coupled to the propargyl derivative 27 of anisomycin using a classical 
click coupling. The presence of an azide group for click coupling makes this protocol 
compatible with the extensive range of propargyl functionalised “click” ligands
82,83
 that 






Figure 24: The novel molecular probe 32 featuring the chemically cleavable linker. 
 
The syntheses of the azobenzene chemically cleavable unit and the solid-supported 
molecular probes will be described in chapter 2. The characterisation of the newly 
synthesised matrices using solid-state nuclear magnetic resonance spectroscopy (NMR) 
techniques will be also discussed.  
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2 Results and discussion  
 
The different routes investigated for the synthesis of the novel chemoselective cleavable 
azobenzene unit 30 are discussed in section 2.1 (Fig. 25). The design and the preparation 
of a solution phase analogue mimicking the last portion of the agarose matrix 33 are 
described in section 2.2.1. The coupling reactions of analogue 34 to anisomycin and 
biotin are described in section 2.2.2 and 2.2.3. Finally, the syntheses of solid-supported 
biotin and anisomycin are discussed in sections 2.2.4 and 2.2.5. 
 
 
Figure 25: Derivatised agarose matrix 33, solution phase analogue 34 and the hypothetical 
chemoselective cleavable linker 30 with orthogonal functionalities. 
 
2.1 Linker Synthesis  
 
2.1.1 Route A 
 
For the synthesis of the chemoselective cleavable unit azobenzene derivative 38 was 
chosen as it can be readily cleaved under reducing conditions using sodium dithionite 
(Scheme 10).
79
 In the approach recently reported by Verhelst et al., reaction of 4-amino-
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benzoic acid 35 with sodium nitrite under acidic conditions gave rise to 4-






Scheme 10: Synthesis of the chemoselective cleavable linker. (a) i. NaNO2,.HCl(aq), 0 °C to RT, 
ii. 37, NaHCO3(aq), ~18 h; (b) FmocCl, 1 h, (59% over two steps). 
 
The diazonium salt was then coupled with tyramine 37 (a tyrosine derivative), followed 
by Fmoc protection of the primary amino group (59%, over two steps).
79
 The 
azobenzene species 38 was appealing because of the presence of both a carboxylic acid 




Scheme 11: Proposed functionalisation of the linker for affinity chromatography. (a) Coupling 
with 3-azidopropan-1-amine; (b) Fmoc cleavage in the presence of piperidine. 
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The carboxylic function could react with an amine bearing an azide functionality to give 
a stable amide (Scheme 11, 39). Following Fmoc deprotection, the newly revealed 
amine could be selectively attached to the agarose matrix 31, the affinity media of 
choice. The presence of an azide functionality in compound 39 would allow coupling to 
a propargyl derivative of the molecule of interest (e.g. propargyl anisomycin 27) using a 
copper(I) catalysed Huisgen 1,3-dipolar cycloaddition.  
Although TLC analysis suggested complete consumption of amine 36, it was not 
possible to isolate compound 38. In the belief that the use of a different protecting group 
could favour the protected amine entering the organic phase to be isolated, CbzCl was 
also employed. However, no better results were achieved. At this point, the use of 
phenol instead of tyramine 37 for the diazocoupling was proposed, following standard 
conditions.
86




Scheme 12: Diazonium salt formation and coupling with phenol. (a) i. NaNO2, HCl, 0 °C, 20 min; 
ii. PhOH, NaOH, K2CO3, 0 °C to RT, 3 h, (90%). 
 
2.1.2 Route B 
 
With compound 40 in hand, a new route for the extension of the phenol terminus to give 
a primary amine was planned. Azobenzene 40 was reacted with the hydrochloride salt 2-
chloro-ethylamine 41 in the presence of a base (Scheme 13). Unfortunately the proposed 
nucleophilic substitution by the phenol of compound 40 proved to be problematic 






Scheme 13: Unsuccessful reactions with unprotected amine 41. (a) NaH, DMF, RT; (b) Cs2CO3, 
DMF, RT; (c) KOH, EtOH, reflux. 
 
For this reason, protection of the amino group was carried out before proceeding with 




Scheme 14: Boc-protected route for the synthesis of compound 44. (a) Et3N, (Boc)2O, DCM, 
(60%); (b) 43, Cs2CO3, DMF, 80 °C, (23%). 
 
Protection of 2-chloro-ethylamine hydrochloride 41 was readily achieved as described in 
the literature.
87
 Compound 40 was reacted with the Boc-protected amine 43 in the 
presence of caesium carbonate to give the desired acid 44 in poor yield (23%). The 
reaction gave rise to a number of side products that were not isolated. Given the low 





2.1.3 Route C 
 
Alkylation of azobenzene 40 has been reported in literature using 1,10-dibromodecane
88
 
(42% yield) and 1,4-dibromobutane
89
 (15% yield). Although the yields reported in 
literature were not excellent the reaction was investigated using 1,3-dibromopropane. In 
this new synthetic route the azide functionality would be inserted on the OH terminus 
(Scheme 15). Once the alkyl bromide 45 was formed, nucleophilic displacement of the 
bromine to give the azide functionality could take place. The primary amine could be 




Scheme 15: Route C. (a) 1,3-dibromopropane 48, KOH, EtOH, reflux, (trace); (b) NaN3, DMF; 
(c) Coupling with BocNHCH2CH2NH2. 
 
Unfortunately, alkylation of 40 with the 1,3-dibromopropane 48 gave only a 
trace of the desired product 47, and numerous side products which it was not possible to 
isolate. The results were in agreement with the literature.
88,89
 For these reasons, it was 
decided to first derivatise the carboxylic functionality before proceeding with the 
alkylation of the phenol. 




In order to establish the most convenient route to prepare the azobenzene linker, both the 
esterification
77
 of compound 40 and its coupling with the protected amine
90
 50 were 
investigated (Scheme 16). The conversion of the acid 40 into the ester 49 procedeed 
smoothly. For the coupling of the mono-Boc-protected diamine 50 with compound 40
91
 
a range of standard reaction conditions were investigated. The best results were obtained 




Scheme 16: Derivatisation of the carboxylic acid of azobenzene 40. (a) Acetyl chloride, MeOH, 
0 °C to RT, (78%); (b) (Boc)2O, dry DCM, (99%); (c) Et3N, DSC, MeCN, 60 °C to RT (no 
reaction); (d) Et3N, DIC, DMF, RT (no reaction); (e) EDC, HOBt, DMF, RT (60%). 
 
Carbodiimides catalyse the formation of amide bonds from carboxylic acids and amines 
by activating the carboxylate to form an O-acylurea (Scheme 17). This intermediate can 
be attacked by an amine directly to form an amide. The driving force of this reaction is 
the formation of the urea by-product. The major advantage of the EDC coupling agent 
with comparison to DIC is the production of a water soluble urea derivative 57 as side 
product.
92
 This species can be easily removed by washing the organic phase with dilute 
acid or water. In carbodiimide-mediated amide formation, racemisation and acetyl 





addition of selected nucleophiles (e.g. HOBt) that react faster than the competing acyl 







Scheme 17: EDC-mediated amine/carboxylic acid coupling in the presence of HOBt as a 
nucleophile. 
 
Despite the fact that the esterification proceeded smoothly in better yield with respect to 
the amide bond formation, a new synthetic route starting from the amide 52 was 
planned. Coupling the carboxylic acid of compound 40 with mono-Boc-protected 
diamine 50 allowed investigation of the alkylation of phenol 40 without interference 
from the free acid. Furthermore, in the same step a Boc-protected primary amino group 
was introduced for subsequent linkage to the agarose matrix 31. Indeed, once the 
formation of the amide bond was achieved, the alkylation of the phenol was carried out 
successfully (Scheme 18). The use of different solvents for the akylation of phenol 40 
such as butan-2-one
85
 did not give an enhanced yield (67% for MeCN, 65% for butan-2-
one). Nucleophilic displacement of alkyl bromide 58 gave rise to the desired azide 
functionality on compound 59 in excellent yield. Monitoring the reaction by TLC was 
found to be difficult due to the almost identical Rf values of the starting material and the 
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azide 59. Thus, the completion of this reaction was monitored by MS (ESI+) checking 
for the disappearance of the bromine-containing molecular ion of the starting material 
58. Boc cleavage of the aminoazide product 60 under acidic conditions readily gave the 
free amino group as confirmed by NMR (disappearance of the singlet at δH = 1.44 ppm 
corresponding to the Bu
t






Scheme 18: Linker synthesis.
78
 (a) i. NaNO2, HCl, 0 °C, 20 min; ii. PhOH, NaOH, K2CO3, 0 °C to 
RT, 3 h, (90%); (b) BocNHCH2CH2NH2, EDC, HOBt, DMF, 18 h, (60%); (c) 1,3-dibromopropane 
48, K2CO3, MeCN, reflux, 5 h, (67%); (d) NaN3, DMF, 18 h, (90%); (e) MeOH, CH3COCl, 0 °C to 
RT, Et2O, 1 h, (90%). 
 
2.2 Solution phase mimic and solid-supported molecular probes 
 
Previous investigations carried out in the Hulme group of the click reaction onto solid 
matrices have proven to be problematic (section 1.7.2).
77
 Optimisation of the coupling 
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conditions as well as the characterisation of the synthesised compounds in the presence 
of a solid support can be quite complex. For these reasons, the synthesis of a solution 
phase analogue mimicking the last portion of the agarose matrix was envisaged. This 
molecule, coupled to ligands of interest, would provide data for the development of 
optimum coupling conditions and NMR data interpretation. 
 
2.2.1 Synthesis of the solution phase analogue  
 
Ethyl 4-(3-azido-1-propylamino)-4-oxobutanoate, compound 34 seemed to be a suitable 
solution phase mimic.
 
This azidoester features similar functionalities of the final portion 





Figure 26: Comparison between the final portion of the derivatised matrix and the solution 
phase analogue. 
 
The conditions for the preparation of compound 34 were optimised using the acid 
chloride 61 with the hydrochloride salt of compound 62 since aminoazide 64 is highly 
volatile and tricky to handle (Scheme 19). Aminoazide 64 is readily achieved from the 
salt 62 as reported in the literature.
92
 The best results were obtained using pyridine as 
base/solvent which yielded compound 63 in a satisfactory yield (71%). When a lower 
amount of pyridine was used (up to 5 equivalents) the reaction proved sluggish. 
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Carrying out the same reaction with aminoazide 64 allowed the preparation of the 
desired azidoester 34 in 60% yields. Product formation was confirmed by NMR and IR 






Scheme 19: Synthesis of the solution phase analogue. (a) Pyridine, 0 °C to RT, 2 h, (71% for 63 
and 60% for 34); (b) NaN3, H2O, 80 °C, ~18 h, (99%). 
 
2.2.2 Coupling of the solution phase analogue to anisomycin 
 
After the successful preparation of the solution phase analogue 34, the coupling of this 
compound to the ligand of interest, anisomycin, was investigated. A propargyl 
derivative of this natural product (with comparable biological activity) is readily 






Scheme 20: Propargylation of the natural product anisomycin 25. (a) Propargyl bromide, K2CO3, 




The biological properties of this potent activator of the SAPK pathway have been 
discussed in section 1.7.1. The conjugation method for the coupling of the compound of 
interest to the solution phase analogue is the copper-catalysed azide-alkyne 
cycloaddition (CuAAC). The ease with which azides and alkynes
85
 are introduced into 
organic compounds, their biorthogonal properties and tolerance to a wide range of 
solvents (including water) and pH make them ideal for bioconjugation purposes.
94
 The 
fact that the azide functionality is absent in all known natural compounds, allows 
selective ligation with a limited number of reaction partners.
94
 Click coupling conditions 
were initially optimised on a simple alkyne, propargyl alcohol, before moving to the 
anisomycin derivative due to the cost of the natural product. Alkyne-azide coupling is 
catalysed by copper (I) which is generally obtained in situ by reduction of a salt such as 
copper sulphate.
95
 The most accredited mechanism features the formation of an unusual 




Scheme 21: Proposed reaction mechanism for the copper-catalysed azide-alkyne cycloaddition 
(CuAAC). 
 
Initially, classical coupling conditions were followed with CuSO4 as the source of 
copper (I), sodium ascorbate as the reducing agent in t-BuOH/water. Since no product 
formation was observed under these reaction conditions, different sources of copper(I) 
such as copper wire or copper powder, were considered. It has been reported that 
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formation of the copper (I) catalyst by the oxidation of Cu metal affords the formation of 
triazole in good yield.
96
 However, reaction with Cu metal requires longer reaction times 
and more copper than other protocols. Coupling with both copper powder and copper 
wire was attempted. Disappointingly, only traces of the triazole formation were obtained 
as confirmed by MS (ESI+ showed a small peak at m/z = 285). At this point, the 
possibility of a ligand-assisted click coupling was investigated. Acceleration of the 
CuAAC click reaction by the amine triazole 65 (TBTA, Fig. 27) has been described in 
the literature as a useful tool for all substrates that seem to be unreactive under classical 
click coupling conditions.
97
 TBTA dramatically reduces the minimum catalyst loading 
(as much as tenfold) without requiring longer reaction times. Ligands such as 65 





Figure 27: Structure of the trisbenzyltriazolamine (TBTA). 
 
The reaction carried out in the presence of ligand 65 gave rise to the coupled product 
with the simple propargyl alcohol substrate as well as with propargyl anisomycin in 






Scheme 22: Ligand assisted Cu(I)-catalysed alkyne-azide cycloaddition. (a) Sodium ascorbate, 
TBTA, CuSO4·5H2O, H2O/t-BuOH, RT, ~18 h, (44% for 66 and 62% for 67). 
 
Both the reactions were monitored by TLC and formation of the products was confirmed 
by NMR. Both the coupling products showed the diagnostic CH peak of the triazole ring 
(δH = 7.65 ppm for compound 66 and δH = 7.51 ppm for compound 67).  
2.2.3 Coupling of the solution phase analogue to biotin  
 
Coupling of the solution phase analogue 34 to biotin was then investigated in order to 
provide NMR data to facilitate the characterisation of solid-supported biotin. 
Furthermore, this solid-supported molecular probe would provide useful material for the 
preliminary affinity studies discussed in chapter 3. D-Biotin can be readily converted 
into an activated ester at its carboxylic extremity (NHSbiotin). This activated ester can 
be readily coupled to propargylamine to form an amide bond and to furnish the desired 








Scheme 23: Coupling of the solution phase analogue to biotin. (a) i. N-hydroxysuccinimide, 
EDC, Et3N, 0 °C to RT, ~18 h, (99%); ii. Propargylamine, DCM, RT, 3 h, (77%); (b) 
Propargylamine, HOBt, DIC, DMF, 60 °C, μwave, 20 min, (88%); (c) Sodium ascorbate, TBTA, 
CuSO4·5H2O, H2O/t-BuOH, RT, ~18 h, (40%). 
 
Alternatively, D-Biotin 68 can be directly submitted to a coupling reaction with 
propargyl amine under microwave irradiation generating the desired amide derivative 69 
in high yield. Under these microwave conditions, conversion of the carboxylic acid 68 
into a more reactive N-hydroxysuccinimide ester is no longer required, hence shortening 
the synthesis. The biotin propargyl amide 69 was coupled to the solution phase analogue 
34 under the optimised TBTA-assisted CuAAC conditions to give compound 70 
(Scheme 23). Full characterisation of compound 70 was extremely valuable for the 
subsequent work in solid phase. 
 
2.2.4 Coupling of the solid support to biotin  
 
Following the characterisation of solution phase analogue 70, the syntheses of two solid-
supported molecular probes were carried out (Schemes 22 and 23). Solid-supported 
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biotin, molecular probes 72 and 74 have been designed to provide a preliminary test of 
the ability of the new matrix featuring a cleavable unit (azobenzene derivative 60) to 
selectively capture the binding partner of a ligand of interest within a biological mixture. 
Furthermore, the preliminary test using solid-supported biotin featuring a cleavable unit 
74 will guarantee that the cleavage of the linker is compatible with biochemical systems. 
The preliminary affinity studies will be discussed in chapter 3. 
Agarose matrix Affi-gel 10 was coupled to azidopropan-1-amine 71 (Scheme 
24). As the conversion to azide is quantitative, the loading of the short chain aminoazide 
is calculated according to the content of active N-hydroxysuccinimide ester (15 µmol 
ml
-1
). On this premise, 3 equivalents of propargyl amide 69 were employed and the 
reaction carried out using the previously optimised click coupling conditions (Scheme 
24). The reaction was monitored by IR and stopped once the azide peak at 2100 cm
-1
 
disappeared. Similarly, the agarose matrix was reacted with the novel azobenzene 
derivative 60 and coupled to biotin propargyl amide 69 (Scheme 24). Successful linkage 
of the cleavable unit was confirmed by an intense orange colour of the beads which 
persisted after extensive washings. Even in this case, the click coupling was monitored 








Scheme 24: Syntheses of solid-supported biotin, molecular probes 72 and 74. (a) azidopropan-
1-amine 64, MeOH, ~18 h; (b) Biotin propargyl amide 69 (3 E), CuSO4·5H2O, sodium ascorbate, 
TBTA, H2O/t-BuOH, 2 d (~48 h). (c) linker 60, Et3N, H2O/MeCN, ~18 h. 
 
Solid-supported azobenzene derivative 73 was also utilised to prepare a simplified 
molecular probe by coupling to propargyl alcohol under the optimised CuAAC 
conditions. This simple derivatised matrix 75 was used to test the desired 
chemoselective reductive cleavage of the azobenzene linker by incubation of the beads 
with an aqueous solution of sodium dithionite (Na2S2O4, scheme 24).
98,99
 The cleavage 
was attempted at various pH values (from 5 to 7) using different concentrations of 
sodium dithionite (from 0.05 M to 0.3 M). The best cleavage conditions were found to 
be the use of a freshly prepared 0.3 M aqueous solution of sodium dithionite at pH 6.5. 
Following dithionite cleavage of matrix 75, the corresponding aniline derivative 77 was 
isolated as confirmed by 
1
H in good yield (70%, based on the weight of the recovered 
aniline 78). This preliminary study demonstrates for the first time that the azo unit is 
compatible with the reductive conditions of click-based methodologies.
78
 The reduction 
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of the azo group was easily followed since it is accompanied by a dramatic loss of 




Scheme 25: Preparation of a simplified molecular probe and dithionite cleavage. (a) propargyl 
alcohol (3 E), CuSO4·5H2O, sodium ascorbate, TBTA, H2O/t-BuOH, ~18 h; (b) Na2S2O4(aq). On 
the left, two Eppendorf tubes containing simplified molecular probe 75 before (tube 1) and after 
(tube 2) the cleavage. 
 
2.2.5 Coupling of the solid support to anisomycin 
 
After the successful preliminary affinity studies (sections 3.2.2 & 3.2.3) a solid-
supported anisomycin, molecular probe 32 was prepared using similar synthetic 
transformations (Scheme 26). The reaction was monitored by IR and stopped once the 
azide peak at 2100 cm
-1
 disappeared. The successful coupling of anisomycin was 
confirmed by identification of the aniline derivative 78 (MS, ESI+, m/z = 496) following 
dithionite cleavage. This novel molecular probe was employed for pull-down 
experiments with HEK 293 cells (which express the SAPK pathway) in collaboration 
with the Cancer Research UK Centre at the Western General Hospital (Edinburgh). 







Scheme 26: Solid-supported anisomycin coupled through the azobenzene unit to the agarose 
matrix 32. (a) propargyl anisomycin, CuSO4·5H2O, sodium ascorbate, TBTA, H2O/t-BuOH, ~18 




In conclusion, the synthesis of a novel azobenzene linker for affinity applications was 
developed (5 steps, 29% overall yield). The central core of compound 60 incorporates an 
azo group which can be readily cleaved under mild reducing conditions.
79
 The amino-
terminus can be selectively attached to a functionalised agarose matrix (Affi-gel 10) 
while the azide functionality can undergo copper(I) catalysed Huisgen 1,3-dipolar 
cycloaddition with a series of compounds of biological interest (e.g. the natural product 
anisomycin). A series of solid-supported molecular probes have been prepared: solid-
supported biotin 72 and 74, for preliminary affinity studies; a simplified solid-supported 
triazole 75, to test the cleavage conditions; and solid-supported anisomycin 79 for pull-
down experiments aimed at the isolation of anisomycin‟s binding partner within the 
SAPK pathway. In parallel to these syntheses, a solution phase mimic of the Affi-gel 10 
agarose matrix has been successfully synthesised and coupled under the optimised 
TBTA-assisted CuAAC conditions to the propargyl derivatives of biotin and 
anisomycin. These compounds furnished valuable NMR data to aid the characterisation 
of the solid-supported molecular probes. 
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3 Results and discussion  
3.1 Solid state NMR studies 
3.1.1 Magic angle spinning (MAS) solid state NMR spectroscopy 
 
Magic angle spinning (MAS) solid state NMR spectroscopy was independently 
described by Andrew et al.
100
 in 1958 and by Lowe
101
 in 1959. Thanks to this 
spectroscopic technique it is possible to obtain NMR spectra from solid materials.
102
 In 
solution NMR, the anisotropic interactions are averaged by the rapid tumbling of 
molecules.
103
 In contrast, in solid-state NMR, anisotropic interactions such as the 
chemical shift and dipolar coupling play a major role. This phenomenon results in a 
broadening of the spectral line width of nuclei in solids.
103
 In order to overcome this 
issue, MAS NMR techniques are applied. This procedure consists of rotating the solid 
sample about an axis inclined at an angle of 57.74º to the direction of the magnetic field 
of the NMR magnet (Fig. 28). It has been demonstrated that sufficiently rapid rotation 
about this particular axis effectively suppresses most broadening interactions, leaving 






Figure 28: Schematic representation of the MAS technique. The spinning axis of the sample is 





This analytical technique can be applied to all kinds of solid materials: ionic solids, 
molecular solids, polymers, semiconductors and metals; the solid can be either 




Among the plethora of applications of this technique in the field of biochemistry, 
two recent reports will be discussed and an example of the technique for the 
characterisation of affinity supports will be given. An investigation carried out by 
Wasner et al.
104
 in 2009 using solid state NMR spectroscopy allowed the structural 
characterisation of a specific type of inclusion bodies (IBs) in E. coli cells. IBs are 
expressed proteins which are deposited as insoluble aggregates. A combination of 
techniques such as; electron microscopy (EM, Fig. 29), NMR spectroscopy (for H/D 
exchange experiments), solid-state NMR spectroscopy, and in vivo prion infectivity 
assays have allowed determining that such IBs consisted of fibrillar structures. Indeed, 
solid-state NMR spectra showed that these IBs adopt virtually the same molecular 
structure as a particular class of insoluble fibrous protein aggregates, called amyloids. 
This class of proteins is involved in a range of diseases (e.g. Alzheimer‟s disease, 
Parkinson‟s disease), although the relation between the formation of these aggregates 
and the pathology is yet to be elucidated.
105
 The finding that these bacterial IBs 
displayed a highly ordered and functional amyloid structure supports the emerging 






Figure 29: a) IBs from E. coli observed by cryo-electron microscopy of entire E. coli cells. b) 




More recently, solid state NMR has been employed to study the interaction of 
proteins and RNA.
106
 The structural investigation of large ribonucleoprotein (RNP) 
complexes can be a difficult task due to the flexibility of RNA and of the protein-RNA 
interfaces, which often hinders crystallisation. Although solution NMR spectroscopy is 
an attractive alternative to X-ray crystallography, the large size of typical RNP 
complexes may limit its applicability. For these reasons, solid-state NMR spectroscopy 
represents a viable route for such investigations. The complex investigated by 
Carlomagno et al. was the one formed by the protein AF L7Ae and certain RNA 
nucleotide sequences from the bacterium Archaeoglobus fulgidis, as the crystallographic 





Figure 30: The X-ray structure of L7Ae complex with the RNA of Archaeoglobus fulgidis 
showing the K-turn motif of the RNA; the amino acid sequence with secondary structure 
elements of L7Ae (helix, green; β-sheets, blue; loop, red) and the RNA nucleotide sequences 
interacting with the protein (turquoise and orange, figure from ref. 106). 
 
Using solid state NMR transferred-echo double resonance (TEDOR), the distances 
between the 
15
N nuclei of the protein backbone and the 
31
P nuclei of the RNA backbone 




N correlation investigated is 




N cross-peaks are intermolecular. The measured intermolecular distances between 
15
N nuclei of L7Ae and the phosphate backbone of specific nucleotide sequences of 
RNA were in very good agreement with those expected from the crystallographic 
structure of the complex (Fig. 30), hence underlining the potential of this technique for 





 In 1983 characterisation of affinity supports by 
13
C MAS NMR spectroscopy 
was reported by Bayer et al. for the analysis of silica gel derivatives.
107
 However, the 
first report which describes the analysis of an agarose-based affinity support was 
disclosed by Zumbrink et al. in 1994.
108
 As discussed in chapter 1, one of the problems 
in affinity technology is the analysis of the synthesised affinity matrices, as liquid phase 
methodology can not generally be applied. In this work by Zumbrink et al.,
108
 the use of 
13
C MAS NMR spectroscopy shed light on the mechanism of the nucleophilic reaction 
of certain trifluoroethylsulfonyl (tresylate) derivatives of agarose gels in the presence of 
a base. As highlighted in scheme 27, tresyl agarose derivative 79 was treated with an 







C MAS NMR spectra of tresyl agarose 79 and its alkaline hydrolysis product 80.  
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A new signal at 168.0 ppm corresponding to a carboxylic acid was found, however it 
was not possible to visualise the α-sulfonyl carbon as the signal had shifted to a higher 
ppm value, underneath the agarose peaks (Scheme 27, b). As well as demonstrating the 
applicability of MAS NMR for characterisation of agarose derivatives, this 
groundbreaking work allowed 
13
C NMR analysis of nucleophilic reaction products of 




3.1.2 Solid-supported biotin molecular probe 
 
Among the solid-supported molecular probes analysed by solid state NMR, molecular 
probe 72 (Fig. 31) gave the most significant results. Hence, the full characterisation of 




C, COSY and HSQC spectra), will be 
reported in this section followed by the 
1
H and HSQC spectra of the solid-supported 
biotin 72 which were analysed by analogy with the data of the solution phase analogue 
(Fig. 35 and 36).  
 
 










C NMR spectra of solution phase analogue 70 (800 MHz, D2O) and its 
starting materials, biotin propargyl amide 69 (250 MHz, CD3OD) and azidoester 34 (250 MHz, 








250 MHz, CD3OD 
SPA−N3 34 
250 MHz, CDCl3 
Bio-SPA 70 
800 MHz, D2O 
C3aH 4.30 dd, 7.8, 4.3  4.35 dd, 7.9, 4.5 
C4H 3.24-3.16 m  3.27-3.25 m 
C6aH 4.49 dd, 7.8, 4.9  4.57 dd, 7.9, 4.5 
C6HaHb 2.93 dd, 12.7,4.9  2.96 dd, 13.0, 5.0 
C6HaHb 2.70 d, 12.7  2.75 d, 13. 
C7HcHd 1.81-1.37 m  1.62-1.58 m 
C7HcHd 1.81-1.37 m  1.54-1.50 m 
C8H2 1.81-1.37 m  1.34-1.30 m 
C9H2 1.81-1.37 m  1.68-1.63 m 
C10H2 2.21 t, 7.3  2.28 t, 7.1 
C13H2 3.94 d, 2.5  4.42-4.40 m 
C15H 2.58 t, 2.5   7.88 s 
C17H2  3.28-3.17 m 4.43 t, 6.7 
C18H2  1.62 qn, 6.7 2.08 qn, 6.7 
C19H2  3.28-3.17 m 3.16 t, 6.7 
C22H2  2.51 t, 6.7 2.62 t, 6.7 
C23H2  2.35 t, 6.7 2.48 t, 6,7 
C26H2  3.98 q, 7.2 4.13 q, 7.1 
C27H3  1.12 t, 7.2 1.21 t, 7.1 
13




250 MHz, CD3OD 
SPA−N3 34 
250 MHz, CDCl3 
Bio-SPA 70 
800 MHz, D2O 
C1 166.15  166.70 
C3aH 63.39  63.30 
C4H 56.99  56.84 
C6aH 61.67  61.71 
C6H2 41.08  41.23 
C7H2 29.49  29.12 
C8H2 29.75  29.25 
C9H2 26.73  26.56 
C10H2 36.53  36.76 
C11 175.66  176.58 
C13H2 29.41  49.46 
C14 72.10  146.27 
C15H 80.73  125.35 
C17H2  48.80 35.80 
C18H2  30.51 30.39 
C19H2  36.63 37.80 
C21  172.74 178.12 
C22H2  28.43 31.04 
C23H2  29.25 31.77 
C24  171.63 176.15 
C26H2  60.63 63.50 
C27H3  13.80 14.88 
 











C NMR spectra unequivocally confirmed the formation of the 
desired triazole with characteristic singlet at 7.88 ppm (Table 1). The signals relating to 
the short hydrocarbon chain (C17 to C19) in azido ester 34 are slightly shifted downfield 
in the product and in particular the 
13
C NMR spectrum shows a huge difference of 
chemical shift for C17 (Table 1, from 48.80 to 35.80 ppm). The 
1
H NMR data shows that 
chemical shift values and multiplicities of the heterocyclic core of biotin propargyl 
amide 69 are fairly consistent with those found in the spectrum of the product (C3a to 
C6HaHb, particularly when allowing for differences in acquisition solvent). Analysis of 
the COSY spectrum of compound 70 allowed confident assignment of the overlapped 
peaks of the hydrocarbon chain of biotin (Fig. 33). The identity of the carbons of 
compound 70 was established by HSQC analysis (Fig. 34). A series of extra peaks were 
found in the 
1
H NMR at 7.90, 4.46-4.40, 3.51, 2.69 and 2.21 ppm. The singlet peak at 
7.90 ppm suggested the presence of a different triazole species; analysis of the COSY 
spectrum confirmed that this series of peaks did belong to the same molecule. The most 
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interesting signal was the singlet peak at 2.69, which is a diagnostic peak for the two 
methylenes of a succinimide ring.
109,110 
 These observations suggested that perhaps 
cyclisation of the amide nitrogen in the last portion of the molecule onto carbonyl C24 
could have generated succinimide 81 as a side product during the click coupling 
(Scheme 27). The chemical shift values and multiplicities of signals at 3.51 ppm (t, J = 
6.7) and at 2.21 (qn, J = 6.7) were consistent with the formation of such a succinimide 
derivative. This cyclisation reaction is not unprecedented; although the formation of 
succinimide derivatives occurs through cyclisation onto methyl or ethyl esters in high 
yield (up to 90%) under basic conditions, isolation of this species as a minor side 
product has been also reported during different type of synthetic 
transformations.
111,112,113
 Indeed, intramolecular cyclisation of a derivatised nucleoside 
in the presence of triethylamine has been employed by Matsumoto et al. for the 
preparation of a class of pro-drug molecules as potential anti-HIV agents.
112
 In 2002, 
Molina Pinilla et al.
111
 reported the formation of the succinimide ring in connection to 
their studies on the hydrolytic degradation of certain poly(ester amide) polymers. 
Isolation of a succinimide derivative as a minor side product (3% yields) was also 
reported by Masanori et al. when carrying out the methylation of a indole derivative in 






C NMR signals relating the last portion 
of side product succinimide derivative 81 are highlighted in the HSQC spectrum of 




Scheme 27: Cyclisation reaction resulting in the formation of succinimide derivative 81 as a side 











The best results for the solid state NMR of solid-supported biotin 72 were obtained for 
1
H and HSQC NMR spectra (Fig 35 and 36) which could be analysed by analogy with 





Figure 35: Stacked 
1
H spectra of the solid-supported biotin 72 (800 MHz, D2O) and the 





Figure 36: Stacked HSQC spectra of the solid-supported biotin 72 (800 MHz, D2O, gray 




H spectrum of the solid-supported biotin 72 showed the characteristic 
singlet of the triazole moiety at 7.84 ppm (Fig. 35) confirming that the click coupling of 
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biotin propargyl amide to the agarose matrix had occurred. Although the spectral lines 
are quite broad, it is also possible to recognise by analogy with the solution phase 
analogue 70 some of the protons of the heterocyclic core of biotin (e.g. C6HaHb + 
C6HaHb, Fig. 35). Furthermore, the chemical shift values of the protons of the 
hydrocarbon chain of biotin (e.g. C7H2 to C9H2, from 1.68 to 1.24 ppm) are in good 
agreement with those of the solution phase analogue. The overlapped HSQC spectra 
show a distinctive peak for C15H (triazole) for both the compounds (Fig. 36). Most of 
the signals of the heterocyclic core and the hydrocarbon chain of the solid-supported 
biotin were fairly consistent with those of the solution phase analogue. Despite the 
presence of side product succinimide 81 in the NMR sample of biotinylated solution 
phase analogue 70, such compound was a valid reference for the characterisation of 
solid-supported biotin 72. This approach for the characterisation of the affinity support 
proved successful, although time consuming. For the other molecular probes synthesised 
featuring the chemoselective cleavable azobenzene unit (e.g. simplified molecular probe 
75, Scheme 28), preliminary cleavage and identification of the aniline derivative by 
either MS or 
1





Scheme 28: Cleavage of the simplified molecular probe 76 and isolation of aniline 77. 
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3.2 Affinity investigations 
 
The preliminary affinity studies using solid-supported biotin, molecular probes 72 and 
74 (Fig. 37) will be discussed in sections 3.2.2 and 3.2.3 while the pull-down 




Figure 37: The molecular probes employed in the preliminary affinity studies. In the description 
of the experiments in sections 3.2.2 and 3.2.3 the cartoon representations will be employed. 
 
3.2.1 Biotin/streptavidin affinity chromatography 
 
In order to test how robust the affinity independent elution protocol based on the use of 
the novel azobenzene derivative linker would be, the biotin/streptavidin affinity pair was 
selected. Biotin and its affinity partner streptavidin have one of the strongest non-
covalent interactions known.
75
 This exceptional binding affinity (Kd ~ 10
-15
 M) and the 
slow dissociation rate are fundamentally due to a series of hydrogen bonds between 
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streptavidin and the heterocyclic core of biotin (Fig. 38). Because of this peculiar 
characteristic the streptavidin/biotin system has been employed in countless affinity-
based purification protocols in the last 30 years. Chicken avidin (originally isolated from 
egg white) as well as streptavidin (secreted by Streptomyces bacteria) are functionally 







Figure 38: (a) Superimposed structure of avidin (gray) and streptavidin (green); the secondary 
structures are determined by X-ray crystallography. The secondary structural elements are 
indicated as a cartoon representation and the bound ligand, D-biotin, is shown in stick format. (b) 
Avidin tetramers. The secondary structural elements are indicated as a cartoon representation 
and bound ligands, four biotin molecules, are shown in stick format (Figure from ref. 114).  
 
Among the countless applications of this affinity pair in biochemistry, a recent report 
investigating new reactivities for biotin will be discussed. A novel approach to the 
biotinylation of electron-rich reporter molecules such as redox-active ferrocene and 
ruthenocene and luminescent pyrene, based on their Friedel-Crafts acylation using D-
biotin, was proposed (Scheme 28) by Plażuk et al.
115
 Although Friedel-Crafts products 
82-84 lacked an amide bond, they retained their affinity for avidin, as confirmed by their 
ability to displace 2-(4-hydroxyphenylazo)-benzoic acid (HABA) in its complex with 
avidin. Formation of the avidin-84 complex was also evidenced by quenching of the 
fluorescence from the protein tryptophan residues (342 nm) and appearance of the 
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emission band of the avidin-bound 84 at 430 nm as a result of a Forster resonance 
energy transfer (FRET) phenomenon. This report introduced a new approach to the 
synthesis of biotin derivatives without an amide bond. Interestingly, these compounds 
should be resistant to the endogenous enzyme biotinidase, which cleaves CO-NH bonds 






Scheme 29: Friedel-Crafts biotinylation of ferrocene, ruthenocene and pyrene. (a) TFAA/TfOH, 
(55% for 82, 53% for 83 and 47% for 84). 
 
3.2.2 Competitive capture and release of avidin 
 
The first set of affinity experiments were designed to ascertain that the solid-supported 
biotin, molecular probes 72 and 74 retained the capability to capture avidin (monomeric) 
despite the presence of the matrix and the linker. This capture must be selective (i.e. 
without any competing non-specific interactions),
117
 hence both the matrices were 
incubated with both avidin and albumin (negative control, Scheme 30). Albumin is 
known as a “sticky” protein that acts as a transporter for blood components such as 
hormones and lipoproteins.
118
 This characteristic makes this protein ideal to ascertain 
the absence of non-specific interactions of the molecular probes 72 and 74 in a pull-
down experiment. For the release of the captured proteins a classical protocol (SDS 
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elution) was followed for matrix 72, while dithionite elution
79
 was performed for matrix 




Scheme 30: Competitive capture and release of avidin. Albumin = red ligand; avidin = green 
ligand. (a) A solution of avidin (1 ml, 1 mg ml
-1
) was added to matrix 72 (1 ml, 15 µmol ml
-1
). 
After extensive washings, the matrix was divided into two aliquots and SDS elution or dithionite 
cleavage were performed to collect the isolated proteins. (b) A solution of avidin (1 ml, 1 mg ml
-
1
) or albumin (1 ml, 1 mg ml
-1
) was added to matrix 74 (1ml, 15 µmol ml
-1
). After extensive 
washings, the matrix was divided into three aliquots and SDS elution or dithionite cleavage were 
performed to collect the isolated proteins.  
 
The isolated proteins were analysed by SDS-PAGE and the results are shown in figure 
39. The absence of a clear band for avidin (15 kDa) in the supernatant following 
incubation shows that both matrices bound avidin (Fig. 39, lanes A, B, D & E). 
Quantitative elution of albumin (band at 66 kDa, Fig. 39, lane C) and the absence of its 
band following SDS cleavage (Fig. 39, lane G) also demonstrated that matrix 74 did not 
exhibit any non-specific interactions for albumin. The efficiency of a classical SDS 
elution procedure (for matrix 73) and chemoselective cleavage with sodium dithionite 
(for matrix 74) were then compared. Gratifyingly, both elution procedures showed the 
expected bands for avidin (Fig. 39, lanes F & J1-3). In order to identify the optimal 





 The best results were obtained by incubating with a phosphate buffer 
solution at pH 6.5 and using a large excess of sodium dithionite (Fig. 39, lane J1). These 
mild cleavage conditions were shown not to release avidin from matrix 39 in the 
absence of the azo linker (Fig. 39, lanes I1-3) demonstrating the chemoselectivity of this 
protocol. On the other hand, the presence of the linker does not interfere with a classical 
SDS elution protocol, as confirmed by the fact that avidin is released from matrix 74 




Figure 39: SDS-PAGE for experiments with avidin and albumin: lanes A-E supernatants after 
incubation; lanes F-H supernatants following SDS elution; lanes I1-J3 supernatants following 
dithionite cleavage. M=marker lane; A & B = supernatant from incubation of matrix 72 with 
avidin; C = supernatant from incubation of matrix 74 with albumin; D & E = supernatant from 
incubation of matrix 74 with avidin; F = supernatant after SDS elution of matrix 72 incubated with 
avidin (Lane A); G = supernatant after SDS elution of matrix 74 incubated with albumin (Lane 
C); H = supernatant after SDS elution of matrix 74 incubated with avidin (Lane D); I1-I3 = 
supernatant after dithionite cleavage of matrix 72 incubated with avidin (Lane B) at pH 6.5, 7.5 & 
8.5; J1-J3 = supernatant after dithionite cleavage of matrix 74 incubated with avidin (Lane E) at 
pH 6.5, 7.5 & 8.5. 
 
The chemical cleavage proved effective only when using freshly prepared aqueous 
solution of sodium dithionite. Increasing the incubation time of the reducing agent with 
the matrix (up to 30 min) did not improve the efficiency of the cleavage. This 





3.2.3 Capture and release of avidin from a protein mixture 
 
The second set of experiments was aimed to determine whether the solid-supported 
biotin featuring a cleavable unit, molecular probe 74 could selectively capture its 
binding partner avidin from a complex mixture of proteins (Fig. 40, a and b). For these 
reasons both matrices 72 and 74 were incubated with an avidin enriched fetal bovine 
serum (FBS) solution (the complexity of this mixture is represented in figure 40, c, in 




Figure 40: Capture and release of avidin from a protein mixture. (a) A solution of avidin-enriched 
(1 ml, 100 μg ml
-1
) 10 % FBS in PBS was added to matrix 72 (1 ml, 15 µmol ml
-1
). After 
extensive washings, SDS elution was performed to collect the isolated proteins. (b) A solution of 
avidin-enriched (1 ml, 100 μg ml
-1
) 10 % FBS in PBS was added to matrix 74 (1 ml, 15 µmol ml
-
1
). After extensive washings, dithionite cleavage was performed to collect the isolated proteins. 
(c) SDS-PAGE for experiments with FBS: M = marker lane; A = FBS + avidin (control lane); B = 
supernatant after incubation of matrix 72 with FBS + avidin; C = supernatant after incubation of 
matrix 74 with FBS + avidin; D = supernatant after SDS elution of matrix 72 incubated with FBS 
+ avidin (Lane B); E = supernatant after dithionite cleavage of matrix 74 incubated with FBS + 
avidin (Lane C). 
 
Because of the abundance and variety of proteins contained, FBS is a standard medium 
for cell cultures.
120
 In these preliminary studies FBS mimics the complexity of a protein 
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mixture resulting from a cell lysate. The use of 10% FBS in buffer PBS proved to be the 
ideal concentration (control lane A); when higher concentrations were used (25 and 25% 
FBS in PBS) it was not possible to distinguish the protein bands. Following incubation 
with the above described mixture of proteins, the experiments were carried out as before 
(Fig. 40, a and b). All the matrices were extensively washed with 4×PBS buffer; the use 
of PBS in smaller concentrations (2× or 3×) or a different buffer (e.g. HEPES) proved 
less effective for the removal of the unbound proteins. All the isolated proteins were 
analysed by SDS-PAGE and the results are shown in figure 40, c. Gratifyingly, both 
matrices were shown to selectively capture avidin (Fig. 40, lanes B & C). Furthermore, 
the release of the bound material could be performed using the optimal cleavage 
conditions for each matrix: boiling with SDS for matrix 72 (Fig. 40, lane D); and 
dithionite cleavage at pH 6.5 for matrix 74 (Fig. 3, lane E). The efficiency of the 
chemical cleavage was only marginally reduced with comparison to the SDS protocol 
(difference in intensity between avidin bands in lanes D & E). 
 
3.3 Pull-down experiments with anisomycin molecular probe 
 
Once the preliminary studies with matrices 72 and 74 were completed, investigations on 
the natural product anisomycin were attempted. The synthesis of a solid-supported 
anisomycin, molecular probe 32 (Fig. 41) was readily achieved as described in section 
2.2.5. Biotinylated anisomycin 28 (Fig. 41) was also prepared following a protocol 
previously developed in the Hulme group.
76
 This molecular probe was employed in the 
pull-down experiments together with the novel molecular probe 32 to be able to directly 
compare these data with the ones previously obtained in the Hulme group with 
compound 28 (as described in section 1.7.2). Both molecular probes were incubated 
with a human embryonic kidney (HEK) 293 cell lysate as this cellular line expresses the 
SAPK pathway with which anisomycin is known to interact. A modified protocol for 
pull-down experiments using biotinylated peptides optimised in the Ball research group 
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Figure 41: Pull-down experiments with HEK 293 cells. (−) = negative control; (+) = positive 
control; (a) Three solutions of: biotinylated anisomycin 28 (+, 1 μl, 50 mmol ml
-1
), propargyl 
amide biotin 69 (−, 1 μl, 50 mmol ml
-1
) and a biotinylated peptide (−, 1 μl, 50 mmol ml
-1
) were 
added to three Eppendorf tubes containing a streptavidin-coated agarose matrix (40 µl, of a 
50/50 mixture beads) and gently shaken for 1 h. After extensive washings, a cleared whole 
lysate of HEK 293 cells (49 µl) was added to all the matrices together with buffer W (151 µl). The 
matrices were incubated with the cell lysate for 1 h with gentle shaking. After extensive 
washings, SDS elution was performed to collect the isolated proteins. (b) Two samples of solid-
supported anisomycin 32 at different concentrations (+, 40 µl, 5 mmol ml
-1
 and 40 µl, 50 mmol 
ml
-1
) and two samples of solid-supported azobenzene unit 73 at different concentrations (−, 40 
µl, 5 mmol ml
-1
 and 40 µl, 50 mmol ml
-1
) were transferred to four Eppendorf tubes. After 
extensive washings, a cleared whole lysate of HEK 293 cells (49 µl) was added to all the 
matrices together with buffer W (151 µl). The matrices were incubated with the cell lysate for 1 h 
with gentle shaking. After extensive washings, dithionite cleavage was performed to collect the 




Along with the anisomycin molecular probes three negative controls (a biotinylated 
peptide, biotin propargyl amide 69 and solid-supported cleavable unit 73) were 
incubated with the cell lysate. After incubation with the cell lysate, biotinylated samples 
were immobilised onto a streptavidin-coated matrix. The isolated proteins were analysed 
by SDS-PAGE (Fig. 42). At the same time the mixture resulting from incubation of 
molecular probe 32 and HEK 293 cell lysate was submitted to dithionite cleavage. The 
isolated proteins were analysed by SDS-PAGE (Fig. 42). Disappointingly, it was not 
possible to interpret the results obtained from the gel electrophoresis. The experiments 
were repeated using different staining solutions (e.g. Coomassie blue, ponceau S) with 
no significant improvement in the visualisation of bands on the gel (data not shown). 
Similarly, increasing the concentration of the molecular probes (from 5 mmol ml
-1
 to 50 
mmol ml
-1




Figure 42: SDS-PAGE for pull-down experiments with HEK 293 cells. (−) = negative control; (+) 
= positive control; M = marker lane; A = cell lysate (control lane); B = supernatant after SDS 
elution of experiment with propargyl amide biotin 69 (−); C = supernatant after SDS elution of 
experiment with a biotinylated peptide (−); D = supernatant after SDS elution of experiment with 
biotinylated anisomycin 28 (+); E = supernatant after dithionite cleavage of experiment with 
matrix 73 (−, 5 mmol ml
-1
); F = supernatant after dithionite cleavage of experiment with matrix 73 
(−, 50 mmol ml
-1
); G = supernatant after dithionite cleavage of experiment with matrix 32 (+, 5 
mmol ml
-1







3.3 Future work 
 
Although the pull-down experiments with HEK 293 needed extensive optimisation to 
obtain a set of more significant data, it was envisaged that the novel azobenzene could 
be employed as means of coupling biotin to the ligand. As the binding partner of 
anisomycin is unknown, there is no data about the dissociation constant (Kd) of the 
complex they form. Hence, a more classical manifold relying on the use of the 
biotin/streptavidin affinity pair for the immobilisation onto a column and a cleavable 
unit for the release of the isolated biomolecules seemed more appealing. 
Interestingly, this strategy has been recently exemplified by Budin et al.
119
 who 
reported a model study using the bacterial type II topoisomerase, DNA gyrase, as the 
target protein and its inhibitor, the aminocoumarin novobiocin, as the molecular hook. In 
this study, a new molecular probe featuring a chemoselective cleavable azobenzene 
derivative, a biotin affinity tag for enrichment on one side and an alkyne moiety and on 
the other side, is described (Fig. 43).
119
 The use of this cleavable linker allowed the 
capture and release of native protein complexes as confirmed by functional assays. This 
work represents an elegant example of the application of this strategy on a complex 







Figure 43: Novobiocin molecular probe 85 used for the capture and release of the target, DNA 
gyrase (bacterial type II topoisomerase).  
 
Hence, an affinity-independent version of the more classical approach for target 
identification based upon immobilisation on a streptavidin-coated matrix will be next 
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attempted. The strategy described below will be applied to anisomycin and to 
bisebromoamide, a recently isolated natural product with interesting biological activity 
(Scheme 31).
122
 The biological properties of this novel cytotoxic peptide and the 
contribution to its synthesis will be discussed in chapters 4 to 6. Completion of the total 
synthesis of natural product bisebromoamide will provide another ligand to test the 
reliability of the protocol described in scheme 31. 
 
 
Scheme 31: Capture of an “unknown” affinity target for a small-molecule ligand by attachment of 
biotin to the ligand through a cleavable linker. Capture of the affinity target in solution, 
immobilisation of the biotinylated ligand complex on a streptavidin-coated matrix, elution under 








3.4 Summary and conclusion 
 
As summarised in section 2.3, a new azobenzene-based linker (compound 60) for 
affinity chromatography applications has been designed and synthesised. The molecule 
may be readily cleaved under mild non-denaturing conditions (elution with Na2S2O4) 
making it suitable for affinity-independent elution protocols. In this protocol, every 
compound of interest (whose propargyl derivative retains the biological activity of the 
lead compound) can be coupled to the terminal azide of the linker using the copper(I)-
catalysed Huisgen 1,3-dipolar cycloaddition reaction (or “click” reaction) generating a 
molecular probe for affinity studies. The model studies described in section 3.2.2 and 
3.2.3 using matrix 74 displaying a ligand (e.g. biotin) coupled to the new linker showed 
that the affinity capture of the binding partner (e.g. avidin) was both efficient and 
selective even from a complex protein mixture. The chemical cleavage (Na2S2O4) was 
directly compared to the classical elution protocol consisting in SDS boiling indicating 
similar efficiency. Indeed, the two processes are both compatible with the presence of 
the new linker. 
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4 Bisebromoamide: a new affinity target 
4.1 Isolation and biological activity 
 
The novel cytotoxic peptide bisebromoamide was isolated in 2009, from the marine 
cyanobacterium Lyngbya sp. by the Suenaga group.
122
 The absolute stereochemistry was 
recently revised by the Ye group who also carried out the first total synthesis of the 
natural product.
123
 Bisebromoamide 86 contains typical features of cyanobacteria 
metabolites such as N-methylated amino acids and residues of nonribosomal origin (Fig. 
44).
124
 The interest in this molecule is connected to its potent antiproliferative 
activity.
125
 Intriguingly, bisebromoamide presents a brominated tyrosine residue which 
provides a reactive site for the insertion of a propargyl handle. Using a protocol for the 
preparation of tyrosine derivatives optimised in the Hulme group,
126
 bisebromoamide 




Figure 44: The natural product bisebromoamide 86 (revised structure) and its propargyl 
derivative 87. 
 
The average 50% growth inhibition (GI50) was evaluated against a panel of 39 human 
cancer cell lines (termed JFCR39) at the Japanese Foundation for Cancer Research and 
found to be 40 nM. Bisebromoamide 86 exhibited cytotoxicity against HeLa S3 cells 
with an IC50 value of 0.04 μg/ml. Perhaps, the most intriguing activity is the selective 
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inhibition of the phosphorylation of the extracellular signal regulated protein kinase 
(ERK) in NRK cells by platelet-derived growth factor (PDGF) stimulation at a 
concentration of 10 to 0.1 μM. Such inhibition was not found for AKT, PKD, PLCγ1, or 
S6 ribosomal protein for the same concentration range.
122
 This preliminary data 
suggested that bisebromoamide had potential anticancer activity as a tubulin modulator. 
Such belief was not confirmed by subsequent specific tests for this class of anti-tumour 
compounds. Tubulin acetylation is one of the markers to assess the stability of 
microtubules which is affected after treatment with some tubulin modulators. After 
treatment with bisebromoamide, the levels of acetylation were unchanged. This data 
suggested that the anticancer activity of compound 86 is mainly related to the inhibiton 
of ERK phosphorylation.
122
 Aberration of the Raf/MEK/ERK mitogen activated protein 
kinase cascade is associated with various cancers.
125
 Hence, the development of new 
molecules that could selectively target components of this pathway has attracted 
increasing attention in the anticancer community.
125
 Recently small molecules targeting 
individual components of the above mentioned pathway have entered clinical trials.
122 
 
4.1.1 The Raf/MEK/ERK cascade: target-based anticancer drug discovery 
 
Historically, oncology drug discovery has relied on assessing the maximum tolerated 
dose (MTD), safety profile and efficacy.
125
 The complete understanding of the mode of 
action of even common chemotherapeutic agents has not been achieved to date. As 
scientists have collected more information about the biology of tumours, many more 
target-based or mechanism-based therapies have made their appearance on the 
market.
125
 As discussed in section 1.7.1, in connection to the biological activity of the 
natural product anisomycin 25, mitogen-activated protein kinase (MAPK) cascades play 
a crucial role in the regulation of cell proliferation, survival and differentiation.
70
 These 
cascades are comprised of three protein kinases which act as a signalling relay, mainly 
controlled by phosphorylation: a MAPK kinase kinase (MAPKKK), a MAPK kinase 
(MAPKK) and a MAPK (Scheme 32).
70
 The terminal serine/threonine kinases (MAPKs) 
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are the ERK1/2, the c-Jun amino-terminal kinases (JNK1/2/3; also called SAPKs), p38 
kinases (p38a/b/g/d) and ERK5. Generally, the ERK pathway is activated by growth 
factor-stimulated cell surface receptors, whereas the JNK, p38 and ERK5 pathways are 
activated by stress and growth factors. The downstream function of cell surface 
receptors and other proteins in the cytoplasm towards such cascades is strongly 




Scheme 32: General scheme of the mitogen-activated protein kinase (MAPK) pathways; the 
Raf/MEK/ERK cascade (green) incorporates the target of the natural product bisebromoamide 
(Figure from ref. 70). 
 
All the individual components of the Raf/MEK/ERK cascade have been considered as 
targets of new anticancer therapeutics. Rafs (MAPKKK) are Thr/Ser kinases which 
activate and phosphorylate MEK1 and 2 (MAPKK), dual specificity kinases.
127,128
 
MEK1/2 trigger phosphorylation of ERK1/2 (MAPK) and the activation of these kinases 
regulates the activity of a wide range of proteins.
129
 Most ERK substrates are nuclear 
proteins while a small portion is found in the cytoplasm and other organelles. At the 
nuclear level, they are responsible for the regulation of transcription factors such as the 
Ets family (e.g. Elk-1) resulting in gene expression.
130,131
 The identification of Raf as a 
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potent retrovirus oncogene defined the importance of this pathway in oncogenesis.
128
 
According to genetic and pharmacological studies, the role of MEK and ERK is vital for 
the activation of Ras and other oncogenes.
125
 To date, the inhibition of the kinase 
function of Raf and MEK represents the most investigated approach towards blocking 
the ERK signalling. Among the Raf inhibitors, it is noteworthy to mention sorafenib 
(Fig. 45, 88, tosylate salt of BAY 43-9006, Nexavar®), which received FDA approval in 
2005 for use in advanced renal cell carcinoma (RCC). Crystallographic analyses of this 
bi-aryl urea derivative complexed with the kinase domain of B-Raf showed that 
sorafenib bound to the ATP-binding pocket and prevented kinase activation.
132
 Among 
the MEK inhibitors, PD0325901 (compound 89) showed anti-tumour activity for a 




Figure 45: Sorafenib 88 and PD0325901 89, respectively Raf and MEK kinase inhibitors. 
 
The number of reports found in the literature suggests that the investigation of molecules 
like bisebromoamide 86, an inhibitor of the Raf/MEK/ERK cascade, is of great interest. 
Hence, it was decided to pursue the total synthesis of compound 86 and its analogues for 
subsequent affinity-based investigations. Before describing the synthetic approach 
developed in the Hulme group (section 4.4), two previous total syntheses of the natural 
product bisebromoamide will also be described (sections 4.2 and 4.3). 




Recently, the Ye group completed the first total synthesis of the natural product 
bisebromoamide which led to the reassignment of its absolute stereochemistry.
123
 The 
synthetic campaign was based on the assumption that the most challenging part would 
probably be the formation of the thiazoline heterocycle, due to the possibility of 
racemisation. Thus, this moiety was assembled from 2-methylcysteine at a late stage in 
the synthesis. The synthetic strategy consisted of the linkage of four main fragments 




Scheme 33: The retrosynthetic analysis of bisebromoamide 86. 
 
The N-Boc-4-methyl proline ester 91 and 2-methylcysteine 92 fragments were prepared 
following previously published procedures,
133,134
 while peptide derivatives 90 and 93 
were synthesised de novo. Starting from previously reported N-methyl D-tyrosine methyl 
ester 94,
135
 selective monobromination was carried out with N-bromosuccinimide and p-
toluenesulfonic acid in MeCN in satisfactory yield (Scheme 34). The use of coupling 
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agent 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazin-4(3H)-one (DEPBT) allowed the 
formation of dipeptide 95 with Boc-L-Ala-OH. Finally, saponification of 95 gave the 




Scheme 34: Synthesis of dipetide 90. (a) NBS, PTSA, MeCN, RT, (87%); (b) DEPBT, Boc-L-
Ala-OH, NMM, THF, (77%); (c) LiOH, THF/MeOH/H2O, (95%). 
 
Bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) was employed for the 







Scheme 35: Synthesis of fragment 93. (a) BOPCl, Boc-D-Leu, Et3N, DCM, (86%); (b) LiOH, 




After saponification of the ester moiety, dipetide 97 was submitted to a DEPBT-
mediated condensation with amine 98 (prepared by addition of ethylmagnesium bromide 
to Boc-protected proline-derived Weinreb amide 99)
137
 yielding the corresponding 
tripeptide. The ammonium trifluoroacetate salt 93 was obtained by cleavage of the Boc 
group (Scheme 35). The initial efforts of the Ye group to couple the fragments and form 
the thiazoline ring focused on the cyclodehydration of a β-hydroxy thioamide and 
proved unsuccessful, probably due to the sterically demanding substrates involved in the 
condensation.
123
 The final strategy commenced with the preliminary transformation of 
N-Boc-4-methyl proline ester into a nitrile derivative to avoid epimerisation (Scheme 
36).
138
 Removal of the Boc group, followed by HATU-mediated condensation, provided 
the corresponding peptide which was re-subjected to acidic cleavage of the Boc group 






Scheme 36: Fragment coupling. (a) LiOH, MeOH/H2O; (b) iBuOCOCl, NMM, THF, then NH3; (c) 
TFAA, Py, THF, (64% over three steps); (d) TFA/DCM; (e) HATU/HOAt, DCM/DMF; (f) 
TFA/DCM; (g) 
t
BuOCOCl, NMM, DCM, (35% over four steps); (h) DIPEA, EtOH (48%); (i) 
HATU/HOAt, collidine, DMF, (51%). 
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The key step of this approach was the cyclocondensation of nitrile 101 with compound 
92. This transformation was carried out in a sealed tube at 90 °C giving the important 
intermediate 102 in moderate yield as a single isomer. Finally, HATU/HOAt collidine 
mediated coupling yielded the natural product bisebromoamide 86 (Scheme 36). The Ye 
group performed cytotoxicity evaluations on both compounds 86 and its epimer (S-
configuration of the stereogenic center at the thiazoline ring) which showed that the two 




4.4 The second total synthesis of bisebromoamide 
 
More recently a new approach to the total synthesis of bisebromoamide has been 
disclosed from the Ma research group,
139
 which confirmed the structural revision 
proposed by the Ye group and gave interesting insights into the structure-activity 
relationship (SAR) of the natural product (Scheme 37).
123
 The Ma group synthesised the 
first proposed structure of bisebromoamide as reported by Teruya et al.
122
 according to 
the described retrosynthetic scheme: an initial disconnection at the thiazoline core 
generates two main fragments; cyanide 103 and protected aminothiol 104, subsequent 
disconnections at the amide bonds lead to N-methylated amino acids 106 and 107, 
dipetide 105 and tripeptide 108 (Scheme 37).
139
 As the stability of the thiazoline ring 
was a major concern, this moiety was generated at a late stage in the synthesis as in the 
previously reported approach by the Ye group.
123
 Tyrosine derivative 108 was prepared 
with a sequence of transformations analogous to the one reported by the Ye group
123
 and 
coupled to pyrrolidine derivative 106. Treatment of 109 with methyltriflate in the 
presence of LiHMDS, generated lactam 110 in high yield and with a good degree of 
selectivity (syn configuration).
140,141
 Treatment with LiBEt3H followed by Et3SiH 
furnished the reduced product 111 in very good yield.
142
 The final transformation to 
cyanide 106 was accomplished in a very similar manner to the previous report. Peptide 






Scheme 37: The retrosynthetic analysis of bisebromoamide 86. 
 
The synthesis of the remaining aminothiol fragment 104 is illustrated in scheme 39. 
Removal of the Fmoc protecting group from compound 112 under basic conditions, 
followed by coupling with D-Fmoc-Leu-OH amino acid in the presence of HATU 
coupling agent furnished the substrate for the deallylation step. Pd chemistry was used 
to displace the allyl group, and the newly revealed carboxylic acid functionality was 







Scheme 38: (a) LiHMDS, then MeOTf, toluene, (60%); (b) LiBEt3H, then Et3SiH, BF3•Et2O, 
(87%); (c) TFA/DCM; (d) NH4OH, HOBt, EDC, DMF; (e) TFAA, Et3N (99% over three steps); (f) 
Pd/C, H2, THF, (99%); (g) HATU, HOAt, DIPEA, (82%). 
 




Scheme 39: (a) Et2NH, MeCN; (b) D-Fmoc-Leu-OH, HATU, DIPEA, DCM (95% over two steps); 
(c) Pd(PPh3)4, NMA, THF; (d) 114, HATU, HOAt, DIPEA, DCM (94% over two steps); (e) Et2NH, 
MeCN; (f) 107, HATU, HOAt, DIPEA, DCM (76% over two steps); (g) DMP, NaHCO3 (100%); (h) 




The coupling strategy optimised for the synthesis of fragment 105 was applied to the 
successful preparation of tetrapeptide 116 which was then submitted to Dess-Martin 
oxidation to give important intermediate 104 in quantitative yield.
139
 Following TFA-
mediated double deprotection of amino thiol 107, the target molecule was finally 
prepared, through coupling of 103 to cyanide 104 in the presence of NaHCO3 in a 
mixture of methanol and buffer.
144
 However, the spectroscopic data of a natural sample 
of bisebromoamide did not match that of the prepared molecule. The structure proposed 
by the Ye group (R-configuration of the stereogenic center at the thiazoline ring, 










This second report confirmed that the absolute stereochemistry of this natural product is 
the one proposed by the Ye group (despite the preliminary assignment following 
isolation). In addition to the syntheses of 86 and 117, simplified analogues of the natural 
product were prepared.
139
 The most intriguing results were obtained with a simplified 
analogue of 86 featuring a proline amino acid instead of 4-Me-Pro. This compound 
proved as potent as the natural product making it an ideal candidate for further structure 




4.5 Hulme group strategy 
 
The proposed synthetic strategy is based on the assembly of seven fragments of which 
three; pivalic acid, and the amino acids alanine and isoleucine, are commercially 
available (Scheme 40). 
 
 
Scheme 40: The retrosynthetic analysis of bisebromoamide proposed in the Hulme group. 
 
Fragments 120 and 121 will be prepared according to published procedures.
145,146
 The 
synthesis of tyrosine derivative 118 will be carried out according to a methodology 
previously developed in the Hulme group.
126
 Fragment 119 will result from the coupling 
of the thiazoline ring, prepared as reported previously
147
 and N-Me-Proline. The 





4.6 Occurrence of 4-methyl proline in natural products 
 
While discussing the isolation of bisebromoamide, it was noted that the most intriguing 
structural feature of this natural product is the 4-methylproline-derived thiazole, which 
was unprecedented until the isolation of the dysideaproline series from the marine 
sponge Dysidea sp.
148
 Conversely, the occurrence of the 4-methyl proline amino acid is 
well documented in natural products of biological importance.
149,150,151
 Recent examples 
are; the nospeptides A and B, potent elastase and chymotrypsin inhibitors from 
cyanobacterium Nostoc minutum,
149
 the glycosidic compound suomilide from Nodularia 
spumigena
150
 and the pteratide series, cytotoxic cyclodepsipeptides from Malaysian 
Basidiomycete Pterula sp.
151
 Proline and its derivatives are often responsible for 
secondary structural motifs in proteins, such as kinks in α-helices and reverse turns.
152
 
The understanding that the presence of proline amino acids could influence the 
conformation of the peptide backbone
153
 has increased the interest in the synthesis of 
substituted analogues. Proline-induced turns in close proximity to pharmacophores are 
often fundamental for biological recognition.
154
 As a consequence of these properties, 
desired functionalities can be projected into specific regions of space within proteins. 
Furthermore, the incorporation of proline derivatives into peptides and peptidomimetics 
remains a valuable tool for structure-activity relationship (SAR) elucidation.
155
 Gmeiner 
et al. utilised this concept elegantly in the development of new 2-methoxybenzamide 
derivatives,
156,157
 a class of compounds used for treatment of psychotic disorders 
including schizophrenia.
158
 The mechanism of action of these compounds is mediated by 
the binding to dopamine and serotonin receptors (D1 to D5 and 5-HT1 5-HT4 
respectively). Unfortunately, their remarkable binding affinity for the dopamine 
receptors D2 is associated with a series of side effects.
159
 The aim of this study was to 
synthesise new 2-methoxybenzamide analogues featuring prolinol derivatives which 
could potentially result in a reduced affinity for these specific dopamine receptors. 
Starting from natural 4-hydroxyproline, all the 2-aminoalkyl pyrrolidine stereoisomers 
were prepared and coupled to benzoic acid derivatives (bearing the pharmacophore for 
antipsychotic activity) leading to the preparation of a series of analogues. Dopamine and 
 
 94 
serotonin receptor binding studies were performed to gain insight into the SAR of all 
different stereoisomers prepared. Binding studies involving the subtypes D1, D2long, 
D2short, D3 and D4 as well as 5-HT1A and 5-HT2, displayed different SARs, especially 
with respect to the absolute and relative configuration of the test compounds (Fig. 47). 
The aminomethyl pyrrolidine derivative 122 and the aminobutyl pyrrolidine derivative 
123 showed remarkable affinity and preference for the dopamine D3 and D4 receptor 




Figure 47: Potential antipsychotic candidates 122 and 123. 
 
4.7 Previous approaches to the synthesis of 4-methyl proline 
 
Two methodologies for the synthesis of 4-methyl proline, from the Goodman
160
 and the 
Munro
133
 research groups will be discussed before describing the approach proposed in 
the Hulme group. 
 
4.7.1 Del Valle and Goodman synthesis of 4-methylproline  
 
As part of a peptidomimetic research program aimed to the development of novel 
pyrrolidine-based building blocks,
160
 the Goodman group envisaged a new route for the 
synthesis of novel 4-arylalkylprolinols and prolines. Starting from trans-4-
hydroxyproline 124, compound 125 was readily prepared using modified literature 
procedures (Scheme 41).
161,162
 Carrying out the synthesis of 125 on the Boc-protected 
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amino acid and performing the reduction step on a mixed anhydride formed in situ was 
found to be convenient especially for the scalability of the process (Scheme 41). 
Compound 125 was submitted to TEMPO-mediated oxidation
163
 yielding pyrrolidinone 
126 which was subjected to Wittig olefination with various triphenylphosphoranes to 




Scheme 41: (a) Boc2O, 10% aq Na2CO3,/dioxane; (b) isobutyl chloroformate, NMM, DME; (c) 
NaBH4 in H2O, (76%, over three steps); (d) TBDMSCl, Et3N, DMAP (cat.), DCM, (78%); (e) 
trichloroisocyanuric acid, TEMPO (cat.), DCM, (88%); (f) ylide, THF, (64-85%). 
 
At this point, two different synthetic paths were envisaged for the hydrogenation step 
required to generate the proline derivatives. Previous studies on the asymmetric 
hydrogenation carried out by the Goodman research group,
164
 led to the conclusion that 
the presence of the protecting group on the hydroxymethyl substituent of substrate 127 
had a dramatic effect for the facial selectivity of the hydrogenation (Scheme 42). When 
the reaction was carried out with silyl-protected pyrrolidine 129, delivery of hydrogen 







Scheme 42: The Crabtree catalyst 128 and the hydrogenation studies in the Goodman group. 
 
Hydrogenation in the presence of Crabtree catalyst 128 with pyrrolidine 131 gave rise to 
trans-substituted pyrrolidine 132.
165
 The exceptional diastereoselectivity is due to the 
coordination of the catalyst to the directing hydroxyl group. Based on this premise, silyl-
protected pyrrolidine 127 was subjected directly to hydrogenation to achieve cis-




Scheme 43: (g) 0.5 M TBAF in THF, (80-95%); (h) Ir(COD)PyPCy3PF6, (3 mol%), H2, DCM, (78-
94%); (i) NaClO2, NaClO (cat.), TEMPO, pH 6.7 phosphate buffer (0.67 M NaH2PO4)/MeCN, 
(80-89%); (j) Raney-Ni, MeOH, (77-85%). 
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The best results were obtained when Raney-nickel was used as the hydrogenation 
catalyst, with stereoselectivity for the cis isomer up to 16:1. Hydrogenation with iridium 
catalyst 128, performed on pyrrolidine 133 carrying the newly revealed hydroxyl group, 
proceeded with trans-selectivity as expected, with a greater degree of selectivity. The 
trans-series could be prepared with >40:1 selectivity for most of the substrates 
investigated. The synthesis of alkylproline derivatives 135a to 135e was readily 
completed with a TEMPO-mediated oxidation at the primary alcohol to give the 
required carboxylic acid.
166
 The same oxidation conditions proved sluggish on 
indolylprolinol derivatives 134f and 137f giving rise to an inseparable mixtures of side 





4.7.2 Munro’s modification 
 
More recently, the strategy proposed by Del Valle and Goodman was slightly modified 
to give a more convergent approach to the synthesis of all four diastereoisomers of 4-
methylproline.
133
 The key transformation in the former synthesis was the asymmetric 
hydrogenation which relied on the directing effect of the hydroxyl substituent on the 
Crabtree catalyst (for the trans-series).
164
 Based on the assumption that an ester 
functionality should similarly influence the stereochemical outcome of this reaction,
167
 a 
more succinct route was proposed.
133
 Starting from the least expensive of the four 
diasteroisomers of 4-hydroxyproline, trans-4-hydroxy-L-proline and cis-4-hydroxy-D-
proline, esterification and Cbz-protection proceeded smoothly (Scheme 44). The 
oxidation step, carried out with chromium oxide, achieved 140/ent-140 in good yield. 
Olefination on 140/ent-140 was attempted using a modified Wittig olefination.
168
 
However, these conditions led to epimerisation of the α-center. When the milder Petasis 








Scheme 44: (a) SOCl2, EtOH, reflux, 4 h; (b) CbzCl, Et3N, MeOH, RT, 16 h; (c) CrO3, Py, DCM, 
RT, 16 h (80% for 140 and 67% for ent-140 over three steps; (d) dimethyltitanocene, toluene, 90 
°C, 3 h (56% for 141 and 42% for ent-141); (e) Crabtree’s catalyst, CHCl3, H2, 5 d, (84% for 144 
and 80% for ent-144); (f) Pd/C, DCM, H2, 16 h, (67% for 142 and 100% for ent-142); (g) HCl(aq) 6 
M, 70 °C, 6 h, (100% for 145 and 87% for ent-145). 
 
Hydrogenation on substrate 141 using Pd/C catalyst with concomitant Cbz-removal 
readily achieved cis-substituted compound 142. Munro and colleagues performed 
Marfey‟s derivatisation
170
 of each of the diastereoismer of the 4-methyl proline which 
allowed determination of the optical purity by HPLC analysis.
133
 The cis-series showed 
an improved diastereoselectivity (7:1) with comparison to the Goodman approach 
(3:1).
160
 Homogeneous hydrogenation conditions with the Crabtree catalyst on the same 
substrate yielded only the isomerisation product enamine 143/ent-143 after 16 h. Alkene 
migration under Crabtree catalyst mediated hydrogenation is reported in the literature.
171
 
Nevertheless, a longer reaction time (5 d) achieved the desired trans 4-methyl proline 
derivative. The selectivity was remarkably reduced for the trans-series (15:1) compared 







Munro‟s protocol for the synthesis of 4-Me-Pro was one of the most attractive found in 
the literature.
133
 Although the synthetic sequence is quite concise, the limited cis-
selectivity for the hydrogenation step and the use of chromium oxide for the oxidation 
reaction suggested that the investigation of a new route was needed. Furthermore, the 
abundance of this unusual amino acid in natural products of biological importance 
underlined the utility of a novel synthetic approach. The proposed strategy for the 
synthesis of 4-Me-Pro started from Schiff bases prepared from glycine esters. 
Asymmetric alkylation in the presence of a chiral phase transfer catalyst (PTC) would 
provide the required absolute stereochemistry. After transformation of the conjugated 
imine into an enamide, ring closing metathesis (RCM) would yield the desired 5-





Scheme 45: Key transformations of the novel synthetic approach to 4-Me-Pro. 
 
This succinct synthetic sequence (6 steps) would then allow a more efficient approach to 
this key amino acid required for the total synthesis of bisebromoamide. 
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5.1 Asymmetric alkylation of glycine Schiff bases 
 
The great interest of the synthetic community in phase-transfer catalysis is well 
documented in the literature by countless reports over the last two decades.
172,173
 Mild 
reaction conditions, the ease of experimental procedures and readily available and 
inexpensive starting materials account for the attention from both academic and 
industrial synthetic groups. The first report of an asymmetric reaction employing 
cinchona alkaloids was disclosed at the end of the 1970s by the Sharpless group
174
 
describing the use of a cinchona derivative as a co-ligand for OsO4 in dihydroxylation 
reactions. In 1984, in a series of pioneering experiments, Dolling and co-workers at the 
Merck laboratories successfully carried out the asymmetric methylation of indanone 
derivatives using cinchona catalyst 146, thus introducing this new class of catalysts (Fig. 
48, first generation).
175
 The development and the successful application of such catalysts 
over the last two decades, for asymmetric alkylation of amino acids will be briefly 
discussed. In this regard, it is noteworthy to mention the outstanding research of 
Maruoka and collaborators
173
 for design of naphtyl-modified phase transfer catalysts 
(Fig. 48, 147) for asymmetric alkylation of amino acids. Although the work of Maruoka 
and collaborators gave an important contribution to this area of synthetic 
methodology,
176




Figure 48: Cinchona-derived PTC 146 (first generation) and synthetic PTC 147 (Maruoka type). 
 




Despite the wide variety of applications of this remarkable class of catalysts, the precise 
mechanism of action is not fully understood and is often simplified as in figure 49. The 




) is involved in the formation of a nucleophilic ionic 
complex with an anion of the nucleophile (e.g. an active methylene compound) 
generated by deprotonation by an inorganic base at the interface of the organic and 




) is formed, it reacts with an 
electrophile (e.g. an alkyl halide, unsaturated enone, Schiff base, aldehyde or ketone) 
yielding the product (Nu-E). The liberated quaternary ammonium salt returns to the 




Figure 49: Proposed interface mechanism in the presence of a cinchonidine-derived quaternary 
ammonium salt. 
 




 that the transfer of 
the chiral information takes place; the least sterically hindered face is approached by the 
electrophile to furnish the desired chiral product. 
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5.1.1.1 N-9-anthracenylmethyl-cinchona PTCs (second generation) 
 
Following the investigations of Dolling at the Merck laboratories,
175
 O‟Donnell and co-
workers developed a similar PTC for the asymmetric benzylation of N-
(diphenylmethylene)glycine tert-butyl ester 148 obtaining alkylated product 149 with a 
good degree of selectivity (up to 66% ee, scheme 46).
177
 This product could be 
hydrolysed to afford α-amino acid phenylalanine in high yield. However, the attention of 
the synthetic community towards this research area only flourished significantly after 
the introduction of catalysts 151 and 152 by the Lygo
178
 and the Corey
179




Scheme 46: Asymmetric benzylation of N-(diphenylmethylene)glycine tert-butyl ester 148 and 
the PTCs from O’Donnell (150, ent-150), Lygo (151, ent-151) and Corey (152) research groups. 
(a) PTC 150 or ent-150 (10 mol%), 50% NaOH(aq), DCM, RT, 9 h, (75%, 66% ee for 149 and 
85%, 64% ee for ent-149); (b) PTC 151 or ent-151 (10 mol%) 50% KOH(aq), toluene, RT, 18 h, 
(63%, 88% ee for 149 and 69%, 91% ee for ent-149); (c) PTC 152 (10 mol%), CsOH·H2O, DCM, 




These groups independently developed a new class of cinchona PTC featuring a N-9-
anthracenylmethyl group (Scheme 46, second generation). This aromatic unit is bulkier 
than the benzyl group present on the first generation PTCs, probably allowing the 
catalysts to perform much better in the same asymmetric transformations (Scheme 45). 





5.1.1.2 Polymeric PTCs (third generation) 
 
Investigations by Sharpless et al. aimed at improving the enantioselectivity and 
expanding the substrate scope of the Sharpless asymmetric dihydroxylation, led to the 






Scheme 47: Asymmetric benzylation. PTC (5 mol%), 50% KOH, toluene/CHCl3, 7/3, -20 °C, 




The same concept was subsequently applied to cinchona PTCs for the asymmetric 





 cinchona PTCs (polymeric PTCs, third generation) di- and tri-substituted in 
the meta, ortho and para positions, using a phenyl spacer. These catalysts were 
evaluated for asymmetric benzylation (Scheme 47). The meta-dimers performed 
remarkably better than the others (meta 94% yield, 95% ee; ortho 88% yield, 35% ee; 
para 92% yield, 86% ee) – the authors speculated this was due to steric factors.
182
 One 
year later, the same team developed an improved series of meta-dimeric cinchona PTCs 
featuring a naphthalene unit as spacer.
184
 The naphthalene spacer in compound 155 (2.4 
Å longer than the phenyl spacer in 153) allows a more favourable conformation which 
decreases the steric hindrance between the two alkaloid units. PTC 155 bearing a 
hydrocinchonidine unit showed better solubility than the unsaturated counterpart 
allowing a lowering of the catalyst loading. The applicability of the 2,7-naphthyl 
dimeric PTC 155 was demonstrated by the Park-Jew team in the first enantioselective 






Scheme 48: First enantioselective synthesis of (+)-hygrine. (a) PTC 155 (10 mol%), 
toluene/CHCl3, 0 °C, 7 h, (95%, 97% ee); (b) Grubbs II catalyst, DCM, RT, 3 h, (99%). 
 
Key steps in the synthesis were asymmetric alkylation of Schiff base 148 with methallyl 
bromide and ring closing metathesis (RCM) for the construction of the pyrrolidine ring. 
Interestingly, epimerisation of the chiral center was not reported after the metathesis 
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reaction. Alkylated product 156 could be converted to (+)-hygrine in a further ten steps 




5.1.1.3 Electronic factor-based cinchona PTC (fourth generation) 
 
The cinchona PTCs of the first three generations were designed mainly taking into 
account steric factors while the electronic properties were not systematically 
considered.
186
 The ion pair of the cinchona quaternary ammonium cation and the anionic 
substrate plays a dramatic role in the transfer of the chiral information, thus, the 
electronic effects of the substituent may influence the enantioselectivity. On this 
assumption the Park-Jew team started to explore the effect of electron withdrawing 
functional groups.
186
 The most representative compound is probably the fluorine 
derivative PTC 159 (X = F) which gave the best performance in the asymmetric 
benzylation reaction.
186
 This result was rationalised by the formation of a network of 
hydrogen bonds among molecules of water, the oxygen of the ether functionality and the 
fluorine atom. The role of the fluorine atom at position 2 was fundamental for the 
enantioselectivity on the model reaction. Although comparable degrees of selectivity 
were obtained with other electron withdrawing groups (e.g. nitrile and nitrogen oxide) at 




Figure 50: Coordination with molecules of water via hydrogen bonding results in a more rigid 




An example of the successful application of the fourth generation PTC was the 
asymmetric dialkylation of the aldimine system (Scheme 49).
187
 After optimisation of 
the reaction conditions and substrate, a series of α-alkylalanines (161a-h) were prepared 




Scheme 49: Enantioselective phase-transfer catalytic alkylation for α-alkylalanines. (a) RbOH, 
toluene, -35 °C. 
 
It is worth noting that solid-supported and supramolecular cinchona PTCs, have also 
been employed in the enantioselective synthesis of α-amino acids.
188,189
 Despite many 
reports and groups working in this research area, the number of organocatalytic 
reactions using cinchona PTCs remains limited. Greater structural diversity and the 








Due to their variety, their occurrence in biologically relevant compounds (e.g. antibiotic 
bacillaene) and their synthetic utility, dienamides are attractive chemical 
intermediates.
190,191
 The most widespread synthetic application is as the diene in the 
Diels-Alder reaction.
192
 More recently, dienamides have been employed in asymmetric 
cycloadditions.
193
 In 2008, an intramolecular Diels-Alder reaction featuring dienamides 
for the synthesis of hexahydroindole carboxylic acids was reported.
194
 Hexahydroindole 
carboxylic acids were targeted by the research group as building blocks for the synthesis 
of the natural product rostratin C. Starting from readily prepared amino ester 
hydrochloride 162, condensation with crotonadehyde proceeded smoothly to yield an 
unstable imine derivative.
194
 This imine was isolated by filtration and immediately 
treated with tertiary amine diethylaniline in the presence of a series of acid chlorides. 
With these protected enamides in hand, the group managed to prepare four 







Scheme 50: Preparation of hexahydroindoles derivatives. (a) crotonaldehyde, Et3N, RT, 15 h, 
(94%); (b) RCl, PhNEt2, toluene, 0 °C to RT, 12 h, (45-96%); (c) N,O-bistrimethylsilylacetamide 
(BSA), toluene, (pressure vessel), 130 to 210 °C (51-62%). 
 
 108 
The methodology for the preparation of the dienamide precursors was developed in 
1975 by the Oppolzer group.
195
 Following previous studies on the use of dienamides as 
substrates for Diels-Alder reactions,
196,197
 the preparation of a series of new dienamides 




Scheme 51: Mechanism of enamide formation in the presence of a strong base at low 
temperature vs simplified method using milder conditions. 
 
Dienamide 169 was initially prepared using strong bases (e.g. NaHMDS) at low 
temperatures
198
 according to the mechanism proposed in scheme 51: deprotonation of 
166 to give intermediate 167, followed by N-acylation of anion 167. Alternatively, prior 
acylation of the imine 166 by an acid chloride provides delocalised cation 168, which 
then needs only a mild base to give the desired dienamide 169. This methodology has 
been applied in the proposed strategy for the synthesis of 4-Me-Pro discussed in chapter 
6. Asymmetric cycloadditon using dienamides was reported by Rawal et al.
193
 in 
connection to their research on the chemistry of 1-amino-3-siloxy-1,3-butadienes. These 
substrates undergo Diels-Alder reaction in the presence of α-substituted acroleins with 
excellent regio- and endo-selectivity. However, it is not possible to discriminate between 
the two enatiomeric endo adducts obtained. The group envisaged that the use of a chiral 
Lewis acid, such as Jacobsen‟s Cr(III)-salen could selectively provide the desired Diels-
Alder adduct. The screening of several counterions of catalyst 172 and alkyl substituents 
on substrate 170 provided the best reaction conditions with enantioselectivity up to 97% 
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(Scheme 52). The optimised conditions were applied to a series of substituted 




Scheme 52: Asymmetric Diels-Alder reaction. (a) methacrolein, catalyst 172 (5 mol%), DCM, -
40 °C, 2 d (~48 h), (93%, 97% ee).  
 
5.3 Enamide-Olefin Ring-closing metathesis (RCM)  
5.3.1 Ring closing metathesis (RCM) and importance in total synthesis 
 
Since Grubbs and his group developed ruthenium catalyst 173 in 1992 and showed the 
synthetic utility of this methodology,
199
 ring closing-metathesis (RCM) has become one 
of the most attractive tools for carbon-carbon bond formation in industrial and academic 
laboratories.
200
 Common RCM catalysts are: first and second generation Grubbs 
catalysts (Fig. 51, Grubbs I and II, 173 and 175),
201,202
 the molybdenum-based reagent 
(Shrock reagent, 177),
203
 first and second generation Hoveyda-Grubbs catalysts (178 
and 179).
204,205
 The introduction of Grubbs II catalyst allowed for ring closure of 
unsaturated carbonyl compounds.
202
 Although the molybdenum-based catalysts are more 
active and offer better selectivity in asymmetric RCM,
206
 the ease of handling, air 
stability and functional group tolerance of the ruthenium-based catalysts make them the 
most commonly employed catalyst in RCM reactions.
207





 and small-molecule libraries
210







Figure 51: Structures of the most common RCM catalysts. Mes = 2,4,6-trimethylphenyl. 
 
A recent report of the total synthesis of alkaloid (−)-nakadomarin A combines 
organocatalysis and a RCM-based methodology.
211
 This marine alkaloid has displayed 
cytotoxic activity and it is not accessible in significant amount through extraction.
212
 
The synthetic plan for nakadomarin A was based on multiple carbon-carbon bond 
forming steps and cascade sequences which allowed a more concise synthesis. The 
retrosynthesis highlights the main transformations involved: a highly Z-selective olefin 
metathesis, a diastereoselective multicomponent nitro-Mannich/lactamisation and 
asymmetric Michael addition using cinchona catalyst 186 (Scheme 54). Fragment 185 
was prepared in six steps from the tosylate of pyroglutamol. In this synthetic sequence 
the first example of intramolecular Z-selective Julia-Kocienski olefination was 
reported.
213
 Fragment 185 was constructed in four steps from inexpensive materials to 
yield furanyl nitro olefin 184. At this point, cinchona derivative 186, known for its 
remarkable selectivity in Michael addition reactions, was successfully employed 
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allowing for the preparation of nitro ester 183 as 10:1 mixture of diastereoisomers. 
Subjecting 183 to a three component nitro-Mannich lactamisation according to a 







Scheme 53: Retrosynthetic analysis of (−)-nakadomarin A. 
 
Gratifyingly, the reduction step proceeded in a regioselective manner on the six-
membered lactam, in the presence of LiAlH4 at low temperature to give the 5-membered 
lactam 188 in high yield (Scheme 54). After extensive optimisation, hydride delivery 
was achieved with DIBAL in toluene at -20 °C; to the resulting mixture was added a 
chilled aqueous solution of hydrochloric acid and heated for 24 h. This 
reduction/iminium ion formation/diastereoselective carbon-carbon bond-forming 
cyclisation was unprecedented. The last step of this synthetic sequence, highlighted in 
2010 in a report by Martin and Vanderwal,
215
 features a Z-selective ring-closing 
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metathesis using Grubbs I in the presence of an excess of either (+)- or (−)-
camphorsulfonic acid (CSA). Due to the stereoselectivity and convergence of the route, 




Scheme 54:The total synthesis of (−)-nakadomarin. (a) PTC 186 (15 mol%), toluene, 30 °C, 8 d, 
(57%, 91:9 dr); (b) hex-5-enamine, CH2=O, MeOH, reflux, 3 h, (68%); (c) AIBN, Bu3SnH, 
toluene, reflux, 4 h, (70%); (d) LiAlH4, toluene, -20 °C, 1 h, then HCOOH, RT, 14 h, (86%); (e) 
DIBAL, toluene, -20 °C, 1 h, then HCl, 90 °C, 24 h, (41%); (f) Grubbs I, (+)-CSA, DCM, reflux, 
3.5 h, (62%, 63/37 = Z/E). 
 
5.3.2 Ene-enamide Ring Closing Metathesis 
 
Despite the plethora of successful applications of RCM, the reports of sulphur, 
phosphorus, and nitrogen-containing heterocycles obtained through olefin metathesis are 
not abundant. In particular, RCM of olefinic enamides was unprecedented until 2001, 
when Rutjes and co-workers reported the preparation of five and six-membered cyclic 
enamides.
216
 The Rutjes group investigated the reactivity of a series of protected 
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enamides towards olefin metathesis in the presence of Grubbs I at temperatures between 
20 and 40 ºC.
216
 The first results were not very encouraging. Indeed, RCM on substrates 
189a-d, with a methyl substituent at position 1, proved sluggish. However, the use of 
more stable Grubbs II at higher temperatures readily yielded product 190 (Table 2). 
Partial degradation of starting material and product was reported for substrates with a 
benzoyl or ethoxycarbonyl protecting group, when increasing the temperature. 




Table 2: RCM of olefinic enamides: 17,5 μM substrate concentration; 1-5 mol%. Grubbs I was 
used in DCM, while Grubbs II was used in dichloroethane. 
 
Since RCM is often employed for the synthesis of pharmaceutically relevant 
molecules,
217
 the question of lowering the catalyst loading has been posed recently.
218
 
As ruthenium removal can be a cumbersome process, decreasing the loading could 
minimise the risk of ruthenium contamination. In this regard, the investigation 
conducted by Pederson et al. proved that using more efficient ruthenium-based catalysts 
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could yield five-, six-, and seven-membered carbamate-protected cyclic amines 






Figure 52: Some of the ruthenium-based catalysts involved in the investigation. Mes = 2,4,6-
trimethylphenyl. 
 
The screening process was performed by Symyx robotic technology to test a large 
number of RCM reactions using ppm catalyst loading and establish the efficiency of the 
catalyst considering both reaction conditions and substrate design (Table 3). Catalysts 
193 and 194 were the most efficient in this RCM reaction. The reaction could be carried 
out neat for five-membered rings while more dilute substrate concentrations were 
needed for larger rings. The screening of several ruthenium-based catalysts for 
trisubsituted heterocyclic olefins proved that NHC-bearing catalysts were more efficient 
at low catalyst loadings. Satisfactory results were also obtained for tetra-subsituted 
alkenes. In the presence of catalyst 194 and with methyl tert-butyl ether (MTBE) as 








Table 3: Effects of concentration on the formation of di-substituted five- and six-membered 
carbamate protected cyclic amines by catalyst complex 194. All the reactions were carried out at 
50 °C.  
 
5.3.4 Applications in total synthesis  
 
Finally, the first example of macrocylisation using an ene-enamide RCM for the total 
synthesis of cyclopeptide alkaloid (−)-paliurine E is worthy of discussion.
219
 The 
retrosynthetic strategy is based on the connection of hydroxyproline-styrene fragment 
202 to a series of enamides 201a-d in order give ene-enamide substrates 200a-d for the 
key RCM macrocyclisation step (Scheme 55). It was envisaged that coupling to the last 
phenylalanine derivative portion at the pyrrolidine nitrogen would yield the desired 
natural product. In order to evaluate the reactivity of different substrates towards RCM, 
different ene-enamides were prepared from N-Boc-isoleucine (Scheme 55).
219
 Careful 
removal of the Boc protecting group using anhydrous zinc bromide, followed by EDC-
HOBt mediated coupling with carboxylic acid 202 furnished ene-amides 201a-d in good 
overall yields. These compounds were subjected to RCM in the presence of Grubbs II 







Scheme 55: The retrosynthetic analysis of paliurine E. 
 
Reaction on substrate 201a proved sluggish under the conditions described below, 
yielding primary amide 203 (Scheme 56). This amide was formed even in the absence of 
the catalyst, thus suggesting instability of the starting material. The presence of a methyl 
group on ene-enamide 200b probably conferred greater stability to the substrate 
allowing macrocyclisation in a preparatively useful yield (49%). The uses of additives 
for this transformation did not lead to significant optimisation.
220
 RCM did not take 
place for substrate 200c; an alternative relay RCM was then considered for this 
particular substrate which unfortunately led to an unidentifiable mixture of products.
221
 
The most stable of the ene-enamides considered, compound 200d featuring a benzyl 
group did not react significantly but decomposed to amide derivative 205 which 
possessed an unusual aldehyde in place of a styrene double bond. The formation of this 
side product will be discussed in the next chapter, in connection to the results of the 






Scheme 56: Synthesis of ene-enamide substrates and RCM. (a) ZnBr2, DCM, 0 °C to RT; (b) 
203, EDC, HOBt, NMM, DMF, 0 °C to RT (86% for 202a, 79% for 202b, 85% for 202c, 91% for 
202d) (c) Hoveyda-Grubbs II (2 x 10 mol%), dicholoroethane (0.005 M), reflux, (8% of 200 for 
201a, 49% of 200 for 201b, no product for 201c, no product for 201d); (d) Hoveyda-Grubbs II (1 
E), dicholoroethane (0.005 M), reflux, (39% of aldehyde 205).  
 
In addition to this new methodology, the group found that fragment 200 could be 
prepared through an intriguing sequence of a ruthenium-catalysed isomerisation 
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followed by ene-enamide RCM (after removal of the benzyl group on substrate 201d), 
thus shortening the synthesis.
222
 Natural product (−)-paliurine E was obtained from 200 
following deprotection of the pyrrolidine nitrogen and coupling to N,N-dimethyl-L-
phenylalanine. This report outlines the potential of ene-enamide RCM while providing 
interesting insights into the macroyclisation mediated by this reaction. 
 
5.4 Selective hydrogenation of cyclic enamides  
 
The synthesis of 4-Me-Pro by Munro et al.
133
 (reported in section 4.8.2) described the 
selective hydrogenation of an exocyclic di-substituted double bond in pyrrolidine 
derivatives with concomitant removal of a Cbz protecting group. This reaction was 
performed with a good degree of cis-selectivity using Pd/C. Pyrrolidine substrate 206 
features an endocyclic tri-substituted double bond, hence it is not possible to predict the 
stereochemical outcome of the reaction for this isomer directly. Several homogeneous 
and heterogeneous stereoselective hydrogenation protocols have been developed in the 
last few decades,
223




Scheme 57: Selective hydrogenation of cyclic enamide and Cbz removal. 
 
Stereoselective hydrogenation of tri-substituted double bonds of enamides has been 
reported by Baldwin et al. in connection to their studies towards the synthesis of the 
kainoids (a family of non-proteinogenic aminoacids). Their substrates featured a 







Table 4: Investigations into the catalytic reduction of cyclic enamide 208. (a) Reduction of the 
phenyl groups occurred; (b) no reaction. 
 
After investigation of a series of reaction conditions, the use of palladium black as a 
catalyst gave the best results in terms of yield and selectivity (81% of diastereoisomer 
209). The use of homogeneous catalysts such as Wilkinson‟s and Crabtree‟s catalysts 
over a range of temperatures and pressures failed to reduce enamide 208, probably 
because of the steric hindrance imposed by the tri-substituted double bond.
224
 In order to 
investigate the role of the substituents, methyl analogues at position 2 and 3 were 
prepared. In agreement with a previous report, the substituent in position 2 had a 
dramatic effect on the stereoselectivity of the reduction step.In a recent report platinum 




In this chapter a general overview of the synthetic methodologies investigated 
for the novel approach towards the synthesis of 4-Me-Pro has been given. The results of 





6 Results and discussion 
 
The synthetic efforts (Scheme 58) towards the synthesis of racemic 4-Me-Pro will be 




Scheme 58: Key transformations of the novel synthetic approach to 4-Me-Pro. 
 
The methodologies investigated to install the stereochemistry at the α-position 
(compound 212), Pd-catalysed allylation (section 6.3.1) and PTC-catalysed asymmetric 
alkylation (section 6.3.2), will be also discussed. 
 
6.1 Racemic route A 
 
The first racemic route started with the preparation of Schiff base 218 from the 
inexpensive starting material methyl glycine ester hydrochloride
227
 and allyl carbonate 
217 from the alcohol precursor.
228
 These species, which could be readily synthesised in 
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Scheme 59: Racemic route A. (a) Et3N, DCM, MgSO4; then PhCHO, ~18 h, (99%); (b) dry THF, 
Pd(PPh3)4, 5-7 h, RT, (72%); (c) 1.5 M HCl(aq),2 h, RT, (85%); (d) acetaldehyde, DCM, molecular 
sieves, 0 °C to RT,~18 h, (traces); (e) i. crotonaldehyde, DCM, molecular sieves, RT, ~18 h; ii. 
benzyl chloroformate, toluene, N,N-Diethylaniline, 0 °C to RT, ~18 h, (49%).  
 
The reaction proceeded smoothly to give monoallylated Schiff base 219 in 5-7 h in the 
presence of 1.5 equivalents of allyl carbonate 217. Longer reaction times and the use of 
a higher number of equivalents of allyl carbonate resulted in a mixture of mono- and di-
allylated products as confirmed by analysis of crude NMR (data not shown). Although 





process resulted in partial hydrolysis of the imine group yielding benzaldehyde and the 
primary amine. This problem was clearly connected to the acid-sensitive nature of the 
imino-group, thus different purification protocols were investigated. Silica deactivation 
by adding 0.1% triethylamine to the eluent before sample loading did not improve the 
overall yield. The use of activated alumina (neutral and basic, Brockmann I) limited the 
decomposition but resulted in low recovery of product 219. Finally, the crude product 
was filtered through a short plug of either basic alumina or Celite in order to remove the 
palladium residues and the material was used without further purification. Hydrolysis of 
the imino group was readily achieved under acidic conditions yielding primary amine 
220 and benzaldehyde as a side product.
229
 At this point, the possibility of using either 
acetaldehyde or crotonaldehyde for imine condensation with 220 was investigated. 
Although the difficulties of handling acetaldehyde (bp ~20 °C) and the possible 
instability of the product 221 were obvious, this route was more appealing because of 
the formation of a more reactive substrate, (following conversion to the corresponding 
enamide, i.e. compound 222) towards RCM. Encouragingly, in 1994 the use of 
acetaldehyde in imine condensation reactions was reported for the preparation of N-






Scheme 60: Synthesis of N-phosphonoalkyl dipeptide inibhitor 229. (a) Acetaldehyde; then 
dibenzyltrimethylsilyl phosphate, DCM, 0 °C; (b) NaOH, MeOH, H2O; (c) H2NCH(Me)CONHMe, 
EDC, HOBt, DCM; (d) EtOH, 10% Pd/C, H2.  
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In addition, the belief that the use of acetaldehyde could generate the desired 
intermediate 222 was supported by other reports.
232,233
 In order to prepare iminoester 
221, a solution of amine 220 in DCM was cooled to 0 °C in the presence of molecular 
sieves. Acetaldehyde was added and the stirring was continued at RT overnight (~18 h). 
Although formation of the product was confirmed by LCMS, crude 
1
H NMR showed an 
unidentifiable mixture of products. The use of shorter reaction times or different drying 
agents (e.g. MgSO4) did not improve the results. Imine condensation carried out with 
crotonaldehyde instead,
194
 yielded the desired iminoester 225 as confirmed by LCMS 
and crude 
1
H NMR. This product could not be stored for any significant length of time 
and was used without further purification for the next step. Following the protocol 
described in chapter 5 for the preparation of dienamides from imine precursors, a 
solution of iminoester 225 was reacted with benzyl chloroformate in the presence of 
N,N-diethylaniline (Scheme 61).
194
 NMR analysis of the isolated material, purified by 
flash chromatography, revealed that half of the starting material was converted to the 




Scheme 61: The synthesis of dienamide 224. 
 
Reducing the amount of the acid chloride
197
 (from 1.5 equivalents to 1) did not result in 
any significant decrease of the formation of side product amide 230. More forcing 





 Thus, a new route starting from tert-butyl ester glycine hydrochloride 
was envisaged, in the hope that this substrate would provide greater stability for the 
subsequent formation of the desired dienamide. 
 
6.2 Racemic route B 
 
In the second racemic route Schiff base 148 was prepared by condensation of tert-butyl 
ester glycine hydrochloride and dibenzophenone imine.
234
 The product could be readily 
recrystallised from hexane yielding the desired Schiff base 148 in high yield and purity. 
This substrate underwent Pd-catalysed allylation smoothly as in the previous approach 
(148 to 232, Scheme 62).
229,230
 Gratifyingly, no purification issue arose from the acid-
sensitive imine group in this case, as the presence of a second aromatic moiety conferred 
greater stability to the compound. Careful flash chromatography, carried out with basic 
silica as recommended in the literature
235
 yielded alkylated Schiff base 232 in excellent 
yield and purity. However, a later study on the use of regular silica showed only a 
marginal reduction of the yield. Acidic hydrolysis
236
 of 232 furnished primary amine 
233, which could be purified by flash chromatography, in high yield. At this point, 
imine condensation was carried out as before in the presence of crotonaldehyde. Upon 
confirmation of the formation of the iminoester 234 by LCMS and 
1
H NMR, the product 
was treated with benzyl chloroformate and N,N-diethylaniline to obtain Cbz-protected 
dienamide 235 in moderate yield.
194,195
 The use of acetaldehyde instead of 
crotonaldehyde yielded the same dienamide 235 in poor yield (data not shown); despite 
the 
1
H NMR of the crude iminoester intermediate showing the desired structure 236. 
This is probably due to partial hydrolysis of the imino group in intermediate 236 (less 
stable than 234); the liberated molecules of acetaldehyde can then react to give 





Scheme 62: Racemic route B. (a) dibenzophenone imine, DCM, RT, ~18 h, (91%); (b) dry THF, 
Pd(PPh3)4, 5-7 h, RT, (92%); (c) 1 M HCl(aq), THF, 2-3 h, RT, (93%); (d) i. crotonaldehyde, DCM, 
molecular sieves, RT, ~18 h; ii. benzyl chloroformate, toluene, N,N-diethylaniline, 0 °C to RT, 
~18 h, (67%); (e) i. acetaldehyde, DCM, molecular sieves, RT, ~18 h; ii. benzyl chloroformate, 
toluene, N,N-diethylaniline, 0 °C to RT, ~18 h. 
 
Indeed, upon storage on the bench for a few days, the compound decomposed to 
crotonaldehyde and Cbz-protected amine 237 (Scheme 63). Storage at -20 °C was 
shown to be possible for up to 2 weeks. High temperature (323 K) NMR experiments 
also showed that this was the most common decomposition pathway (Scheme 63). 
Crotonaldehyde peaks at δ 6.93-6.84 and 6.22-6.15 (Scheme 63, b) and diagnostic 
aldehyde peak at δ 9.50 (data not shown) confirmed the formation of such compound. 
Comparison between 
1
H NMR of isolated Cbz-protected amine 237 and the one of the 
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dienamide 235 heated at 323 K overnight (~18 h) revealed the presence of the 237 in the 






Scheme 63: Decomposition of dienenamide 235 to Cbz-protected amine 237 and 
crotonaldehyde and chemical shifts of diagnostic peaks (top). High temperature 1H NMR 
experiments with dienamide 235 and comparison with 
1
H NMR of Cbz-protected amine 237 at 
RT (bottom).  
 
Although further optimisation was needed for the imine/enamide conversion, 
efforts were focussed on the ene-enamide metathesis step to ascertain the feasibility of 
this synthetic sequence. The first series of ene-amide RCM on 235 was carried out using 
Grubbs II and Hoveyda-Grubbs II catalysts (Table 5, entries 1-5), as these catalysts are 
known to have a wider substrate scope compared to the first generation catalysts.
202
 
Besides this consideration, Grubbs II catalyst has been employed before on dieneamide 
substrates showing selectivity for the internal double bond.
237
 Furthermore, ring closure 





and toluene were used as solvents at a range of different temperatures. After 2-3 hours a 
new species was visualised on the TLC plate for all the reactions with Rf = 0.27 which 
was believed to be the desired RCM product as eventual dimers were more likely to be 
at Rf values higher than the starting material (Rf = 0.40). Therefore, the reactions were 
allowed to run overnight (~18 h) in the hope of a total conversion of the starting 
material. Disappointingly, the isolated compound at Rf = 0.27 appeared to be aldehyde 
238. Increasing the catalyst loading (up to 25 mol% in three portions) as suggested in 
the literature
239
 and employing a longer reaction time resulted in higher conversion of 




Table 5: Summary of investigation of ene-enamide ring-closing metathesis on dienamide 235. 




Similarly, the use of Grubbs I catalyst gave no better results (Table 5, entries 7-10). A 
third species appeared on the TLC plate in some cases, as summarised in the table (this 
species was never observed when Hoveyda-Grubbs II catalyst was employed). 
Unfortunately, it was not possible to isolate this compound (Rf = 0.37).  
The formation of this atypical aldehyde is not unprecedented; a similar result has 






Scheme 64: Possible intermediate for the formation of aldehyde 205 and analogy with the 
dienamide substrate used in the investigation of the ene-enamide RCM reaction. 
 
The authors speculated that the ortho methoxy group in the styrene substrate may 
contribute to the formation of a relatively stable alkylidene complex (Scheme 64).
240
 At 
this point, a change in conformation of the enamide, probably due to the presence of the 
benzyl group, or simply steric hindrance prevents the desired [2 + 2] cycloaddition from 
occurring. It is likely that the alkylidene complex 240 reacts with a molecule of water 
instead of the enamide substrate, and a subsequent rearrangement furnishes aldehyde 
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205. Perhaps the carbonyl functional group in the enamide substrate 242 triggers a 
similar phenomenon (Scheme 64). 
 
6.3 Installing the stereochemistry at the α-position 
 
6.3.1 Pd-catalysed allylation  
 
Allylic alkylation is a well established transformation for carbon-carbon bond formation 
which may be catalysed by transition metal complexes.
241









 have been used recently for this 






Scheme 65: General mechanism of transition metal-catalysed allylic alkylation. 
 
This variety of metals has been introduced in order to achieve selective transformations 
by modulating the reactivity of allylic complex 244, generated in situ by oxidative 
addition to an allylic substrate 243 (e.g. ethers, alcohols, esters, carbonates etc.). In 
1987, Genet et al. reported the first example of transition metal-catalysed allylic 
alkylation, using Schiff bases derived from α-amino acid esters as prochiral nucleophiles 
and allylic carbonates under neutral conditions.
246
  
More recently, the asymmetric Pd-catalysed allylic alkylation of glycine imino 
ester with a series of allyl acetates in the presence of an inorganic base was reported by 
the Takemoto group.
247
 The investigation was carried out using an achiral metal 
complex [Pd(π-allyl)Cl)]2 with different ligands and a chiral cocatalyst, phase-transfer 
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catalyst (PTC) derived from cinchona alkaloids. The results obtained using allyl acetate 
are summarised in table 6. The use of second generation cinchona PTC (chloride 
version)
247
 yielded allylated product 247 in high yield but with poor enantioselectivity 
(entry 1); O-alkylated PTCs performed marginally better with regard to the selectivity 
(entries 2 & 3). The screening of different ligands showed that the use of (PhO)3P and 




Table 6: Asymmetric alkylation of 148 with allyl acetate in the presence of chiral PTCs; (a) 
toluene, solid KOH, [PdCl( -C3H5)]2 RT; (b) toluene, 50% KOH(aq), [PdCl( -C3H5)]2, 0° C. 
 
The best results in terms of chemical yield and enantioselectivity were obtained using O-
methylated PTC (iodide version) with either (PhO)3P or 1,2-
bis(diphenylphosphine)ethane monoxide [DPPE(O)] (entries 9 & 10). These last two 
sets of conditions were of particular interest and were employed to investigate the 
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reactivity of substrate 248a-c towards allylic substitution with ethyl 2-methylallyl 
carbonate. Three different prochiral nucleophiles (derived from different esters of 
glycine), were used to investigate the role that the substituent could have on the 
selectivity. All the substrates could be easily prepared in high yield and purity as 
before.
234
 Although allylic alkylation on substrate 248c with (PhO)3P has been reported, 
in our hands this transformation led only to isolation of the starting material (entry 3, 
Table 7). Similar results were obtained when methyl- and ethyl-derivatives 248a and 
248b were employed (entries 1 & 2). Next, the use ligand [DPPE(O)] was considered, 
and the reaction repeated with the tert-buyl derivative 248c used in the literature with 
two different PTCs (chloride and iodide version, entries 4-7). The use of PTC (chloride) 
yielded the desired product in high yield essentially as a racemic mixture (entry 4). The 
use of PTC (iodide) at room temperature gave rise to the desired product in good yield 
with some enantioselectivity (5%). Decreasing the temperature (0 °C and -20 °C) 
improved the selectivity of the transformation at the expense of the chemical yield. 
Moreover, the product obtained was actually ent-248c so the reaction yielded allylated 






Table 7: Asymmetric alkylation of 248a-c with ethyl-methylallyl carbonate in the presence of 
chiral PTCs. (a) toluene, 50% KOH(aq). *The product obtained in the last three entries is ent-
249c. 
 
The increased steric hindrance of ethyl 2-methylallyl carbonate compared to the allyl 
acetate used in the literature
247
 probably accounts for the differences of stereoselectivity 
observed in these reactions. 
 
6.3.2 Phase-transfer-catalysed asymmetric alkylation  
 
The next investigation centred on the preparation of the alkylated Schiff base 250 by 





Scheme 66: Enantioselective alkylation of glycine Schiff base 148. (a) Cinchona derivative PTC; 
(b) Maruoka type.  
 
As presented in chapter 5, a plethora of methods for the alkylation of glycine derived 
Schiff bases have been devised over the years.
172,173
 Both cinchona derivatives and 
Maruoka type catalysts (Fig. 48, 146 and 147) have been successfully employed for this 
transformation. However, the ease of preparation of cinchona derivatives makes them 
ideal for preparation on large-scale often needed in total synthesis. The reported 
example of enantioselective alkylation of glycine Schiff base 148 for the total synthesis 
of natural product (+)-hygrine in section 5.1.1.2 was particularly appealing due to its 
close parallel with the intermediate 235 (Scheme 66).
185
 Hence, cinchona PTC 258 was 
prepared according to published procedures.
184,185
 The synthesis of the desired cinchona 
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PTC started with the Pd-catalysed hydrogenation of (+)-cinchonidine. This 
transformation readily achieved (+)-hydrocinchonidine,
184
 but careful removal of the 
palladium was required to guarantee the purity of the product.
248
 In order to prepare 
dibromominated naphthalene derivative 256, a radical bromination was carried out with 







Scheme 67: Preparation of cinchona PTC 258. (a) H2, 10% Pd/C, MeOH, RT, ~18 h, (80%); (b) 
NBS, AIBN, CCl4, reflux, 10 min (~20%); (c) NBS, benzoyl peroxide, PhH, reflux, 2 h, (77%); (d) 
EtOH, DMF, CHCl3, reflux, 2 h, (71%); (e) allyl bromide, 50% KOH(aq), DCM, RT, ~ 5 h, (92%). 
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In our hands, this reaction proved sluggish giving rise to a mixture of mono- and 
dibrominated naphthalene derivatives. These brominated compounds could be separated 
by flash chromatography furnishing dibromominated naphthalene derivative 256 in poor 
yield (~20%). Using NBS in the presence of the radical initiator benzoyl peroxide, 
dibrominated naphthalene derivative 256 could be prepared in high yield and purity.
248
 
Dimeric quaternary ammonium salt 257 was obtained by stirring dibromide 255 and 
quinoline 256 in a mixture of EtOH, DMF and DCM at high temperature (~ 100 °C). 
Subsequent O-allylation of diol 257 was carried out in the presence of allyl bromide and 
aqueous potassium hydroxide, furnishing 258 in excellent yield (52% over three steps). 
Enantioselective alkylation of glycine Schiff base 148 (Scheme 68) with cinchona PTC 





Scheme 68: Enantioselective alkylation of glycine Schiff base 148. (a) Cinchona derivative PTC, 
50% KOH(aq), toluene, CHCl3, 0 °C, ~10 h, (92%, 91% ee). 
 
The reduced degree of selectivity reported compared to the literature
185
 (up to 97% ee) 
can be rationalised by the presence of possible impurities in the catalyst. Further 
purification of catalyst 258 could have resulted in improved selectivity. Investigation of 
this enantioselective transformation is ongoing in the Hulme group and will certainly 






6.4 Future work 
 
Following the disappointing results of the investigations of RCM on substrate 235, new 
strategies are envisaged for the synthesis of 4-Me-Pro. Primarily, a ring-relay metathesis 
approach was considered (scheme 69).
249
 This expedient reaction is often used in the 
presence of comparatively unreactive or hindered alkenes.
250
 The rationale behind this 
strategy is that although initiation of the catalytic cycle of a hindered or unreactive 
alkene is complicated, the intramolecular reaction of a ruthenium alkylidene onto such 
an alkene is possible.
250
 Such a relay approach is often promoted by the presence of a 
tether featuring an unencumbered alkene. As the end of the tether gives the least 
hindered position within the metathesis substrate, this site becomes the most likely point 




Scheme 69: General description of ring-relay metathesis on the proposed substrate. 
 
Both alkyl and ethereal tethers (R = CH2 or O) are commonly employed. Promisingly, 
the formation of 5-membered rings is reported to be favourable and side products easily 
separated from the desired olefin. This approach to expedite this transformation is 
currently under investigation in the Hulme group. Another alternative strategy is a 
ruthenium catalysed isomerisation followed by RCM as reported by Toumi et al. 
(Scheme 70).
219
 Hydrolysis of the iminogroup and Cbz-protection of the primary amino 
group in compound 148, followed by N-allylation of the secondary amine, would furnish 







Scheme 70: Ruthenium-induced isomerisation/RCM strategy. 
 
As reported in the total synthesis of paliurine E,
219
 the isomerisation of the double bond 
and subsequent RCM would be attempted by treatment with Grubbs II catalyst. A final 
alternative strategy is based on the Buchwald-Hartwig amination, a Pd or Cu- catalysed 
cross coupling reaction between primary or secondary amino groups and vinyl or aryl 






Scheme 71: Buchwald-Hartwig cross coupling-based strategy. 
 
Substrate 261 (racemic) would be prepared using a Pd-catalysed alkylation of 1,3-
dibromo-1-propene. Next, a PTC-based asymmetric strategy will be attempted to obtain 
alkylated glycine Schiff base 262 in an enantioselective manner. After hydrolysis of the 
imino group, the newly revealed primary amino group would undergo an intramolecular 
Buchwald-Hartwig type coupling with the vinyl bromide within 261. Successfully 
carrying out both PTC-catalysed enantioselective alkylation with 1,3-dibromo-1-
propene and the Buchwald-Hartwig coupling would expand the substrate scope of these 




6.5 Summary and conclusion 
 
To conclude, the synthetic route to functionalised amine 233 (Scheme 72) has been 
optimised allowing multigram scale preparation for effective investigation of the 




Scheme 72: Optimised route to functionalised amine 233. 
 
For the installation of the stereochemistry at the α-position to the nitrogen in 4-Me-Pro, 
two different methodologies have been investigated (Scheme 73): Pd-catalysed 
allylation in the presence of a cinchona catalyst and PTC-catalysed asymmetric 




Scheme 73: Enantioselective alkylation of glycine Schiff base 148. 
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After screening different substrates and reaction conditions for Pd-catalysed allylation, 
the preparation of alkylated Schiff base in high yield and purity (Scheme 73) was readily 
achieved using a PTC-based strategy. 
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7 Experimental procedures 
7.1 General experimental 
 
All starting materials and reagents were purchased from commercial suppliers and were 
used as supplied. Anhydrous DCM was distilled from calcium hydride. Unless otherwise 




H nuclear magnetic resonance (NMR) spectra were recorded at room temperature 
(unless otherwise stated) on Bruker AC250 (250 MHz), Bruker DPX360 (360 MHz) 
Bruker 400 (400 MHz), Bruker 500 (500 MHz) and Bruker 800 (800 MHz) Fourier 
Transform instruments. The data is presented as follows; chemical shift (in ppm on the 
scale relative to δtms = 0), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn 
= quintet, m = multiplet), coupling constants and interpretation. 
13
C nuclear magnetic 
resonance (NMR) spectra were recorded at room temperature (unless otherwise stated) 
on Bruker AC250 (62.9 MHz), Bruker DPX360 (90.6 MHz), Bruker 500 (201.3 MHz). 
Fourier transform instruments were referenced to the solvent carbon peak. The data is 
presented as follows: chemical shift (in ppm on the δ scale), relative intensity and 
assignment and were confirmed by DEPT90 and DEPT135. 
 
Flash column chromatography was carried out on Merck Kieselger 60 (Merck 9385). 
Basic silica was used for the purification of acid sensitive compounds. Aminopropyl 
silica gel (FLUKA 09298) was used for sample loading while the silica gel used for 
column packing was prepared as follows: 100 g of activated silica were mixed to NaOH 
(30 ml, 1N aq.) and mechanically stirred until a uniform mixture was obtained. Eluent 




Infra-red spectra were recorded on a Perkin Elmer Paragon 100 FT-IR machine using 5 
mm sodium chloride plates or potassium bromide discs. The wavelengths of maximum 
absorbance (υmax) are quoted in cm
-1
. Melting points were determined on a Gallenkamp 
Electrothermal melting point apparatus and are uncorrected. 
 
Electrospray Ionisation (ESI) mass spectra were recorded on a Finnigan 450 or 
micromass platform instrument at the University of Edinburgh. The parent ion or 
relevant fragment is quoted, followed by significant figures and their percentages. Chiral 
HPLC analysis was performed on an Agilent 1100 instrument. Optical rotations were 
performed on an Optical Activity POLAAR 20 polarimeter. Microwave reactions were 
performed using a Biotage microwave synthesiser. Thin Layer Chromatography (TLC) 
was performed on MERCK 60F254 (0.25 mm) glass silica plates and visualised by 
ultraviolet (UV) light and potassium permanganate. 
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7.2 Experimental procedures for chapters 2 and 3 
 





To a stirred solution of 3-chloro-1-propylamine hydrochloride (260 mg, 2.00 mmol) in 
pyridine (5 ml) was added ethyl 4-chloro-4-oxobutanoate (165 mg, 1.00 mmol) at 0 °C. 
The reaction was allowed to reach RT and stirred for 2 h. The solvent was removed in 
vacuo to give the crude ester as a pale yellow oil. The crude ester was purified by flash 
chromatography (25% cyclohexane in EtOAc) to give the desired ester as a colourless 
oil (290 mg, 71% yield ); Rf (50% EtOAc in cyclohexane) = 0.61; νmax (neat)/cm
-1
 1729 
(CO), 1654 (CO); 
1
H NMR δ (250 MHz, CDCl3) 6.71 (1H, br s, NH), 4.28 (2H, q, J = 
7.1 Hz, CH2CH3), 3.73 (2H, t, J = 6.5 Hz, CH2Cl), 3.53 (2H, q, J = 6.5 Hz, CH2NH), 
2.80 (2H, t, J = 7.1 Hz, CH2CO), 2.63 (2H, t, J = 7.1 Hz, CH2CO), 2.13 (2H, qn, J = 6.5 
Hz, CH2CH2CH2), 1.40 (3H, t, J = 7.1 Hz, CH3); 
13
C NMR δ (62.9 MHz, CDCl3) 
172.85 (C), 171.72 (C), 60.49 (CH2), 42.26 (CH2), 36.77 (CH2), 31.96 (CH2), 30.70 




, 100%), 222 ([M+H]
+
, 
5), 176 (40), 56 (98); HRMS (FAB, THIOG) [ClM+Na]
+
 found 244.0709, 
C9H16O3
35







To a stirred solution of the 3-azido-1-propylamine (400 mg, 4.00 mmol) in pyridine (6 
ml) was added ethyl 4-chloro-4-oxobutanoate (428 mg, 2.60 mmol) at 0 °C. The 
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reaction was allowed to reach RT and stirred overnight (~18 h). The solvent was 
removed in vacuo to give the crude ester as a pale yellow oil. Flash chromatography 
(30% EtOAc in cyclohexane) gave the desired azidoester as a colourless oil (356 mg, 
60% yield ); Rf (50% EtOAc in cyclohexane) = 0.61; νmax (neat)/cm
-1
 2098 (N3), 1733 
(CO), 1652 (CO); 
1
H NMR δ (250 MHz, CDCl3) 6.56 (1H, br s, NH), 3.98 (2H, q, J = 
7.2 Hz CH2CH3), 3.28-3.17 (4H, m, CH2NH+CH2N3), 2.51 (2H, t, J = 6.3 Hz, CH2CO), 
2.35 (2H, t, J = 6.3 Hz, CH2CO), 1.62 (2H, qn, J = 6.7 Hz, CH2CH2CH2), 1.12 (3H, t, J 
= 7.2 Hz, CH3); 
13
C NMR δ (62.9 MHz, CDCl3) 172.74 (C), 171.63 (C), 60.63 (CH2), 
48.80 (CH2), 36.63 (CH2), 30.51 (CH2), 29.25 (CH2), 28.43 (CH2), 13.80 (CH3); m/z 
(FAB, 3-NOBA) 229 ([M+H]
+
 100%), 154 (71), 136 (64); HRMS (FAB, 3-NOBA) 
[M+H]
+
 found 229.1299, C9H17O3N4 requires 229.1295. 
 




To a solution of ethyl 4-(3-azido-1-propylamino)-4-oxobutanoate (55 mg, 0.20 mmol) in 
a mixture of H2O/t-BuOH (2/1, 3 ml), propargyl alcohol (0.15 µl, 0.20 mmol,), TBTA 
(~2.0 mg, 2.0 µmol), sodium ascorbate (10.3 mg, 0.05 mmol) and copper sulphate (8.0 
mg, 0.020 mmol) were added. The reaction was stirred at RT for 24 h. The organic 
solvent was removed in vacuo while the aqueous layer was extracted with DCM (2 × 5 
ml) and EtOAc (2 × 5 ml). The organics were collected and concentrated in vacuo. The 
crude material was purified by flash chromatography (5% MeOH in DCM) to give the 
desired triazole as a colourless oil (25 mg, 44% yield); Rf (5% MeOH in DCM) = 0.13; 
νmax (neat)/cm
-1
 1728 (CO), 1653 (CO); 
1
H NMR δ (360 MHz, CDCl3) 7.65 (1H, s, 
ArH), 6.02 (1H, br s, NH), 4.79 (2H, s, CH2OH), 4.42 (2H, t, J = 6.5 Hz, CH2NN), 4.13 
(2H, q, J = 7.1 Hz, CH2CH3), 3.27 (2H, q, J = 6.5 Hz, CH2NH), 2.75 (1H, br s, OH), 
2.64 (2H, t, J = 6.5 Hz, NCOCH2) 2.41 (2H, t, J = 6.5 Hz, OCOCH2), 2.10 (2H, qn, J = 
6.5 Hz, CH2CH2CH2), 1.25 (3H, t, J = 7.1 Hz, CH2CH3); 
13
C NMR δ (90.6, CDCl3) 
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173.25 (C), 172.04 (C), 145.30 (C), 105.78 (CH), 60.81 (CH2), 56.43 (CH2), 47.84 
(CH2), 36.53 (CH2), 30.80 (CH2), 30.02 (CH2), 29.38 (CH2), 14.14 (CH3); m/z (ESI+), 
307 ([M+Na]
+
 100%), 285 ([M+H]
+
 7), 105 (52); HRMS (ESI+) found [M+Na]
+
 






To a stirred solution of anisomycin (50 mg, 0.19 mmol) in DMF (2 ml) potassium 
carbonate (26 mg, 0.19 mmol) and propargyl bromide (16 µl, 0.19 mmol) were added. 
The reaction was stirred for 8 h at RT. The solvent was removed in vacuo and the crude 
material purified by flash chromatography (5% MeOH in DCM) to give propargyl 
anisomycin 27 as a colourless oil (54 mg, 95% yield); Rf (5% MeOH in DCM = 0.25); 
νmax (neat)/cm
-1
 3374 (OH), 1727 (CO);
 1
H NMR δ (250 MHz, CDCl3) 7.09 (2H, d, J = 
8.6 Hz, ArH), 6.80 (2H, d, J = 8.6 Hz, ArH), 4.47 (1H, dd, J = 5.7 & 1.6 Hz, C3H), 4.13 
(1H, br t, J = 7.0 Hz, C4H), 3.78 (3H, s, OMe), 3.58 (2H, d, J = 2.3 Hz, HCCCH2), 3.34 
(1H, dd, J = 9.8 & 7.0 Hz, C5HaHb), 3.21 (1H, dt, J = 10.2 & 5.2 Hz, C2H), 2.85 (1H, 
dd, J = 13.4 & 4.5 Hz, CHcHdAr), 2.70 (1H, dd, J = 13.4 & 10.2 Hz, CHcHdAr), 2.61 
(1H, dd, J = 9.8 & 7.0 Hz, C5HaHb), 2.30 (1H, t, J = 2.3 Hz, CHCCH2), 2.14 (3H, s, 
OAc); 
13
C NMR δ (62.9 MHz, CDCl3) 172.20 (C), 158.53 (C), 130.54 (C), 130.24 (2 × 
CH), 114.28 (2 × CH), 82.80 (CH), 76.71 (C), 75.60 (CH), 74.24 (CH), 63.47 (CH) 
57.86 (CH2), 55.20 (CH3), 39.85 (CH2), 32.00 (CH2), 21.03 (CH3); m/z (ESI+) 326 
([M+Na]
+
, 23%), 304 ([M+H]
+
, 100), 244 (22). 
 










To a stirred solution of propargyl anisomycin 27 (20.0 mg, 0.060 mmol) in H2O/t-BuOH 
(1/1, 2 ml) azidoester 34 (16.4 mg, 0.07 mmol) was added, followed by sodium 
ascorbate (2.4 mg, 0.010 mmol), TBTA (~1.00 mg, 0.0010 mmol) and copper sulphate 
(3.5 mg, 0.010 mmol). The mixture was stirred overnight (~18 h) at RT. The organic 
layer was removed in vacuo and the aqueous layer extracted with DCM (3 × 5 ml). The 
organics were collected and concentrated in vacuo. The crude material was purified by 
flash chromatography (2% MeOH in DCM) to give anisomycin derivative 67 as 
colourless solid (20 mg, 60% yield); Rf (2% MeOH in DCM) = 0.25; νmax (neat)/cm
-1
 
1727 (CO), 1669 (CO); 
1
H NMR δ (360 MHz, CDCl3) 7.51 (1H, s, ArH), 7.10 (2H, d, J 
= 8.6 Hz, ArH), 6.80 (2H, d, J = 8.6 Hz, ArH), 6.04 (1H, br s, NH), 4.54 (1H, dd, J = 4.7 
& 1.2 Hz, C3H), 4.40 (2H, t, J = 6.5 Hz, C10H2), 4.13 (2H, q, J = 7.1 Hz, C19H2), 4.11-
4.07 (1H, m, C4H), 4.06 (1H, d, J = 15.0 Hz, C6HaHb), 3.96 (1H, d, J = 15.0 Hz, 
C6HaHb), 3.77 (3H, s, OMe), 3.45 (1H, dd, J = 10.4 & 6.5 Hz, C5HcHd), 3.22-3.16 (2H, 
m, C2H + CHeHfAr), 3.15-3.08 (2H, m, C12H2), 2.79 (1H, dd, J = 14.5 & 10.8 Hz, 
CHeHfAr), 2.66 (2H, t, J = 6.5 Hz, C15H2), 2.52 (1H, dd, J = 10.4 & 5.5 Hz, C5HcHd), 
2.44 (2H, t, J = 6.5 Hz, C16H2), 2.13 (3H, s, OAc) 2.11 (2H, qn, J = 6.5 Hz, C11H2), 1.25 
(3H, t, J = 7.1 Hz, C20H3); 
13
C NMR δ (62.9, CDCl3) 173.06 (C), 172.08 (C), 171.44 
(C), 158.02 (C), 142.61 (C), 130.65 (C), 129.91 (2 × CH), 123.38 (CH), 113.80 (2 × 
CH), 81.80 (CH), 75.07 (CH), 64.52 (CH), 60.78 (CH2), 58.32 (CH2), 55.21 (CH3), 
47.40 (CH2), 46.10 (CH2), 36.23 (CH2), 32.43 (CH2), 30.96 (CH2), 30.15 (CH2), 29.44 
(CH2), 21.06 (CH3), 14.16 (CH3); m/z (ESI+) 554 ([M+Na]
+
, 28%), 532 ([M+H]
+
, 100), 
123 (100); HRMS (ESI+) [M+H]
+









To a solution of ethyl 4-(3-azido-1-propylamino)-4-oxobutanoate (39 mg, 0.17 mmol) in 
H2O/t-BuOH (2/1, 3 ml), propargyl biotin (50 mg, 0.14 mmol), sodium ascorbate (10 
mg, 0.050 mmol) and copper sulphate (8.0 mg, 0.020 mmol) were added. The reaction 
was stirred at RT for 3 h. The organic solvent was removed in vacuo and the aqueous 
layer was extracted with DCM (2 × 5 ml) and with EtOAc (2 × 5 ml). The organics were 
collected and concentrated in vacuo. Flash chromatography (2 to 10% MeOH in DCM) 
gave the desired triazole as a colourless solid (60 mg, 40% yield); Rf (10% MeOH in 
DCM = 0.33); mp 174-176 °C νmax (nujol)/cm
-1
 2389 (NH), 2251 (NH), 1768 (CO), 
1664 (CO); 
1
H NMR δ (800 MHz, D2O) 7.88 (1H, s, C15H), 4.57 (1H, dd, J = 7.9 & 4.5 
Hz, C6aH), 4.43 (2H, m, t, J = 6.7 Hz, C19H2), 4.35 (1H, dd, J = 7.9 & 4.5 Hz, C3aH), 
4.13 (2H, q, J = 7.1 Hz, C26H2), 3.27-3.25 (1H, m, C4H), 3.16 (2H, t, J = 6.7 Hz, C17H2), 
2.96 (1H dd, J = 13.0 & 5.0 Hz, C6HaHb), 2.75 (1H d, J = 13.0 Hz, C6HaHb), 4.42-4.40 
(2H, m, C13H2), 2.62 (2H, t, J = 6.7 Hz, C22H2), 2.48 (2H, t, J = 6.7 Hz, C23H2), 2.28 
(2H, t, J = 7.1 Hz, C10H2), 2.08 (2H, qn, J = 6.7 Hz, C18H2), 1.68-1.63 (2H, m, C9H2), 
1.62-1.58 (1H, m, C7HcHd) 1.54-1.50 (1H, m, C7HcHd) 1.34-1.30 (2H, m, C8H2) 1.21 
(3H, t, J = 7.1 Hz, C27H3); 
13
C NMR δ (200 MHz, D2O) 178.12 (C21), 176.58 (C11), 
176.15 (C24), 166.70 (C1), 146.27 (C14), 125.35 (C15H), 63.50 (C26H2), 63.30 (C3aH), 
61.71 (C6aH), 56.88 (C4H), 49.46 (C13H2), 41.23 (C6H2), 37.80 (C17H2), 36.76 (C10H2), 
35.80 (C19H2), 31.77 (C23H2), 31.04 (C22H2), 30.39 (C18H2), 29.25 (C8H2), 29.12 (C7H2), 
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26.56 (C9H2), 14.88 (C27H3); m/z (ESI+) 532 ([M+Na]
+
, 5%), 510 ([M+H]
+
, 6%), 312 
(9); HRMS (ESI+) found [M+H]
+







D-Biotin (200 mg, 0.820 mmol) was dissolved in DMF (5ml) and the solution cooled to 
0 °C. N-hydroxysuccinimide (188 mg, 1.64 mmol), EDC (314 mg, 1.64 mmol) and Et3N 
(237 µl, 1.64 mmol) were added and the mixture was stirred overnight (~ 18 h). The 
solvent was removed in vacuo and the resulting residue dissolved in DCM (10 ml). The 
organic phase was washed with H2O (2 × 5 ml) and the solvent was removed in vacuo. 
The crude material was purified by flash chromatography (10% MeOH in DCM) to give 
the NHS ester 263 as a colourless solid (280 mg, 99% yield); Rf (10% MeOH in DCM) 
= 0.33; mp 170-172 °C; νmax (KBr)/cm
-1
 1820 (CO), 1790 (CO), 1730 (CO), 1703 (CO); 
1
H NMR δ (250 MHz, (CD3)2SO2) 6.42 (1H, s, NH), 6.36 (1H, s, NH), 4.30 (1H, dd, J = 
7.6 & 4.1 Hz, C3aH), 4.14 (1H, ddd, J = 7.6 & 4.5 & 1.6 Hz, C6aH), 3.14-3.06 (1H, m, 
C4H), 2.88 (1H, m, C6Ha), 2.80 (4H, s, 2 × CH2O), 2.72 (1H, m, C6Hb), 2.66 (2H, m, 
C10H2), 1.70-1.56 (6H, m, C7H2 + C8H2 + C9H2); 
13
C NMR δ (62.9 MHz, (CD3)2SO2), 
170.18 (2 × C), 168.85 (C), 162.61 (C), 60.93 (CH), 59.11 (CH), 55.15 (CH), 35.71 
(CH2), 29.92 (CH2), 27.76 (CH2), 27.50 (CH2), 25.36 (2 × CH2), 24.22 (CH2); m/z 
(ESI+) 342 ([M+H]
+
, 18%), 227 (18), 146 (44).  
 












A suspension of biotin NHS ester (280 mg, 0.81 mmol) and propargyl amine (104 µl, 
1.62 mmol) in DCM (20 ml) was stirred for 3 h at RT. Completion of the reaction was 
determined by TLC. The solvent was removed in vacuo. The crude product was purified 
by flash chromatography (10 to 15% MeOH in DCM). Propargyl amide 69 was isolated 
as a colourless solid (210 mg, 77% yield). 
 
Method B 
A solution of D-Biotin (200 mg, 0.81 mmol) was dissolved in DMF (20 ml). HOBt (324 
mg, 2.4 mmol) and DIC (373 µl, 2.40 mmol) were added and the solution stirred at RT 
for 10 min. Propargyl amine (167 µl, 2.40 mmol) was added and the reaction mixture 
was heated to 60 °C by microwave irradiation (20 min). The solvent was removed in 
vacuo. The crude product was purified by flash chromatography (0 to 10% MeOH in 
DCM). The product was isolated as a colourless solid (200 mg, 88% yield); Rf (15% 
MeOH in DCM = 0.45); mp 168-170 °C; νmax (nujol)/cm
-1
 3288 (NH), 1694 (CO), 1648 
(CO); 
1
H NMR δ (250 MHz, CD3OD) 4.49 (1H, ddd, J = 7.8 & 4.9 & 0.8 Hz, C6aH), 
4.30 (1H, dd, J = 7.8 & 4.3 Hz, C3aH), 3.94 (2H, d, J = 2.5 Hz, C13H2), 3.24-3.16 (1H, 
m, C4H), 2.93 (1H, dd, J = 12.7 & 4.9 Hz, C6HaHb), 2.70 (1H, d, J = 12.7 Hz, C6HaHb), 
2.58 (1H, t, J = 2.5 Hz, CHCC), 2.21 (2H, t, J = 7.3 Hz, C10H2), 1.81-1.37 (6H, m, C7H2 
+ C8H2 + C9H2); 
13
C NMR δ (62.9 MHz, CD3OD), 175.66 (C11), 166.15 (C1), 80.73 
(C15), 72.10 (C15H), 63.39 (C3aH), 61.67 (C6aH), 56.99 (C4H), 41.08 (C6H2), 36.53 
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(C10H2), 29.75 (C8H2), 29.49 (C7H2), 29.41 (C13H2), 26.73 (C9H2); m/z (ESI+) 585 
([2M+Na]
+
, 31%) 304 ([M+Na]
+
, 37), 282 ([M+H]
+
, 32), 158 (27), 141 (12). 
 








A solution of D-Biotin (100 mg, 0.40 mmol) was dissolved in DMF (10 ml). HOBt (108 
mg, 0.80 mmol) and DIC (124 µl, 0.80 mmol) were added and the solution stirred at RT 
for 10 min. 3-Azido-1-propylamine (120 mg, 1.20 mmol) was added and the reaction 
mixture was heated to 60° C by microwave irradiation (20 min). The solvent was 
removed in vacuo. Flash chromatography (dry loaded silica column, 0 to 8% MeOH in 
DCM) gave the product as a colourless solid. (92 mg, 70% yield); Rf (10% MeOH in 
DCM = 0.18); mp 175-177 °C; νmax (KBr)/cm
-1
 2102 (N3), 1696 (CO), 1646 (CO); 
1
H 
NMR δ (500 MHz, CD3OD) 4.49 (1H, ddd, J = 7.8 & 4.6 Hz, C6aH), 4.30 (1H, dd, J = 
7.8 & 4.6 Hz, C3aH), 3.36 (2H, t, J = 6.7 Hz, C15H2), 3.25 (2H, t, J = 6.7 Hz, C13H2), 
3.23-3.19 (1H, m, C4H), 2.93 (1H, dd, J = 12.7 & 5.0 Hz, C6HaHb), 2.71 (1H, d, J = 12.7 
Hz, C6HaHb), 2.21 (2H, t, J = 7.3 Hz, C10H2), 1.75 (2H, qn, J = 6.7 Hz, C14H2), 1.70-
1.54 (4H, m, C7H2 + C9H2), 1.49-1.38 (2H, m, C8H2); 
13
C NMR δ (126 MHz, CD3OD), 
176.31 (C11), 166.27 (C1), 63.53 (C3aH), 61.77 (C6aH), 57.16 (C4H), 50.24 (C15H2), 
41.18 (C6H2), 37.83 (C13H2) 36.92 (C10H2), 29.94 (C14H2), 29.89 (C8H2), 29.63 (C7H2), 
27.00 (C9H2); m/z (ESI+) 675 ([2M+Na]
+
, 100%) 349 ([M+Na]
+
, 82), 327 ([M+H]
+
, 39), 
141 (13); HRMS, (ESI+) found [M+H]
+










To a solution of biotin azido derivative 264 (78 mg, 0.24 mmol) in H2O/t-BuOH (1/2, 3 
ml), sodium ascorbate (4.0 mg, 0.020 mmol) and copper sulphate (3.0 mg, 0.010 mmol) 
were added. The mixture was strirred for 10 min, and then propargyl anisomycin (50 
mg, 0.16 mmol) was added. The reaction was stirred at RT overnight (~ 18 h). The 
organic solvent was removed in vacuo and the aqueous layer was extracted with DCM 
(2 × 5 ml) and EtOAc (2 × 5 ml). The organics were collected and concentrated in 
vacuo. Flash chromatography (2 to 10% MeOH in DCM) gave the desired triazole 28 as 
a colourless solid (65 mg, 64% yield); Rf (20% MeOH in DCM = 0.35); mp 175-177 
°C; νmax (KBr)/cm
-1
 3410 (OH), 1687 (CO), 1646 (CO) 
1
H NMR δ (360 MHz, CD3OD) 
7.97 (1H, s, C17H), 7.13 (2H, d, J = 8.6 Hz, ArH), 6.84 (2H, d, J = 8.6 Hz, ArH), 4.66 
(1H, dd, J = 5.0 & 1.5 Hz, C23H), 4.52-4.48 (1H, m, C6aH), 4.47 (2H, t, J = 6.7 Hz, 
C15H2), 4.30 (1H, dd, J = 7.8 & 4.5 Hz, C3aH), 4.06 (1H, d, J = 14.2 Hz, C19HcHd), 4.04-
3.99 (1H, m, C22H), 3.84 (1H, d, J = 14.2 Hz, C19HcHd), 3.77 (3H, s, OMe), 3.41-3.35 
(1H, m, C4H), 3.23 (2H, t, J = 6.8 Hz, C13H2), 3.21-3.18 (1H, m, C24H), 3.16 (1H, dd, J 
= 9.4 & 4.5 Hz C21HeHf), 3.05 (1H, dd, J = 13.1 & 5.0 Hz C6HaHb), 2.93 (1H, dd, J = 
13.1 & 5.0 Hz, C6HaHb), 2.74 (1H, dd, J = 13.1 & 5.0 Hz, C25HgHh + C25HgHh), 2.51 
(1H, dd, J = 10.7 & 4.2 Hz, C21HeHf), 2.23 (2H, t, J = 7.3 Hz, C10H2), 2.13 (2H, t, J = 
6.7 Hz, C13H2) 2.12 (3H, s, OAc), 1.84-1.55 (4H, m, C7H2 + C9H2), 1.49-1.38 (2H, m, 
C8H2); 
13
C NMR δ (90 MHz, CD3OD), 176.21 (C11), 172.02 (C, OAc), 166.05 (C1), 
159.67 (C, Ar), 144.16 (C18), 131.82 (C, Ar), 130.98 (2 × CH, Ar), 125.54 (C17H), 
114.92 (2 × CH, Ar), 81.21 (C23H), 74.65 (C22H), 66.48 (C24H), 63.33 (C3aH), 61.60 
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(C6aH), 60.12 (C21H2), 56.97 (C4H), 55.66 (CH3, OMe), 48.76 (C15H2), 48.30 (C19H2), 
41.04 (C6H2), 37.35 (C13H2), 36.74 (C10H2), 33.58 (C25H2), 31.17 (C14H2), 29.76 (C8H2), 
29.46 (C7H2), 26.77 (C9H2), 20.97 (CH3, OAc); m/z (ESI+) 652 ([M+Na]
+
, 20%) 630 
([M+H]
+
, 100), 315 (15); HRMS, (ESI+), found [M+H]
+
 630.3067, C30H44O6N7S 
requires 630.3068. 
 




A mixture of triethylamine (3.00 ml, 20.0 mmol), di-tert-butylcarbonate (3.94 g, 20.0 
mmol), and 2-chloroethylamine hydrochloride (2.32 g, 20.0 mmol) in DCM (30 ml) was 
stirred for 3 d. Then HCl (20 ml, 0.5 M aq.) was added to the mixture. The organic layer 
was separated, washed with NaCl (sat. aq.) and worked up to yield the carbonate 43 
(1.93 g, 60% yield); Rf (25% MeOH in DCM) = 0.1; νmax (neat)/cm
-1
 3345 (NH), 1698 
(CO); 
1
H NMR δ (250 MHz, CDCl3) 4.95 (1H, br s, NH), 3.59 (2H, t, J = 5.4 Hz, 
CH2Cl), 3.50-3.41 (2H, m, CH2NH), 1.44 (9H, s, 3 × CH3); 
13
C NMR δ (62.9 MHz, 









, 16), 126 (11), 124 (32), 102 (100). 
 










To a stirred solution of 4-(4-hydroxy-phenylazo)-benzoic acid (67.0 mg, 0.300 mmol) in 
DMF (2 ml) caesium carbonate (228 mg, 0.700 mmol) was added. After 15 min the 
chlorocarbonate 43 (50.0 mg, 0.300 mmol) was added and the mixture stirred at 80 °C 
overnight (~18 h). The solvent was removed in vacuo and the product purified by flash 
chromatography (33% EtOAc in cyclohexane). The ether 44 was isolated as an orange 
solid (25.0 mg, 23 yield%); Rf (33% EtOAc in cyclohexane) = 0.31; mp 133-135 °C; 
νmax (neat)/cm
-1
 1716 (CO), 1698 (CO); 
1
H NMR δ (360 MHz, CD3OD) 8.20 (2H, d, J = 
8.9 Hz, ArH), 7.93-7.85 (4H, m, ArH), 6.93 (2H, d, J = 8.9 Hz, ArH), 4.36 (2H, t, J = 
5.3 Hz, CH2), 3.41 (2H, t, J = 5.3 Hz, CH2), 1.43 (9H, s, 3 × CH3); m/z (ESI-) 384 ([M-
H]
-
, 3), 113 (21), 59 (100); HRMS (ESI-) [M+NH4]
+
 found 403.1979, C20H27O5N4 
requires 403.1976. 
 




To a solution of MeOH (3 ml) cooled to 0 °C acetyl chloride (42 µl, 0.60 mmol) was 
added and the mixture was stirred for 30 min 4-(4-hydroxy-phenylazo)-benzoic acid (50 
mg, 0.20 mmol) was added portionwise and the mixture heated to reflux for 3 h. The 
solvent was removed in vacuo and the crude material purified by flash chromatography 
(25% EtOAc in cyclohexane) to achieve the methyl ester 49 (40 mg, 78%); Rf (33% 
EtOAc in cyclohexane) = 0.31; mp; 214 °C; νmax (neat)/cm
-1 
1693 (CO), 1424 (NN); 
1
H 
NMR δ (250 MHz, (CD3)2CO) 8.15 (2H, d, J = 9.0 Hz, ArH), 7.89 (2H, d, J = 9.0 Hz, 
ArH), 7.86 (2H, d, J = 9.0 Hz, ArH), 6.93 (2H, d, J = 9.0 Hz, ArH), 3.94 (1H, s, CH3); 
13
C NMR δ (62.9 MHz, CD3OD) 195.75 (C), 163.13 (C) 156.94 (C), 147.54 (C), 132.25 
(C), 131.58 (2 × CH), 126.49 (2 × CH), 123.27 (2 × CH), 116.91 (2 × CH), 52.78 (CH3); 
 
 152 
m/z (ESI+) 535 ([2M+Na]
+
, 5%), 257 ([M+H]
+
, 28), 157 (100); HRMS (ESI+) [M+H]
+
 
found 257.0928, C14H13N2O3 requires 257.0921. 
 




Boc-protected aminoazide 59 (600 mg, 1.28 mmol) was dissolved in a mixture of 
TFA/DCM (10/1, 11 ml) and the solution was stirred for 1 h. The solvent was removed 
in vacuo. Flash chromatography (5 to 20% MeOH in DCM) gave the desired 
aminoazide 59 as an orange oil (450 mg, 95%), (85:15, E:Z); Rf (10% MeOH in DCM) 
= 0.51; νmax (neat)/cm
-1
 2071 (N3), 1675 (CO); 
1
H NMR δ (400 MHz, CD3OD); 8.04 
(1.70H (E), d, J = 8.7 Hz, ArH), 7.96 (1.70H (E), d, J = 8.7 Hz, ArH), 7.95 (1.70H (E), 
d, J = 8.7 Hz, ArH), 7.85 (0.30H (Z), d, J = 8.7 Hz, ArH), 7.12 (1.70H (E), d, J = 8.8 
Hz, ArH), 6.99-6.91 (0.60 H(Z), m, ArH), 6.84 (0.30H (Z), d, J = 9.0 Hz, ArH), 4.20 
(1.70H (E), t, J = 6.0 Hz, CH2), 4.00 (0.30 H (Z), t, J = 6.0 Hz, CH2), 3.66 (1.70H (E), t, 
J = 6.0 Hz, CH2), 3.64-3.59 (0.30 H (Z), m, CH2), 3.56 (1.70H (E), t, J = 6.0 Hz, CH2), 
3.49 (0.30H (Z), t, J = 6.0 Hz, CH2), 3.13 (1.70H (E), t, J = 6.0 Hz, CH2), 3.08 (0.30H 
(Z), t, J = 6.0 Hz, CH2), 2.10 (1.70 H (E), qn, J = 6.3 Hz, CH2), 2.01 (0.30 H (Z), qn, J = 
6.3 Hz, CH2); 
13
C NMR δ (101 MHz, CD3OD), 170.27 (C) (E), 169.93 (C) (Z), 163.52 
(C) (E), 160.46 (C) (Z), 158.26 (C) (Z), 156.03 (C) (E), 148.38 (C) (E), 147.52 (C) (Z), 
136.41 (C) (E), 133.42 (C) (Z), 129.63 (2 × CH) (Z), 129.54 (2 × CH) (E), 126.16 (2 × 
CH) (E), 125.05 (2 × CH) (Z), 123.45 (2 × CH) (E), 120.70 (2 × CH) (Z), 116.03 (2 × 
CH) (E), 115.46 (2 × CH) (Z), 66.42 (CH2) (E), 66.23 (CH2) (Z), *49.43 (CH2) (E), 
49.30 (CH2) (Z), 41.31 (CH2) (E), 41.27 (CH2) (Z), 40.19 (CH2) (E), 40.13 (CH2) (Z), 
29.76 (CH2) (E), 29.67 (CH2) (Z); m/z (ESI+) 390 ([M+Na]
+
, 8%), 368 ([M+H]
+
, 20), 56 
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(100); HRMS (FAB, 3-NOBA) [M+H]
+
 found 368.1838, C12H22N7O2, requires 
368.1835. 
 







4-aminobenzoic acid (1.23 g, 9.00 mmol), was dissolved in a mixture of hydrochloric 
acid (1.2 ml, conc.) and H2O (24 ml) and the suspension obtained was cooled to 0 °C. 
Sodium nitrite (1.04 g, 15.0 mmol) dissolved in H2O (5 ml) was added next and the pale 
yellow solution formed was stirred for 20 min. A second solution of phenol (667 mg, 
7.20 mmol), sodium hydroxide (257 mg, 6.42 mmol) and potassium carbonate (1.33 g, 
9.60 mmol) dissolved in H2O (20 ml) was prepared, cooled to 0 °C and added dropwise 
to the reaction mixture. The reaction was allowed to reach RT and stirred for 3 h. The 
brown suspension formed was acified with HCl (1 M aq.) and filtered. The filtrate was 
dissolved in MeOH, silica was added and the mixture dried in vacuo. Flash 
chromatography (dry loaded silica column, 15% MeOH in DCM) gave product 40 as an 
orange solid (1.57 g, 90% yield); Rf (5% MeOH in DCM = 0.25); mp 275-277 °C; νmax 
(neat)/cm
-1
 3286 (OH), 1642 (CO), 1538 (NN); 
1
H NMR δ (250 MHz, CD3OD) 8.19 
(2H, d, J = 8.5 Hz, ArH), 7.92 (2H, d, J = 8.5 Hz, ArH), 7.90 (2H, d, J = 8.8 Hz, ArH), 
7.17 (2H, d, J = 8.8 Hz, ArH); 
13
C NMR δ (62.9 MHz, CD3OD) 163.23 (C), 162.88 (C), 
156.84 (C), 147.58 (C), 133.00 (C), 131.81 (2 × CH), 126.46 (2 × CH), 123.21 (2 × 
CH), 116.87 (2 × CH); m/z (ESI ) 241 ([M H] , 48%), 226 (12), 112 (100). 
 










To a stirred solution of ethane-1,2-diamine (9.97 g, 167 mmol) in DCM (100 ml) at RT 
was added a solution of di-tert-butylcarbonate (6.10 g, 28.0 mmol) in DCM (400 ml) 
over 5 h. The resulting solution was stirred for 24 h at RT and then concentrated in 
vacuo to obtain a colourless oil which was partitioned between Na2CO3 (20 ml, 2 M aq.) 
and DCM (20 ml). The aqueous layer was extracted with DCM (2 × 20 ml) and 
concentrated under reduced pressure to give the Boc-protected amine 50 as a colourless 
oil (4.45 g, 99% yield); Rf (10% MeOH in DCM) = 0.1; νmax (neat)/cm
-1
 3446 (NH), 
1710 (CO);
 1
H NMR δ (360 MHz, CD3OD) 3.13 (2H, t, J = 6.2 Hz, CH2NHCO), 2.73 
(2H, t, J = 6.2 Hz, CH2NH2), 1.44 (9H, s, 3 × CH3); 
13
C NMR δ (90.6 MHz, CD3OD), 
158.68 (C), 80.18 (C), 43.26 (CH2), 42.20 (CH2), 28.79 (3 × CH3); m/z (ESI+) 183 
([M+Na]
+




All spectroscopic data were in good agreement with the literature.
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To a solution of benzoic acid 2 (100 mg, 0.413 mmol), in DMF (3 ml), EDC (94.0 mg, 
0.500 mmol) and HOBt (27.0 mg, 0.200 mmol) were added. After stirring for 15 min N-
Boc-ethylenediamine 50 (131 mg, 0.800 mmol) was added and the reaction stirred for 
48 h at RT. The solvent was removed in vacuo, the crude material was dissolved in 
DCM (2 ml) and the solution washed with HCl (5 ml, 1 M aq.). The solvent was 
removed in vacuo. The crude product was dissolved in MeOH (2 ml), silica was added 
and the mixture dried in vacuo. Flash chromatography (dry loaded silica column, 2% 
MeOH in DCM) yielded the desired amide as an orange solid (94 mg, 60% yield); Rf 
(5% MeOH in DCM) = 0.31; mp 169-171 °C; νmax (neat)/cm
-1
 3361 (NH), 1689 (CO), 
1637 (CO), 1535 (NN); 
1
H NMR δ (250 Mz, (CD3)2CO) 8.06 (2H, d, J = 8.6 Hz, ArH), 
7.90 (2H, d, J = 8.6 Hz, ArH), 7.89 (2H, d, J = 8.8 Hz, ArH), 7.04 (2H, d, J = 8.8 ArH), 
6.47 (1H, br s NH), 3.73-3.66 (2H, m, CH2), 3.55-3.48 (2H, m, CH2), 1.58 (9H, s, CH3); 
13
C NMR δ (62.9 MHz, (CD3)2CO) 167.11 (C), 162.20 (C), 161.66 (C), 155.17 (C), 
147.27 (C), 137.13 (C), 129.18 (2 × CH), 126.15 (2 × CH), 123.03 (2 × CH), 116.91 (2 
× CH), 79.02 (C), 41.63 (CH2), 41.06 (CH2), 28.71 (3 × CH3); m/z (ESI-) 383 ([M-H]
-
, 
18%), 134 (100), 113 (72); HRMS (ESI+) [M+NH4]
+








To a stirred solution of phenol 52 (800 mg, 2.08 mmol) in MeCN (30 ml) was added 
potassium carbonate (430 mg, 16.6 mmol) and the mixture was heated to 70 °C. 1,3-
Dibromopropane (1.70 ml, 16.6 mmol) was added and the reaction heated to reflux for 5 
h. The solvent was removed in vacuo to give the crude bromide. Purification by flash 
chromatography (5% MeOH in DCM) yielded the desired bromide 58 (710 mg, 67% 
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yield) as a yellow solid; Rf (5% MeOH in DCM) = 0.58; mp 188-190 °C; νmax 
(neat)/cm
-1
 1700 (CO), 1659 (CO); 
1
H NMR δ (250 MHz, CDCl3) 7.98-7.88 (6H, m, 
ArH), 7.44 (1H, br s, NH), 7.26-7.21 (2H, m, ArH), 5.12 (1H, br s, NH), 4.20 (2H, t, J = 
6.0 Hz, CH2), 3.64 (2H, t, J = 6.4 Hz, CH2), 3.60-3.55 (2H, m, CH2), 3.48-3.40 (2H, m, 
CH2), 2.37 (2H, qn, J = 6.0 Hz, CH2), 1.44 (9H, s, CH3); 
13
C NMR δ (62.9 MHz, 
CDCl3) 175.55 (C), 175.27 (C), 167.57 (C), 162.00 (C), 154.70 (C), 135.24 (C), 128.40 
(2 × CH), 125.50 (2 × CH), 122.96 (2 × CH), 115.21 (2 × CH), 80.49 (C), 66.06 (CH2), 


















2); HRMS (FAB, 3-NOBA) [M+H]
+










The Boc-protected bromide 58 (710 mg, 1.40 mmol) was dissolved in DMF (15 ml) and 
sodium azide (273 mg, 4.20 mmol) was added. The solution was stirred overnight (~18 
h) at RT. The solvent was removed in vacuo and the crude material dissolved in diethyl 
ether (20 ml), washed with brine (20 ml) and H2O (20 ml) to give the azide 59 (588 mg, 
90% yield) as a pale yellow solid (90:10, E:Z); Rf (5% MeOH in DCM) = 0.58; mp 173-
174 °C; νmax (neat)/cm
-1
 3366 (NH), 3317 (NH), 2100 (N3), 1680 (CO), 1636 (CO); 
1
H 
NMR δ (250 MHz, CDCl3), 7.96-7.86 (5.40 H (E), m, ArH), 7.74 (0.20 H (Z), d, J = 8.5 
Hz ArH), 7.35 (0.90 H (E), br s, NH), 7.07-6.93 (1.80 H (E), m, ArH), 6.87 (0.40 H (Z), 
m, ArH), 6.71 (0.20 H (Z), d, J = 8.8 Hz, ArH), 5.00 (0.90 H (E), br s, NH), 4.13 (1.80 
H (E), t, J = 6.0 Hz, CH2), 3.98 (0.20 H (Z), t, J = 6.0 Hz, CH2), 3.66-3.34 (6H, m, 2 × 
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CH2NH+CH2N3), 2.14-1.94 (2H , m, CH2CH2CH2), 1.42 (8.10 H (E), s, 3 × CH3) 1.39 
(0.90 H (Z), s, 3 × CH3); 
13
C NMR δ (62.9 MHz, CDCl3) 167.35 (C), 161.79 (C), 
157.95 (C), 154.62 (C), 147.34 (C), 135.53 (C), 128.21 (2 × CH), 125.32 (2 × CH), 
122.80 (2 × CH), 115.00 (2 × CH), 80.40 (C), 65.09 (CH2), 48.36 (CH2), 42.68 (CH2), 
40.09 (CH2), 28.94 (CH2), 28.56 (3 × CH3); m/z (ESI+) 957 ([2M+Na]
+
, 27%), 490 
([M+Na]
+
, 100), 390 (52), 71 (43); HRMS (FAB, 3-NOBA) found [M+H]
+
 468.2351, 







Acetyl chloride (10 ml) was added to dry MeOH (60 ml) at 0 °C and the solution was 
stirred for 30 min. Boc-protected aminoazide 59 (850 mg, 1.82 mmol) was dissolved in 
this solution and stirred for 1 h. Completion of the reaction was monitored by TLC. 
Diethyl ether (20 ml) was added and the amine hydrochloride salt precipitated as a 
yellow solid. The salt 60 was filtered and used without further purification (720 mg, 
95% yield), (80:20, E:Z); Rf (20% MeOH in DCM = 0.42); mp 250 °C (decomposition); 
νmax (nujol)/cm
-1
 3413 (NH), 3273 (NH), 2100 (N3), 1639 (CO); 
1
H NMR δ (800 MHz, 
(CD3)2CO) 8.77 (0.80 H (E), br s, NH), 8.61 (0.20 H (Z), br s, NH), 8.06 (1.60 H (E), d, 
J = 8.5 Hz, ArH), 7.95-7.93 (3.20 H (E), ArH), 7.82 (0.40 H (Z), d, J = 8.5 Hz, ArH), 
7.17 (1.60 H (E), d, J = 8.8 Hz, ArH), 6.94 (0.40 H (Z), d, J = 8.5 Hz, ArH), 6.91-6.87 
(0.80 H (Z), ArH), 4.18 (1.60 H (E), t, J = 6.1 Hz, CH2), 4.00 (0.40 H (Z), t, J = 6.1 Hz, 
CH2), 3.56-3.52 (3.20 H (E), m, 2 × CH2), 3.48-3.46 (0.80 H (Z), m, 2 × CH2 ), 3.03 
(1.60 H (E) br s, NH2), 2.98 (0.40 H (Z) br s, NH2), 2.03 (1.60 H (E), qn, J = 6.4 Hz, 
CH2), 1.94 (0.40 H (Z), qn, J = 6.4 Hz, CH2); 
13
C NMR δ (200 MHz, (CD3)2CO), 
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166.21 (C) (E), 166.04 (C) (Z), 161.60 (C) (E), 156.46 (C) (Z), 153.55 (C) (E), 146.25 
(C) (E), 146.19 (C) (Z), 135.51 (C) (E), 131.88 (C) (Z), 128.69 (2 × CH) (E), 128.40 (2 
× CH) (Z), 124.87 (2 × CH) (E), 123.21 (2 × CH) (Z), 121.98 (2 × CH) (E), 118.95 (2 × 
CH) (Z), 115.19 (2 × CH) (E), 114.36 (2 × CH) (Z), 65.27 (CH2) (E), 64.91 (CH2) (Z), 
47.63 (CH2) (E), 47.56 (CH2) (Z), 38.65 (CH2) (E), 37.20 (CH2) (E), 37.10 (CH2) (Z), 
28.01 (CH2) (E), 27.96 (CH2) (Z); m/z (ESI+) 368 ([M+H]
+
, 60%) HRMS, (FAB, 3-






To a stirred solution of 3-chloropropylamine hydrochloride (560 mg, 4.31 mmol), 
dissolved in H2O (5 ml) sodium azide was added (840 mg, 12.0 mmol), and the mixture 
heated to 80 ºC. After 15 h, KOH in pellets was added to basify the solution, followed 
by extraction with diethyl ether (3 × 5 ml). The combined organic phases were dried 
over magnesium sulphate and concentrated to give the desired amine as a colourless 
volatile oil (413 mg, 99% yield); νmax (neat)/cm
-1
 2104 (N3) 
1
H NMR δ (250 MHz, 
CDCl3) 3.35 (2H, t, J = 6.8 Hz, CH2NH), 2.90 (2H, t, J = 6.8 Hz CH2N3) 1.83 (2H, qn, J 
= 6.8 Hz CH2CH2CH2) 1.35 (2H, br s, NH2); 
13
C NMR δ (62.9 MHz, CDCl3) 49.12 
(CH2), 39.30 (CH2), 32.43 (CH2); m/z (ESI+) 101 ([M+H]
 +
, 68%), 76 (32), 58 (100). 
 
All spectroscopic data were in good agreement with the literature.
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Safety in the Handling of Sodium Azide and other Azides:
256
 Sodium azide is toxic 
and can be absorbed through the skin. It decomposes explosively upon heating to above 
275 °C. Sodium azide reacts vigorously with CS2, bromine, nitric acid, dimethyl sulfate, 
and a series of heavy metals, including copper and lead. In reaction with H2O or 
Brønsted acids the highly toxic and explosive hydrogen azide is released. It has been 
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reported that sodium azide and polymer-bound azide reagents form explosive di- and 
triazidomethane with DCM and CHCl3, respectively. Heavy-metal azides that are highly 
explosive under pressure or shock are formed when solutions of NaN3 or HN3 vapors 
come into contact with heavy metals or their salts. Heavy-metal azides can accumulate 
under certain circumstances, for example, in metal pipelines and on the metal 
components of diverse equipment (rotary evaporators, freeze drying equipment, cooling 
traps, H2O baths, waste pipes), and thus lead to violent explosions. Some organic and 
other covalent azides are classified as toxic and highly explosive, and appropriate safety 
measures must be taken at all times. 
 




3-Azido-1-propylamine (562 mg, 5.62 mmol), was added to a solution of Affi-Gel 10 in 
isopropanol (25.0 ml, 0.375 mmol). The suspension was shaken gently for 48 h. The 
matrix was filtered, washed with MeOH (3 × 5 ml), H2O (3 × 5 ml), and stored in 
isopropanol (12.0 ml); νmax (KBr)/cm
-1
 2103 (N3), 1656 (CO).  
 




The hydrochloride salt of diazobenzene linker 60 (226 mg, 0.560 mmol) was dissolved 
in H2O/MeCN (1/1, 4 ml) and Et3N (81.0 µl, 0.560 mmol) was added. The mixture was 
added to a solution of Affi-Gel 10 in isopropanol (12.5 ml, 0.187 mmol) and the 
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suspension was shaken gently for 24 h. The matrix was filtered, washed with MeOH (3 
× 5 ml), H2O (3 × 5 ml) and stored in isopropanol (12.5 ml) νmax (KBr)/cm
-1
 2103 (N3), 
1660 (CO).  
 




Affi-Gel supported azide 73 in isopropanol (10 ml, 0.15 mmol) was filtered, washed 
with MeOH (3 × 3 ml), H2O (3 × 3 ml) and resuspended in H2O/t-BuOH (1/1, 10 ml). 
Sodium ascorbate (6.0 mg, 0.030 mmol) and CuSO4 (4.0 mg, 0.010 mmol) were 
dissolved in a minimal amount of H2O and the solution was added to the suspended 
resin, followed by a solution of TBTA (8.00 mg, 0.010 mmol) dissolved in t-BuOH (0.5 
ml). After stirring for 10 min propargyl alcohol (26 µl, 0.45 mmol) was added and the 
mixture was shaken gently for 48 h. The reaction was monitored by IR and stopped once 
the azide peak at 2100 cm
-1
 disappeared. The matrix was filtered, washed with MeOH (3 
× 3 ml), H2O (3 × 3 ml), EDTA (3 × 3 ml, 0.1 M aq.) and the matrix 75 was stored in 
isopropanol (12.5 ml); νmax (KBr), 1626 (CO). 
 




Affi-Gel supported azide 71 in isopropanol (25.0 ml, 0.375 mmol) was filtered, washed 
with MeOH (3 × 5 ml), H2O (3 × 5 ml) and resuspended in H2O/t-BuOH (2/1, 24.0 ml). 
Propargyl biotin (316 mg, 1.12 mmol), sodium ascorbate (14.8 mg, 0.0750 mmol) and 
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CuSO4 (10.0 mg, 0.0370 mmol) were dissolved in H2O (0.5 ml) and the solution was 
added to the suspended resin. The suspension was shaken gently for 48 h. The reaction 
was monitored by IR and stopped once the azide peak at 2100 cm
-1
 disappeared. The 
matrix was filtered, washed with MeOH (3 × 5 ml), H2O (3 × 5 ml), EDTA (3 × 5 ml, 
0.1 M aq.) and matrix 72 was stored in isopropanol (25.0 ml); νmax (KBr), 1638 (CO), 
1618 (CO). 
 




Affi-Gel supported azide 73 in isopropanol (12.5 ml, 0.187 mmol) was filtered, washed 
with MeOH (3 × 5 ml), H2O (3 × 5 ml) and resuspended in H2O/t-BuOH (2/1, 12 ml). 
Sodium ascorbate (6.00 mg, 0.0300 mmol) and CuSO4 (4.00 mg, 0.0100 mmol) were 
dissolved in H2O (0.5 ml) and the solution was added to the suspended resin, followed 
by a solution of TBTA (8.00 mg, 0.0100 mmol) dissolved in t-BuOH (0.5 ml). After 
stirring for 10 min propargyl biotin was added (158 mg, 0.562 mmol) and the mixture 
was shaken gently for 48 h. The reaction was monitored by IR and stopped once the 
azide peak at 2100 cm
-1
 disappeared. The matrix was filtered, washed with MeOH (3 × 
5 ml), H2O (3 × 5 ml), EDTA (3 × 5 ml, 0.1 M aq.) and matrix 74 was stored in 
isopropanol (12.5 ml); νmax (KBr), 1651 (CO).  
 






Affi-Gel supported azide 73 in isopropanol (5.0 ml, 0.075 mmol) was filtered, washed 
with MeOH (3 × 3 ml), H2O (3 × 3 ml) and resuspended in H2O/t-BuOH (1/1, 8 ml). 
Sodium ascorbate (6.0 mg, 0.030 mmol) copper sulphate (4.0 mg, 0.010 mmol) 
previously dissolved in a minimal amount of H2O and TBTA (8.0 mg, 0.010 mmol) 
dissolved in t-BuOH, were added. After strirring for 10 min, propargyl anisomycin (45 
mg, 0.15 mmol) was added. The mixture was gently shaken for 48 h. The reaction was 
monitored by IR and stopped once the azide peak at 2100 cm
-1
 disappeared. The matrix 
was filtered, washed with MeOH (3 × 3 ml), H2O (3 × 3 ml), EDTA (3 × 3 ml, 0.1 M 






Affi-Gel supported alcohol 75 in isopropanol (0.075 mmol, 5 ml) was filtered and 
resuspended in a solution of sodium dithionite, (3 ml, 0.3 M aq.) and shaken gently for 
10 min. The matrix was filtered and the procedure repeated twice. The cleavage was 
monitored by the change in colour of the matrix (from bright orange to colourless). The 
combined washings were extracted with EtOAc (3 × 5 ml) to give the aniline 77 as a 
colourless oil (13 mg, 70 % yield). 
1
H NMR δ (250 MHz, CDCl3) 7.50 (1H, s, ArH), 
6.76-6.54 (4H, m, ArH), 4.77 (2H, s, CH2OH), 4.56 (2H, t, J = 6.8 Hz, CH2O), 3.87 (2H, 
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t, J = 6.0 Hz, CH2N), 2.33 (2H, qn, J = 6.5 Hz, CH2), 1.56 (2H, br s, NH2); m/z (ESI+) 
271 ([M+Na]
+





7.3 Preliminary affinity studies 
7.3.1 Material and methods 
 
SDS-PAGE materials and avidin were from Invitrogen; NuPAGE 4-12% Bis-Tris Gels 
(NP0321) were run according to manufacturers descriptions using 4×SDS loading buffer 
(NP0007) and 10×reducing agent (NP0004). Molecular weight markers were Precision 
Plus unstained standards from Bio-Rad (161-0363). Phosphate Buffered Saline (PBS) 
was prepared by dissolving PBS tablets from Oxoid (BR0014G) in distilled water. 
Avidin was purchased from Invitrogen. All other reagents were from Sigma Aldrich and 
were of the highest available purity. 
 
7.3.2 Competitive capture and release of avidin 
 
Five affinity experiments were carried out in parallel as follows: 
 
1: Compound 72 + avidin (classical elution method) 
2: Compound 72 + avidin (chemical cleavage) 
3: Compound 74 + albumin (classical elution method) 
4: Compound 74 + avidin (classical elution method) 
5: Compound 74 + avidin (chemical cleavage) 
 
Matrix 72 or 74 in isopropanol (0.015 mmol, 1 ml) was transferred to a Falcon tube, 
pelleted by centrifugation (5 min at 3,000g) and the solvent was decanted. The matrix 
was washed with water (3 × 5 ml) and HEPES buffer (3 × 5 ml, 50 mM HEPES, pH 7.5, 
150 mM NaCl). A solution of avidin (1 ml, 1 mg ml
-1
) was added to matrix 72 (exp 1 & 
2) and matrix 74 (exp 4 & 5), and a solution of albumin (1 ml, 1 mg ml
-1
) was added to 
matrix 74 (exp 3). The matrix was further diluted with HEPES buffer (4 ml) and 
incubated for 30 min with gentle shaking. The matrix was pelleted and the supernatant 
 
 165 
collected and analysed by SDS-PAGE (Fig. 39, Lanes A-E). The matrix was further 
washed with HEPES buffer (3 × 5 ml) prior to the elution protocol. The matrix (exp 1, 3 
& 4) was suspended in 2×SDS loading buffer (1 ml) and HEPES buffer (1 ml), heated 
for 10 min at 100 ºC, pelleted by centrifugation (2 min at 10,000g), and the supernatant 
collected. The supernatants were analysed by SDS-PAGE (Fig. 39, Lanes F-H). The 
matrix (exp 2 & 5) was divided into three aliquots which were treated with a freshly 
prepared solution of sodium dithionite (25 μl, 0.3 M) at three different pHs (6.5, 7.5 & 
8.5, 50 mM KPO4). The matrix was gently shaken for 10 min, pelleted by centrifugation 
(2 min at 10,000g) and the supernatant collected. The cleavage procedure was repeated 
and the supernatants were pooled, treated with 2×SDS loading buffer and heated for 10 
min at 100 ºC. The supernatants were analysed by SDS-PAGE (Fig. 39, Lanes I1-J3). 
 
7.3.3 Capture and release of avidin from a protein mixture 
 
Two affinity experiments were carried out in parallel as follows: 
 
1: Compound 72 + avidin enriched FBS in PBS (classical elution method) 
2: Compound 72 + avidin enriched FBS in PBS (chemical cleavage) 
 
Matrix 72 or 74 in isopropanol (0.015 mmol, 1 ml) was transferred to a Eppendorf tube, 
pelleted by centrifugation (2 min at 10,000g) and the solvent was decanted. The matrix 
was washed with water (3 × 1.5 ml) and PBS buffer (3 × 1.5 ml). A solution of avidin 
enriched (100 μg ml
-1
) 10 % FBS in PBS (1 ml) was added. The matrix was incubated 
with the protein mixture for 30 min with gentle shaking. The matrix was pelleted and the 
supernatant collected and analysed by SDS-PAGE (Fig. 40, Lanes B & C). The matrix 
was washed with 4×PBS buffer (3 × 1.5 ml) prior to the elution protocol. Matrix 72 was 
resuspended in 4×SDS loading buffer (100 μl) and 10× reducing agent (10 μl) and 
heated for 10 min at 100 ºC, centrifuged (2 min at 10,000g) and the supernatant 
collected. The supernatant was analysed by SDS-PAGE (Fig. 40, Lane D). Matrix 74 
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was incubated with a freshly prepared solution of sodium dithionite (25 μl, 0.3 M) at pH 
6.5. The matrix was gently shaken for 10 min, pelleted by centrifugation (2 min at 
10,000g) and the supernatant collected. The cleavage procedure was repeated and the 
supernatants were pooled, treated with 4×SDS loading buffer (25 μl) and 10×reducing 
agent (8 μl) and heated for 10 min at 100 ºC. The supernatants were analysed by SDS-
PAGE (Fig. 40, Lane E). 
 
7.3.4 Pull-down experiments with HEK 293 cells 
 
A series of pull-down experiments were carried out using biotinylated anisomycin 28 
and solid supported anisomycin featuring a cleavable unit 32. Along with these two 
molecular probes (positive controls, +), a series of negative controls (−) at various 
concentrations were employed and indicated as follows: 
 
1: Biotin propargyl amide 69, 50 mM (BP): (−) 
2: A biotinylated peptide, 50 mM (BPe): (−) 
3: Biotinylated anisomycin 28, 50 mM (BA): (+) 
4: Solid-supported cleavable unit 73, 50 mM (SL50): (−) 
5: Solid-supported cleavable unit 73, 5 mM (SL5): (−) 
6: Solid-supported anisomycin featuring a cleavable unit 32, 50 mM (SLA50): (+) 
7: Solid-supported anisomycin featuring a cleavable unit 32, 5 mM (SLA5): (+) 
 
A streptavidin-coated agarose matrix (40 µl, of a 50/50 mixture beads) was transferred 
to three Eppendorf tubes. The matrices were washed with Buffer W* (3 × 300 µl), 
pelleted by centrifugation (2 min at 4,000g) and the solvent was decanted. Biotinylated 
compounds (BP, BPe and BA, 1 µl, 50 mmol ml
-1
) were added to the matrices together 
with Buffer W (200 µl). The matrices were incubated with the biotinylated compounds 
for 1 h with gentle shaking at RT. The matrices were then washed with Buffer W* (3 × 
300 µl), pelleted by centrifugation (2 min at 4,000g) and the solvent was decanted. 
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Solid-supported compounds (SL50, SL5, SLA50 and SLA5, 40 µl) were transferred to 
four Eppendorf tubes. The matrices were washed with Buffer W (3 × 300 µl), pelleted 
by centrifugation (2 min at 4,000g) and the solvent was decanted. A cleared whole 
lysate of HEK 293 cells (49 µl) was added to all the matrices together with Buffer W 
(151 µl). The matrices were incubated with the cell lysate
1
 for 1 h with gentle shaking. 
All the matrices were washed with Buffer W (3 × 300 µl), than PBS + 0.2% Triton (4 × 
300 µl) and again Buffer W (1 × 300 µl), pelleted by centrifugation (4 min at 2,000g) 
and the solvent was decanted. Matrices BP, BPe and BA were resuspended in 2×SB 
loading buffer (40 μl), heated for 15 min at 95 ºC, pelleted by centrifugation (5 min at 
2,000g) and the supernatants collected. The supernatants were analysed by SDS-PAGE. 
Solid supported compounds SL50, SL5, SLA50 and SLA5 were incubated with a freshly 
prepared solution of sodium dithionite (25 μl, 0.3 M) at pH 6.5. The matrix was gently 
shaken for 10 min, pelleted by centrifugation (2 min at 10,000g) and the supernatant 
collected. The cleavage procedure was repeated and the supernatants were pooled, 
treated with 2×SB loading buffer (40 μl), heated for 15 min at 95 ºC and analysed by 
SDS-PAGE. 
 
(1) HEK 293 cell lysate preparation. 
The cells were harvested (7 min, 4 °C, 4,000g), lysed in in 0.1% Triton Lysis buffer** 
(400ul/plate, 20min) and pelleted by centrifugation (12 min, 4 °C, 13,200g). Cell lysate 
was treated with avidin (40 µg ml
-1
 of a 2mg/ml stock) for 30 min on ice and and the 
pellets were discarded. Treated lysate was pre-cleared of endogenous biotinylated 
proteins using Sepharose-4B (Sigma) beads for 1 h at 4 °C. The supernatant was 
collected and the protein content was estimated by Bradford assay. 
 
*Buffer W: 100 mM Tris pH 8, 150 mM NaCl, 1mM EDTA. 
**0.1% Triton Lysis Buffer: 50 mM HEPES, 0.1 mM EDTA, 150 mM NaCl, 10 mM 
NaF, 2 mM DTT, 0.1% Triton×100, 1×PIM. 
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7.4 Experimental procedures for chapters 5 and 6 
 




To a suspension of glycine methyl ester hydrochloride (30.0 g, 240 mmol) and MgSO4 
(38.1 g, 320 mmol) in DCM (400 ml), Et3N (40.4 ml, 280 mmol) was added. The 
mixture was stirred at RT for 1 h, and then benzaldehyde (20.4 ml, 200 mmol) was 
added. The reaction was stirred overnight (~18 h) at RT. The mixture was filtered and 
the filtrate was washed with H2O (500 ml). The aqueous phase was extracted with DCM 
(2 × 250 ml) and the combined organic layers were washed with NaCl (3 × 400 ml, sat. 
aq.), dried over MgSO4 and the solvent removed in vacuo. The resulting glycine 
iminoester was isolated as a yellow oil (35.4 g, 99% yield) with minor impurities and 
used without further purification; Rf (30% EtOAc in hexane) = 0.41; νmax (neat)/cm
-1
 
1743 (CO), 1648 (CN); 
1
H NMR δ (500 MHz, CDCl3) 8.29 (1H, s, CHN), 7.84-7.74 
(2H, d, J = 6.5 Hz, ArH), 7.48-7.37 (3H, m, ArH), 4.42 (2H, s, CH2), 3.77 (3H, s, CH3); 
13
C NMR δ (126 MHz, CDCl3) 170.60 (C), 165.50 (CH), 135.55 (C), 131.29 (CH), 
128.64 (2 × CH), 128.51 (2 × CH), 61.98 (CH2), 52.15 (CH3); m/z (ESI+) 200 
([M+Na]
+
, 58 %), 178 ([M+H]
+
, 100), 118 (7). 
 










To a slurry of glycine methyl ester hydrochloride (5.00 g, 40.0 mmol) in DCM (40 ml) 
was added benzophenone imine (6.71 ml, 40.0 mmol) in DCM (40 ml), and the reaction 
was stirred overnight (~18 h) at RT. The milky mixture was washed with H2O (2 × 15 
ml) and NaCl (15 ml, sat. aq.). The organic layer was separated and dried over MgSO4. 
The crude product was recrystallised from hexane/DCM to obtain glycine iminoester 
248 as a pale yellow solid (8.76 g, 88% yield); Rf (30% EtOAc in hexane) = 0.51; νmax 
(neat)/cm
-1
 1746 (CO), 1626 (CN); 
1
H NMR (500 MHz, CDCl3) δ 7.66 (2H, d, J = 7.5 
Hz, ArH), 7.50-7.37 (4H, m, ArH), 7.33 (2H, t, J = 7.5 Hz, ArH), 7.18 (2H, d, J = 7.5 
Hz, ArH), 4.22 (2H, s, CH2), 3.75 (3H, s, CH3); 
13
C NMR δ (126 MHz, CDCl3) 172.10 
(C), 171.27 (C), 139.35 (C), 136.06 (C), 130.64 (CH), 129.00 (CH), 128.91 (2 × CH), 
128.85 (2 × CH), 128.22 (2 × CH), 127.78 (2 × CH), 55.75 (CH2), 52.16 (CH3); m/z 
(ESI+) 529 ([2M+Na]
+
, 17%), 276 ([M+Na]
+




All spectroscopic data were in good agreement with the literature.
234,257 
 




To a slurry of glycine ethyl ester hydrochloride (5.00 g, 36.0 mmol) in DCM (40 ml) 
was added benzophenone imine (6.04 ml, 36.0 mmol) in DCM (40 ml), and the reaction 
was stirred overnight (~18 h) at RT. The milky mixture was washed with H2O (2 × 15 
ml) and NaCl (15 ml, sat. aq.). The organic layer was separated and dried over MgSO4. 
The crude product was recrystallised from hexane/DCM to obtain glycine iminoester 
248b as a colourless solid (8.20 g, 85% yield); Rf (30% EtOAc in hexane) = 0.56; νmax 
(neat)/cm
-1
 1739 (CO), 1625 (CN); 
1
H NMR δ (500 MHz, CDCl3) 7.69 (2H, d, J = 7.5 
 
 170 
Hz, ArH), 7.53-7.40 (4H, m, ArH), 7.36 (2H, t, J = 7.5 Hz, ArH), 7.21 (2H, d, J = 7.5 
Hz, ArH), 4.23 (2H, q, J = 7.1 Hz, CH2CH3), 4.22 (2H, s, CH2CO), 1.30 (3H, t, J = 7.1 
Hz, CH3);
 13
C NMR δ (126 MHz, CDCl3) 171.99 (C), 170.79 (C), 139.34 (C), 136.12 
(C), 130.51 (CH), 128.95 (CH), 128.89 (2 × CH), 128.81 (2 × CH), 128.19 (2 × CH), 





, 25), 268 ([M+H]
+
, 100), 254 (18). 
 








To a slurry of glycine tert-butyl ester hydrochloride (5.00 g, 30.0 mmol) in DCM (40 
ml) was added benzophenone imine (5.03 ml, 30.0 mmol) in DCM (40 ml), and the 
reaction was stirred overnight (~18 h) at RT. The milky mixture was extracted with H2O 
(2 × 15 ml) and NaCl (15 ml, sat. aq.). The organic layer was separated, dried over 
MgSO4 and the solvent removed in vacuo. The crude product was obtained as a 
colourless solid which was recrystallised from hexane to obtain iminoester 148 as 
colourless crystals (8.10 g, 91% yield); Rf (30% EtOAc in hexane) = 0.70; νmax 
(neat)/cm
-1
 1734 (CO), 1634 (CN); 
1
H NMR δ (500 MHz, CDCl3) 7.69 (2H, d, J = 7.5 
Hz, ArH), 7.53-7.39 (4H, m, ArH), 7.36 (2H, t, J = 7.5 Hz, ArH), 7.21 (2H, d, J = 7.5 
Hz, ArH), 4.14 (2H, s, CH2), 1.49 (9H, s, 3 × CH3); 
13
C NMR δ (126 MHz, CDCl3) 
171.64 (C), 170.00 (C), 139.53 (C), 136.29 (C), 130.49 (CH), 128.88 (3 × CH), 128.74 
(2 × CH), 128.16 (2 × CH), 127.86 (2 × CH), 81.20 (C), 56.45 (CH2), 28.24 (3 × CH3); 
m/z (ESI+) 613 ([2M+Na]
+
, 100%), 318 ([M+Na]
+
, 25), 296 ([M+H]
+












To a stirred solution of 2-methylallyl alcohol (14.4 g, 200 mmol) in DCM (100 ml) 
cooled to 0 ºC, pyridine (15.8 g, 200 mmol) and ethyl chlorocarbonate (21.7 g, 200 
mmol) were added. The reaction mixture was allowed to reach RT and stirred overnight 
(~18 h). The mixture was quenched with NH4Cl (100 ml, sat. aq.). The organic layer 
was separated and the aqueous layer extracted with Et2O (2 × 100 ml). The combined 
organic layers were washed with H2O (100 ml) and dried over Na2SO4. The solvent was 
removed in vacuo to give the crude allylic carbonate. Flash chromatography (10% 
EtOAc in hexane) gave the desired allylic carbonate as a colourless oil (23.2 g, 80% 
yield); Rf (20% EtOAc in hexane) = 0.80; νmax (neat)/cm
-1
 1742 (CO) 1660 (C=C); 
NMR δ (500 MHz, CDCl3) 5.00 (s, 1H, C=CHaHb), 4.93 (s, 1H, C=CHaHb), 4.52 (s, 2H, 
CH2O), 4.19 (2H, q, J = 7.1 Hz, CH2CH3), 1.76 (s, 3H, CH3), 1.30 (3H, t, J = 7.1 Hz, 
CH2CH3); 
13
C NMR δ (126 MHz, CDCl3) 155.18 (C), 139.54 (C), 113.53 (CH2), 71.03 
(CH2), 64.12 (CH2), 19.43 (CH3), 14.36 (CH3); m/z (ESI+) 311 ([2M+Na]
+
, 8%), 145 
([M+H]
+
, 10), 101 (5). 
 











To a solution of Schiff base 218 (35.4 g, 200 mmol) and allyl carbonate 217 (43.2 g, 300 
mmol) in dry THF (200 ml), Pd(PPh3)4 (10.0 g, 8.00 mmol) was added. The reaction 
mixture was stirred at RT until the starting material was consumed (~6 h). The mixture 
was poured onto Et2O and filtered through Celite. The solvent was removed in vacuo to 
yield the product as pale yellow oil with minor triphenyl phosphine impurities (33.5 g, 
72% yield); Rf (20% EtOAc in hexane) = 0.60; νmax (neat)/cm
-1
 1736 (CO), 1641 
(C=N); 
1
H NMR δ (500 MHz, CDCl3) 8.24 (1H, s, ArCHN), 7.80 (2H, dd, J = 7.5 & 1.6 
Hz, ArH), 7.52-7.37 (3H, m, ArH), 4.84 (1H, br s, CCHaHb), 4.76 (1H, br s, CCHaHb), 
4.19 (1H, dd, J = 8.3 & 5.6 Hz, CHN), 3.78 (3H, s, OMe), 2.78 (1H, dd, J = 13.8 & 5.6 
Hz, CHCHcHd), 2.58 (1H, ddd, J = 13.8 & 8.3 & 0.7 Hz, CHCHcHd), 1.77 (3H, s, Me); 
13
C NMR δ (126 MHz, CDCl3) 172.46 (C), 163.41 (CH), 141.18 (C), 135.77 (C), 
131.27 (CH), 128.73 (2 × CH), 128.69 (2 × CH), 114.13 (CH2), 72.21 (CH), 52.36 
(CH3), 41.74 (CH2), 22.93 (CH3); m/z (ESI+) 254 ([M+Na]
+












To a solution of Schiff base 148 (1.00 g, 3.83 mmol) and allyl ethyl carbonate 217 
(0.730 g, 5.07 mmol) in dry THF (5 ml), Pd(PPh3)4 (0.195 g, 0.169 mmol) was added. 
The reaction mixture was stirred at RT until the starting material was consumed (~7 h). 
The mixture was poured onto Et2O and filtered through Celite. The solvent was removed 
in vacuo. Flash chromatography (dry loaded basic silica, 1% EtOAc in hexane) gave the 





 1708 (CO), 1624 (CN); 
1
H NMR δ (400 MHz, CDCl3) 7.69 (2H, d, J = 
7.0 Hz, ArH), 7.50-7.27 (6H, m, ArH), 7.24-7.17 (2H, m, ArH), 4.76 (1H, br s, C5HaHb), 
4.74 (1H, br s, C5HaHb), 4.12 (1H, dd, J = 8.3 & 5.2 Hz, C2H), 2.67 (1H, dd, J = 13.6 & 
5.2 Hz, C3HcHd), 2.60 (1H, dd, J = 13.6 & 8.3 Hz, C3HcHd), 1.54 (3H, s, C4CH3), 1.47 
(9H, s, 3 × CH3); 
13
C NMR δ (101 MHz, CDCl3) 171.25 (C), 169.92 (C), 141.89 (C), 
139.83 (C), 136.55 (C), 130.15 (CH), 128.86 (2 × CH), 128.57 (CH), 128.35 (2 × CH), 
128.12 (2 × CH), 127.99 (2 × CH), 113.39 (CH2), 81.02 (C), 64.85 (CH), 41.96 (CH2), 
28.10 (3 × CH3), 22.65 (CH3); m/z (ESI+) 722 ([2M+Na]
+





, 100), 130 (48). 
 








Alkylated Schiff base 219 (33.0 g, 140 mmol) was stirred with HCl (186 ml, 1.5 M aq., 
280 mmol) at RT (~2 h). The reaction was monitored for the consumption of the starting 
material (LC-MS). After washing with Et2O, solid NaHCO3 was added to the aqueous 
phase until pH 8 was reached. After saturation with solid NaCl, the aqueous phase was 
extracted with CHCl3 (3 × 100 ml) and dried over MgSO4. The solvent was removed in 
vacuo affording the product as yellow oil (17.0 g, 85% yield); Rf (20% EtOAc in 
hexane) = 0.10; νmax (neat)/cm
-1
 1735 (CO), 1648 (C=C); 
1
H NMR δ (500 MHz, CDCl3) 
4.87 (1H, br s, C5HaHb), 4.78 (1H, br s, C5HaHb), 3.73 (3H, s, OMe), 3.63 (1H, dd, J = 
8.9 & 5.1 Hz, C2H), 2.50 (1H, dd, J = 13.7 & 5.1 Hz, C3HcHd), 2.24 (1H, dd, J = 13.7 & 
8.9 Hz, C3HcHd), 1.75 (3H, s, Me); 
13
C NMR δ (126 MHz, CDCl3) 176.11 (C), 141.39 
(C), 114.22 (CH2), 52.66 (CH), 52.14 (CH3), 43.67 (CH2), 22.03 (CH3); m/z (ESI+) 166 
([M+Na]
+
, 37%), 144 ([M+H]
+












Alkylated Schiff base 232 (1.00 g, 2.86 mmol) was stirred for 2-3 h with an aqueous 
solution of HCl (20.0 ml, 1 M aq., 20.0 mmol) and THF (20 ml) at RT. The reaction was 
monitored for the consumption of the starting material (LC-MS). The mixture was 
diluted with H2O (40 ml). The aqueous phase was basified with solid NaHCO3, 
extracted with DCM (3 × 20 ml) and dried over Na2SO4. The solvent was removed in 
vacuo. Flash chromatography (40 to 60% EtOAc in hexane) afforded the desired amine 
as a colourless oil (0.495 g, 93% yield); Rf (50% EtOAc in hexane) = 0.20; νmax 
(neat)/cm
-1
 1728 (CO) 1647 (C=C); 
1
H NMR δ (400 MHz, CDCl3) 4.77 (1H, br s, 
C5HaHb), 4.70 (1H, br s, C5HaHb), 3.40 (1H, dd, J = 8.6 & 5.4 Hz, C2H), 2.38 (1H, dd, J 
= 13.7 & 5.4 Hz, C3HcHd), 2.12 (1H, ddd, J = 13.7 & 8.6 & 0.5 Hz, C3HcHd), 1.68 (3H, 
s, Me), 1.43 (2H, br s, NH2), 1.38 (9H, s, 3 × CH3); 
13
C NMR δ (101 MHz, CDCl3) 
174.79 (C), 141.60 (C), 113.73 (CH2), 81.00 (C), 52.99 (CH), 43.75 (CH2), 28.01 (3 × 
CH3), 21.90 (CH3); m/z (ESI+) 208 ([M+Na]
+
, 17%), 186 ([M+H]
+
, 10), 102 (7). 
 










To a stirred solution of alkylated Schiff base 232 (45 mg, 0.12 mmol) in Et2O (0.30 ml) 
at 0 ºC, HCl (0.15 ml, 1 M aq., 0.15 mmol) was added dropwise. The reaction mixture 
was allowed to reach RT and stirred overnight (~18 h). The layers were separated, and 
the aqueous phase was concentrated in vacuo to yield the desired amino ester 
hydrochloride as a colourless solid (20 mg, 90% yield); Rf (50% EtOAc in hexane) = 
0.10; νmax (neat)/cm
-1
 1741 (CO); 
1
H NMR δ (400 MHz, D2O) 5.06-5.04 (1H, m, 
C5HaHb), 4.95-4.93 (1H, m, C5HaHb), 4.21-4.12 (1H, m, C2H), 2.80-2.72 (1H, m, 
C3HcHd), 2.63-2.56 (1H, m, C3HcHd), 1.79 (3H, s, Me), 1.51 (s, 9H, 3 × CH3); m/z 
(ESI+) 208 ([M+Na]
+
, 17%), 185 ([M]
+
, 42), 102 (7); HRMS (ESI+) [M+Na]
+
 found 
209.1381, C10H20O2NNa requires 209.1386. 
 
2-[Benzyloxycarbonyl-((E)-buta-1’,3’-dienyl)-amino]-4-methyl-pent-4-enoic acid 




To a solution of amine 220 (40 mg, 0.28 mmol) in DCM (1 ml) crotonaldehyde (24 µl, 
0.28 mmol) and molecular sieves (~50 mg) were added at RT. The reaction mixture was 
stirred overnight (~18 h), then filtered. The filtrate was concentrated in vacuo to give the 
desired imine as a pale yellow oil as confirmed by LC-MS. The imine was dissolved in 
toluene (1 ml) and added dropwise to a flask containing diethylaniline (45 µl, 0.33 
mmol) and benzyl chloroformate (67 µl, 0.42 mmol) at 0 ºC. The reaction mixture was 
allowed to reach RT and stirred overnight (~18 h). The resulting precipitate was 
removed by filtration, washed with Et2O and the filtrate was concentrated in vacuo. 
Flash chromatography (dry loaded silica column, 2% EtOAc in hexane) gave the desired 
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enamide 224 as a pale yellow oil (27 mg, 30% yield) and amide 230 as a colourless solid 
(38 mg, 49% yield); Rf (20% EtOAc in hexane) = 0.42; νmax (neat)/cm
-1
 1707 (CO) 
1645 (CO); 
1
H NMR δ (400 MHz, 323 K, CDCl3) 7.36-7.34 (5H, m, ArH), 6.96 (1H, d, 
J = 14.6 Hz, NCHC), 6.27 (1H, dt, J = 17.0 & 10.2 Hz, CH=CHcisHtrans), 5.62 (1H, dd, J 
= 14.3 & 10.2 Hz, CH=CHCH), 5.27-5.13 (2H, m, CH2O), 5.06 (1H, d, J = 17.0 Hz, 
CHCHcisHtrans) 4.93 (1H, d, J = 10.2 Hz, CHCHcisHtrans), 4.90-4.80 (1H, m, C2H), 4.77 
(1H, br s, C5HaHb), 4.68 (1H, br s, C5HaHb), 3.67 (3H, br s, OMe), 2.78-2.75 (2H, m, 
C3H2), 1.71 (3H, s, Me); m/z (ESI+) 681 ([2M+Na]
+
, 6%), 352 ([M+Na]
+
, 100), 107 
(47); HRMS (ESI+) [M+Na]
+
 found 352.1518, C19H23O4NNa requires 352.1519. 
 




Rf (20% EtOAc in hexane) = 0.32; νmax (neat)/cm
-1
 3340 (NH), 1716 (CO) 1651 (CO); 
1
H NMR δ (400 MHz, CDCl3) 7.48-7.21 (5H, m, ArH), 5.21-5.20 (1H, m, NH) 5.11 
(2H, s, CH2O), 4.85 (1H, br s, C5HaHb), 4.75 (1H, br s, C5HaHb), 4.49 (1H, dd, J = 13.8 
& 8.2 Hz, C2H), 3.74 (3H, s, OMe), 2.55 (1H, dd, J = 13.8 & 5.4 Hz, C3HcHd), 2.39 (1H, 
dd, J = 13.8 & 8.2 Hz, C3HcHd), 1.74 (3H, s, Me); 
13
C NMR δ (101 MHz, CDCl3) 
172.88 (C), 155.92 (C), 140.38 (C), 136.36 (C), 128.64 (2 × CH), 128.30 (CH), 128.21 
(2 × CH), 114.92 (CH2), 67.12 (CH2), 52.43 (CH3), 52.32 (CH), 40.83 (CH2), 21.94 
(CH3); m/z (ESI+) 300 ([M+Na]
+
, 100%), 278 ([M+H]
+
, 7), 102 (6); HRMS (ESI+) 
[M+H]
+
 found 278.1387, C15H20O4N requires 278.1387. 
 
2-[Benzyloxycarbonyl-((E)-buta-1,3-dienyl)-amino]-4-methyl-pent-4-enoic acid tert-






To a solution of amine 233 (254 mg, 1.37 mmol) in DCM (5 ml) crotonaldehyde (0.113 
ml, 1.36 mmol) and molecular sieves (~200 mg) were added at RT. The reaction mixture 
was stirred overnight (~18 h), then filtered. The filtrate was concentrated in vacuo to 
give the desired imine as a pale yellow oil as confirmed by LC-MS. The imine was 
dissolved in toluene (5 ml) and added dropwise to a flask containing diethylaniline 
(0.273 ml, 1.72 mmol) and benzyl chloroformate (0.219 ml, 1.56 mmol) at 0 ºC. The 
reaction mixture was allowed to reach RT and stirred overnight (~18 h). The resulting 
precipitate was filtered off, washed with Et2O and the filtrate was concentrated in vacuo. 
Flash chromatography (dry loaded silica column, 2% EtOAc in hexane) gave the desired 
enamide 235 as a pale yellow oil (341 mg, 67% yield) and amide 237 as a colourless 
solid (85 mg, 20% yield); Rf (20% EtOAc in hexane) = 0.40; νmax (neat)/cm
-1
 1718 (CO) 
1645 (CO); 
1
H NMR δ (400 MHz, 323 K, CDCl3) 7.42-7.28 (5H, m, ArH), 7.04-6.88 
(1H, m, NCH=C + CH=CHcisHtrans), 6.27 (0.4H, dt, J = 17.0 & 10.3 Hz, 
CH=CHcisHtrans), 5.62 (0.4H, dd, J = 14.3 & 10.3 Hz, CH=CHCH), 5.27-5.17 (2H, m, 
CH2O), 5.03 (0.4H, d, J = 17.0 Hz, CH=CHcisHtrans), 4.92 (0.4H, d, J = 10.3 Hz, 
CH=CHcisHtrans), 4.86-4.79 (1H, m, C2H), 4.75 (1H, s, C5HaHb), 4.68 (1H, br s, C5HaHb), 
4.40 (0.6H, d, J = 17.0 Hz, CH=CHcisHtrans), 4.36 (0.6H, d, J = 10.3 Hz, CH=CHcisHtrans) 
2.73 (2H, m, C3H2), 1.71 (3H, s, Me), 1.40 (9H, s, 3 × CH3); 
13
C NMR δ (101 MHz, 323 
K, CDCl3) 169.54 (C), 169.49 (C), 154.15 (C), 154.10 (C), 141.79 (C), 141.57 (C), 
136.24 (C), 136.14 (C), 135.32 (CH), 132.52 (CH), 130.04 (CH), 128.68 (2 × CH), 
128.66 (2 × CH), 128.43 (CH), 128.37 (CH), 128.21 (CH), 128.19 (CH), 113.80 (CH2), 
113.78 (CH2), 113.68 (CH), 113.65 (CH), 94.46 (CH), 82.15 (C), 81.95 (C), 68.38 
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(CH2), 68.18 (CH2), 57.27 (CH2), 56.55 (CH2), 36.51 (CH2), 36.27 (CH2), 28.03 (3 × 
CH3), 28.01 (3 × CH3), 22.37 (CH3), 22.33 (CH3); m/z (ESI+) 394 ([M+Na]
+
, 47%), 102 
(100); HRMS (ESI+) [M+Na]
+
 found 394.1989, C22H29O4NNa requires 394.1988. 
 




Rf (20% EtOAc in hexane) = 0.22; νmax (neat)/cm
-1
 3342 (NH), 1714 (CO), 1651 (CO); 
1
H NMR δ (400 MHz, CDCl3) 7.40-7.28 (5H, m, ArH), 5.20-5.18 (1H, m, NH), 5.11 
(2H, s, CH2O), 4.83 (1H, br s, C5HaHb), 4.75 (1H, br s, C5HaHb), 4.36 (1H, dd, J = 14.0 
& 7.8 Hz, C2H), 2.51 (1H, dd, J = 14.0 & 6.0 Hz, C3HcHd), 2.37 (1H, dd, J = 14.0 & 7.8 
Hz, C3HcHd), 1.76 (3H, s, Me) 1.45 (9H, s, 3 × CH3); 
13
C NMR δ (101 MHz, CDCl3) 
171.48 (C), 155.89 (C), 140.81 (C), 136.52 (C), 128.62 (3 × CH), 128.25 (CH), 128.20 
(CH), 114.66 (CH2), 82.24 (C), 66.98 (CH2), 52.79 (CH), 41.23 (CH2), 28.11 (3 × CH3), 
22.04 (CH3); m/z (ESI+) 661 ([2M+Na]
+
, 40%), 342 ([M+Na]
+
, 100), 102 (6); HRMS 
(ESI+) [M+Na]
+
 found 342.1682, C18H25O4NNa requires 342.1675. 
 
4-Methyl-2,3-dihydro-pyrrole-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester 
 






To a solution of enamide 235 (10 mg, 0.027 mmol) in dry DCM (1 ml), Hoveyda-
Grubbs II (1.8 mg, 0.0020 mmol) was added. The mixture was stirred and heated to 
reflux (~40 °C) overnight (~18 h). To the reaction mixture, DMSO (10 µl) was added 
and the solvent removed in vacuo. Flash chromatography (dry loaded silica, 1% EtOAc 
in hexane) yielded starting material 235 (4.2 mg, 42% yield) and by-product aldehyde 
238 as a colourless oil (3.5 mg, 34% yield). 
 
2-[Benzyloxycarbonyl-((E)-3-oxo-propenyl)-amino]-4-methyl-pent-4-enoic acid tert-




Rf (20% EtOAc in hexane) = 0.27; νmax (neat)/cm
-1
 1732 (CO), 1676 (CO), 1622 (CO); 
1
H NMR δ (400 MHz, 323 K, CDCl3) 9.38 (1H, d, J = 7.4 Hz, CHO), 7.92 (1H, d, J = 
14.5 Hz, NCHC), 7.38 (5H, s, ArH), 5.60 (1H, dd, J = 14.5 & 7.4 Hz, CH=CHCHO), 
5.30 (2H, ABq, J = 12.1 Hz, CH2O), 4.82 (1H, t, J = 7.4 Hz, C2H), 4.74 (1H, s, 
C5HaHb), 4.61 (1H, s, C5HaHb), 2.72 (2H, d, J = 7.4 Hz, C3H2), 1.68 (3H, s, Me), 1.40 
(9H, s, 3 × CH3); 
13
C NMR δ (101 MHz, 323 K, CDCl3) 191.44 (C), 167.80 (C), 153.07 
(C), 149.65 (CH), 140.75 (C), 134.95 (C), 129.05 (CH), 128.92 (2 × CH), 128.66 (2 × 
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CH), 114.62 (CH2), 112.33 (CH), 83.10 (C), 69.79 (CH2), 57.54 (CH), 36.50 (CH2), 
28.00 (3 × CH3), 22.20 (CH3); m/z (ESI+) 396 ([M+Na]
+
, 13%), 373 ([M]
+
, 7), 130 
(100); HRMS (ESI+) [M+Na]
+






A mixture of ( )-cinchonidine 253 (1.0 g, 3.4 mmol) and 10% Pd/C (0.20 g) in dry 
MeOH (30 ml) was stirred under hydrogen (1 atm, balloon) at RT overnight (~18 h). 
The crude reaction mixture was then filtered through Celite as follows: a filter cup filled 
with Celite was placed over a flask and bathed in DCM. The crude reaction mixture was 
then added to the top of the Celite and vacuum-filtered through the Celite, with DCM 
being added to the top to prevent air from being introduced into the filter cup. Periodic 
samples with capillary tubes were taken as the liquid passed through the filter. Each 
sample was monitored under UV light for luminescence, indicating the presence of the 
hydrocinchonidine product. When the luminescent color had dissipated under UV, the 
filtration was stopped. The solvent was removed in vacuo and the resulting colourless 
solid was suspended in hexane and stirred at RT for 1 h. The resulting precipitate, 
hydrocinchonidine, was then filtered, concentrated in vacuo, and collected as a 
colourless solid (0.80 g, 80% yield); Rf (MeOH) = 0.15; mp = 110-113 °C, lit.
259
 107-
108 °C; νmax (neat)/cm
-1
 3305 (OH); 
1
H NMR δ (500 MHz, CD3OD) 8.83 (1H, d, J = 
4.6 Hz, ArH), 8.19 (1H, d, J = 8.4 Hz, ArH), 8.06 (1H, d, J = 8.4 Hz, ArH), 7.78 (1H, t, 
J = 7.7 Hz, ArH), 7.73 (1H, d, J = 4.6 Hz, ArH), 7.66 (1H, t, J = 7.7 Hz, ArH), 5.68 (1H, 
d, J = 3.9 Hz, CHOH), 3.29-3.22 (1H, m, CH), 3.07 (1H, m, CHN), 2.94-2.83 (2H, m, 
CHCH2N), 2.81-2.72 (1H, m, CH), 2.17-2.09 (1H, m, CH), 1.72 (1H, br s, CHCH2CH3), 
1.67-1.42 (5H m, CH2CH2N + CH2CH3 + CH), 1.16-1.07 (1H, m, CH), 0.94 (3H, t, J = 
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7.2 Hz, CH2CH3); 
13
C NMR δ (126 MHz, CD3OD) 152.22 (C), 150.91 (CH), 148.81 
(C), 130.68 (CH), 130.01 (CH), 128.13 (CH), 127.18 (C), 124.52 (CH), 119.90 (CH), 
72.30 (CH), 61.38 (CH), 51.77 (CH2), 50.95 (CH2), 38.51 (CH), 27.86 (CH2), 27.51 
(CH), 26.17 (CH2), 21.53 (CH2), 12.29 (CH3); m/z (ESI+) 297 ([M+H]
+
, 100%), 157 
(38). 
 








To a stirred solution of 2,7-dimethylnaphthalene 254 (200 mg, 1.28 mmol) in benzene 
(25 ml), N-bromosuccinimide (506 mg, 2.84 mmol) was added, followed by benzoyl 
peroxide (16.7 mg, 0.0700 mmol). This suspension was stirred and heated to reflux 
(~120 °C) for 2 h. The reaction was monitored for consumption of the starting material 
by TLC. The reaction mixture was cooled to 0 °C and filtered. The filtrate was 
concentrated in vacuo and the residue was recrystallized from CHCl3/hexane as follows: 
warm CHCl3 was added until the crude solid was dissolved; then a generous amount of 
hexane at RT was added until precipitation occurred; the resultant suspension was 
cooled in the freezer overnight. The next morning the solvent was filtered off to give 
2,7-Bis(bromomethyl)naphthalene as a colourless solid (310 mg, 77% yield); Rf (5% 
EtOAc in hexane) = 0.34; mp = 150-155 °C, lit.
260





H NMR δ (400 MHz, CDCl3) 7.84-7.78 (4H m, ArH), 7.52 (2H, dd, J = 8.4 & 
1.8 Hz, ArH), 4.65 (s, 4H, 2 × CH2) 
13
C NMR δ (126 MHz, CDCl3) 136.00 (2 × C), 
133.13 (C), 132.85 (C), 128.75 (2 × CH), 128.03 (2 × CH), 127.66 (2 × CH), 33.86 (2 × 
CH2). 
 












Bis(bromomethyl)naphthalene 256 (220 mg, 0.700 mmol) and ( )-hydrocinchonidine 
255 (424 mg, 1.43 mmol) were suspended in a mixture of EtOH (1 ml), DMF (2.50 ml), 
and CHCl3 (423 µl). This suspension was heated to reflux (100-120 ºC) and stirred 
vigorously for 2 h. The reaction was monitored by TLC for consumption of the starting 
material bis(bromomethyl) naphthalene 256. The reaction mixture was allowed to cool 
to RT and MeOH (4.30 ml) and Et2O (12.80 ml) were added. This suspension was 
stirred at room temperature for 1 h. The crude, light-pink precipitate, was removed by 
filtration, rinsed with Et2O (3 × 10 ml) and the product 257 was isolated as a pink solid 
(450 mg, 71% yield); Rf (MeOH) = 0.10; mp = 170 °C (decomp); [α]D = 115 (c 1.00, 
MeOH), lit.
184
 ent-257 127 (c 0.57, MeOH) νmax (neat)/cm
-1
 3101 (OH); 
1
H NMR δ 
(500 MHz, (CD3)2CO) 9.02 (2H, d, J = 4.5 Hz, ArH), 8.49 (2H, s, ArH), 8.37 (2H, d, J = 
8.5 Hz, ArH), 8.24 (2H, d, J = 8.5 Hz, ArH), 8.13 (2H, d, J = 8.5 Hz, ArH), 8.00 (2H, d, 
J = 8.5 Hz, ArH), 7.90 (2H, d, J = 4.5 Hz, ArH), 7.87 (2H, t, J = 7.2 Hz, ArH), 7.75 (2H, 
t, J = 7.2 Hz, ArH), 6.88 (2H, d, J = 3.5 Hz, 2 × CHOH), 6.59 (2H, s, 2 × OH), 5.31 
(2H, d, J = 12.5 Hz, ArCH2N), 5.12 (2H, d, J = 12.5 Hz, ArCH2N), 4.15-4.01 (2H, m, 2 
× CH), 3.97 (2H, t, J = 10.0 Hz, CHCHaHbN), 3.61 (2H, t, J = 10.0 Hz, CHCHaHbN), 
3.11-2.92 (2H, m, 2 × CHN), 2.39-2.22 (2H, m, CH2), 1.87 (2H, br s, 2 × CHCH2CH3), 
1.85-1.62 (8H, m, 4 × CH2), 1.60-1.44 (4H, m, 2 × CH2CH3), 1.16-0.98 (2H, m, CH2), 
0.86 (6H, t, J = 7.2 Hz, 2 × CH3); 
13
C NMR δ (126 MHz, (CD3)2CO) 150.22 (2 × CH), 
147.66 (2 × C), 145.07 (2 × C), 134.54 (2 × CH), 133.52 (C), 132.28 (C), 131.70 (2 × 
 
 183 
CH), 129.86 (2 × CH), 129.45 (2 × CH), 128.32 (2 × CH), 127.23 (2 × CH), 126.51 (2 × 
C), 124.40 (2 × C), 123.87 (2 × CH), 120.21 (2 × CH), 67.35 (2 × CH), 64.85 (2 × CH), 
62.20 (2 × CH2), 56.25 (2 × CH2), 55.96 (2 × CH2), 34.76 (2 × CH), 24.11 (2 × CH), 
23.83 (2 × CH2), 23.55 (2 × CH2), 20.40 (2 × CH2), 11.30 (2 × CH3); m/z (ESI+) 373 
([M/2-2Br]
2+
, 100%), 157 (63). 
 










To a suspension of 2,7-bis(hydro-cinchonidinium-N-methyl) naphthalene dibromide 
(400 mg, 0.440 mmol) in DCM (1.26 ml) allyl bromide (224 µl, 2.65 mmol) was added, 
followed by KOH (4.41 ml, 50% aq., 84.0 mmol). The reaction was monitored for the 
consumption of the starting material by LC-MS. The reaction was quenched by addition 
of H2O (20 ml). The suspension was then extracted with DCM (3 × 50 ml). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The residue was purified by recrystallization thusly: the crude solid was dissolved in a 
minimal amount of warm DCM; then hexane at RT was added generously until 
precipitation occurred. This precipitate was filtered immediately to yield the allylated 
product 258 as a light-orange solid (400 mg, 92% yield); Rf (100% MeOH) = 0.15; mp 
= 175 °C (decomposition); [α]D = 139 (c 1.00, CHCl3), lit.
184
 ent-258 196 (c 0.62, 
CHCl3) νmax (neat)/cm
-1
 1058 (CO); 
1
H NMR δ (500 MHz, (CD3)2CO) 9.04 (2H, d, J = 
4.5 Hz, ArH), 8.44 (2H, s, ArH), 8.33 (2H, d, J = 8.5 Hz, ArH), 8.25 (2H, d, J = 8.5 Hz, 
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ArH), 8.16 (2H, d, J = 8.5 Hz, ArH), 7.97 (2H, d, J = 8.5 Hz, ArH), 7.89 (2H, t, J = 7.3 
Hz, ArH), 7.78 (2H, t, J = 7.3 Hz, ArH), 7.74 (2H, d, J = 4.5 Hz, ArH), 6.53 (2H, s, 2 × 
CHO), 6.21 (2H, ddt, J = 17.1 & 10.6 & 5.3 Hz, 2 × CHCHcisHtrans), 5.51 (2H, dd, J = 
17.1 & 1.6 Hz, 2 × CHCHcisHtrans), 5.36 (2H, d, J = 13.0 Hz, ArCH2N), 5.33 (2H, dd, J = 
10.6 & 1.6 Hz, 2 × CHCHcisHtrans), 5.14 (2H, d, J = 13.0 Hz, ArCH2N), 4.45 (2H, dd, J = 
12.7 & 5.1 Hz, CH2), 4.16 (2H, br t, J = 11.5 Hz, CH2), 4.12-3.98 (4H, m, CH2 + 2 × 
CH), 3.63-3.53 (2H, m, CH2), 3.46-3.35 (4H, m, 2 × CHCH2N), 2.37-2.25 (2H, m, CH2), 
2.19-2.08 (2H, m, CH2), 2.00 (2H, br s, 2 × CHCH2CH3), 1.80-1.75 (4H, m, CH2 + 2 × 
CH), 1.52 (2H, br t, J = 11.5 Hz, CH2), 1.32-1.11 (4H, m, 2 × CH2CH3), 0.71 (6H, t, J = 
7.3 Hz, 2 × CH3); 
13
C NMR δ (126 MHz, (CD3)2CO) 150.27 (2 × CH), 148.07 (2 × C), 
141.27 (2 × C), 134.51 (2 × CH), 134.33 (2 × CH), 133.58 (C), 132.17 (C), 131.81 (2 × 
CH), 129.98 (2 × CH), 129.67 (2 × CH), 128.33 (2 × CH), 127.46 (2 × CH), 126.33 (2 × 
C), 125.12 (2 × C), 123.76 (2 × CH), 119.73 (2 × CH), 117.47 (2 × CH2), 72.11 (2 × 
CH), 69.28 (2 × CH2), 67.74 (2 × CH), 63.43 (2 × CH2), 61.49 (2 × CH2), 51.23 (2 × 
CH2), 34.98 (2 × CH), 25.21 (2 × CH2), 24.82 (2 × CH2), 23.66 (2 × CH), 20.63 (2 × 
CH2), 11.27 (2 × CH3); m/z (ESI+) 413 ([M/2-2Br]
2+
, 37%), 157 (90), 130 (100). 
 









To a suspension of N-(9-anthracenylmethyl)cinchonidium chloride (2.20 g, 4.22 mmol) 
in DCM (30 ml) were added methyl iodide (1.69 g, 21.2 mmol) and NaOH (0.660 ml, 
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50% aq., 12.7 mmol). The resulting mixture was stirred at RT for 4-5 h, during which 
time all of the solids were dissolved. The mixture was diluted with CHCl3 (300 ml), 
washed with water (3 × 20 ml) and NaCl (20 ml, sat. aq.). The combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. The residue was poured 
onto Et2O (50 ml) and the mixture was stirred at RT for 1 h. The suspension was filtered 
and the dark orange solid was collected and used for the next step without further 
purification (2.30 g, 86% yield); Rf (20% MeOH in DCM) = 0.21; mp = 180-185 °C; 
[α]D = 294 (c 1.0, DCM), lit.
247
 288 (c 1.0, DCM); νmax (neat)/cm
-1
 1640 (CN); 
1
H 
NMR δ (500 MHz, CDCl3) 9.67 (1H, d, J = 9.1 Hz, ArH), 9.06 (1H, d, J = 4.4 Hz, 
ArH), 8.67 (1H, s, ArH), 8.36-8.31 (1H, m, ArH), 8.20 (1H, d, J = 9.1 Hz, ArH), 8.15 
(1H, d, J = 8.4 Hz, ArH), 8.06 (1H, d, J = 8.4 Hz, ArH), 7.99-7.91 (1H, m, ArH), 7.92-
7.81 (2H, m, ArH), 7.75-7.68 (2H, m, ArH), 7.62-7.55 (3H, m, ArH), 7.07 (1H, d, J = 
14.0 Hz), 6.53 (1H, brs, CHO), 6.05-5.84 (1H, m, CHCHcisHtrans), 5.19 (1H, d, J = 17.1 
Hz, CHCHcisHtrans), 5.07 (1H, d, J = 10.5 Hz, CHCHcisHtrans), 4.98-4.87 (1H, m), 4.54-
4.40 (1H, m), 3.82 (3H, s, OMe), 3.13-3.02 (2H, m), 2.73-2.65 (1H, m), 2.42-2.33 (1H, 
m), 2.04-1.87 (2H, m), 1.59-1.36 (4H, m); 
13
C NMR δ (126 MHz, CD3OD) 151.09 
(CH), 149.38 (C), 142.96 (C), 138.52 (CH), 134.79 (C), 134.66 (C), 133.99 (CH), 
133.11 (C), 133.08 (C), 131.50 (CH), 131.30 (CH), 131.21 (CH), 130.66 (CH), 129.46 
(CH), 129.39 (2 × CH), 127.23 (C), 126.65 (CH), 126.63 (CH), 125.32 (CH), 124.79 (2 
× CH), 124.32 (CH), 121.66 (CH), 118.94 (C), 117.79 (CH2), 70.31 (CH), 63.46 (CH2), 
57.52 (CH), 57.51 (CH2), 53.82 (CH2), 39.53 (CH3), 27.29 (CH), 26.22 (CH2), 23.09 
(CH2); m/z (ESI+) 499 ([M-I]
+
, 100%), 309 (7), 191 (10). 
 











To a suspension of Schiff base 148 (50.0 mg, 0.169 mmol), chiral catalyst 267 (10.6 mg, 
0.0169 mmol), [PdCl(π-C3H5)]2 (5.2 mg, 0.0140 mmol) and DDPE (7.00 mg, 0.0169 
mmol) in toluene (0.56 ml) were added allyl carbonate 217 (49.0 mg, 0.340 mmol) then 
KOH (44.0 µl, 50% aq., 0.850 mmol), at 0 °C. The reaction mixture was stirred at 0 °C 
until the starting material had been consumed (~7 h), and then the mixture was diluted 
with Et2O (15 ml). The organic phase was washed with NaHCO3 (3 × 5 ml, sat. aq.) and 
NaCl (5 ml, sat. aq.). The organic layer was dried over Na2SO4, filtered, and 
concentrated in vacuo. Flash chromatography (dry loaded basic silica*, 1% EtOAc in 
hexane) gave the product as a colourless solid (51.0 mg, 85% yield, 5 to 15 % ee, see 
table 6).The enantioselectivity was determined by chiral HPLC Agilent 1100 (Chiralcel 
OD-H column, 1% 2-propanol in hexane, 0.8 ml min , 254 nm). Rt (S-major) = 4.91 
min, Rt (R-minor) = 5.58 min. 
 
Method B 
To a suspension of Schiff base 148 (50.0 mg, 0.169 mmol) and chiral catalyst 258 (1.70 
mg, 0.00169 mmol) in a mixture of toluene/CHCl3 (3/1, 1 ml) methallyl bromide 251 
(85.0 µl, 0.850 mmol) was added. The reaction mixture was then cooled to 0 °C and 
KOH (0.25 ml, 50% aq., 4.75 mmol) was added. The reaction mixture was stirred at 0 
°C until the starting material had been consumed (~10 h). The suspension was diluted 
with Et2O (20 ml), washed with water (2 × 5 ml), dried over MgSO4, filtered and 
concentrated in vacuo. Flash chromatography (dry loaded basic silica*, 1% EtOAc in 
hexane) gave the product as a colourless solid (55.0 mg, 92% yield, 91 % ee). The 
enantioselectivity was determined by chiral HPLC (Chiralcel OD-H column, 1% 2-
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propanol in hexane, 1.0 ml min , 254 nm). Rt (S-minor) = 4.96 min, Rt (R-major) = 




Figure 53: HPLC traces for enantioselective alkylation of 148. 
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H Bio−N3 Ani−≡ Bio-Ani 
C3aH 4.30 dd, 7.8, 4.6  4.30 dd, 7.8, 4.5 
C4H 3.23-3.19 m  3.21-3.18 m 
C6aH 4.49 dd, 7.8, 4.6  4.52-4.48 m 
C6HaHb 2.93 dd, 12.7, 5.0  2.93 dd, 13.1, 5.0 
C6HaHb 2.71 d, 12.7  2.73 d, 13.0 
C7H2 1.70-1.54 m  1.84-1.55 m 
C8H2 1.49-1.38 m  1.49-1.38 m 
C9H2 1.70-1.54 m  1.84-1.55 m 
C10H2 2.21 t, 7.3  2.23 t, 7.3 
C13H2 3.25 d, 6.7  3.23 t, 6.7 
C14H 1.75 qn, 6.7  2.13 qn, 6.7 
C15H2 3.36 t, 6.7  4.47 t, 7.0 
C17H   7.97 s 
C19HcHd  3.58 d, 2.3 4.06 d, 14.2 
C19HcHd  3.58 d, 2.3 3.84 d, 14.2 
C21HeHf  3.34 dd, 9.8, 7.0 3.41-3.35 m 
C21HeHf  2.61 dd, 9.8, 7.0 2.52 dd, 10.7, 4.2 
C22H  4.13 t, 7.0 4.04-3.99 m 
C23H  4.47 dd, 5.7, 1.60 4.66 dd, 5.0, 1.5 
C24H  3.21 dt, 10.2, 5.2 3.16 dd, 9.4, 4.5 
OAc  2.14 s 2.12 s 
C25HgHh  2.85 dd, 13.4, 4.5 3.05 dd, 13.1, 5.0 
C25HgHh  2.70 dd, 13.4, 10.2 2.74 dd, 13.4, 10.2 
OMe  3.78 s 3.77 s 
 









H spectra of compound 28 and its starting materials 27 and 264 and COSY 































C, OAc  172.02 
CH3, OAc 20.97 
C25H2 33.58 
C, Ar 131.82 
C, Ar 159.67 



















Å   Angstrom 
ABPP   Activity-based probe profiling 
Ac   Acetyl 
Ag   Antigen 
AIBN   Azobisisobutyronitrile 
ATP   Adenosine triphosphate 
aq   Aqueous 
Ar   Aryl 
Boc   Di-tert-butyl dicarbonate 
Bn   Benzyl 
BODIPY  Dipyrromethene boron difluoride 
BOP Benzotriazol-1-yloxy tris (dimethylamino)-phosphonium 
hexafluorophosphate 
BSA Bovine serum albumin 
CbzCl   Benzyl chloroformate 
CID   Collision-induced dissociation 
CML   Chronic myeloid leukemia 
CCCP   Compound-centric chemical proteomics 
COSY   Correlation spectroscopy 
CSA   Camphorsulfonic acid 
CuAAC  Copper-catalysed azide-alkyne cycloaddition 
DCM   Dichloromethane 
DIBAL  Diisobutylaluminium hydride 
DIPEA  N,N-Diisopropylethylamine 
DEPBT  3-(Diethoxy-phosphoryloxy)-3H-benzo[d][1,2,3] triazin-4-one  
DEPT   Distortionless enhancement polarisation transfer 
2D-GE   Two-dimensional gel electrophoresis  
DIC   Diisopropylcarbodiimide 
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DUB   Deubiquitinating 
DMAP   4-Dimethylaminopyridine 
DME   Dimethyl ether  
DMF   Dimethylformamide 
DMP   Dess-Martin periodinane 
DNA   Deoxyiribonucleic acid 
DPPE   1,2-Bis(diphenylphosphino)ethane 
DSC   Disuccinimidyl carbonate 
ee   enantiomeric excess 
EDC   Ethyl (dimethylaminopropyl) carbodiimide 
EDTA   Ethylenediaminetetraacetic acid 
ERK   Extracellular signal regulated protein kinase 
ELISA   Enzyme-linked immunosorbent assay 
EM   Electron microscopy 
ESI   Electrospray ionization 
Et   Ethyl 
EtOH   Ethanol  
Fab   Fragment antigen-binding 
FAB   Fast atom bombardment 
FBS   Fetal bovine serum 
FDA   Food and Drug Administration 
FKBP   FK506 binding protein 
Fmoc   Fluorenylmethoxycarbonyl 
FRET   Forster resonance energy transfer 
h   Hours 
HABA   2-(4-hydroxyphenylazo)-benzoic acid 
HATU 2-(7-Aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HCV   Hepatitis C virus 
HEK   Human embryonic kidney 
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HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV   Human immunodeficiency virus 
HOAT   1-Hydroxy-7-Azabenzotriazole 
HOBt   Hydroxybenzotriazole 
HPIAC  High performance immunoaffinity chromatography 
HPLC   High performance liquid chromatography 
HRMS   High Resolution Mass Spectrometry 
HSQC   Heteronuclear Single Quantum Coherence 
IBs   Inclusion bodies 
ICAT   Isotope-coded affinity tag 
iTRAQ  Isobaric tag for relative and absolute quantification 
Ig   Immunoglobulin 
IMAC   Immobilised metal ion affinity chromatography 
IR   Infra red 
JNK   c-Jun N-terminal kinase 
kDa   Kilodalton 
LC-MS  Liquid chromatography-mass spectrometry 
LDI   Laser desorption ionization 
LRMS   Low Resolution Mass Spectrometry 
MAGL  Monoacylglycerol lipase 
MALDI-TOF  Matrix assiste laser/desorption ionization-time of flight 
MAPK   Mitogen activated protein kinase 
MAPKK  Mitogen activated protein kinase kinase 
MAPKKK  Mitogen activated protein kinase kinase kinase 
MAS   Magic angle spinning 
Me   Methyl 
Mes   2,4,6-trimethylphenyl 
MHz   Megahertz 
mp   Melting point 
MTBE   Methyl tertiary butyl ether 
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MTD   Maximum tolerated dose 
NBS   N-Bromosuccinimide 
NMM   N-Methyl morpholine 
NOBA   m-nitrobenzyl alcohol 
µ-BACC  microbead-based affinity chromatography 
min   Minutes 
MRC PPU  Medical research council protein phosphorilation unit 
MS   Mass spectrometry 
NAD   Nicotinamide adenine dinucleotide 
NADP   Nicotinamide adenine dinucleotide phosphate 
NBD   Nitrobenz-2-oxa-1,3-diazole 
NHS   N-hydroxy succinimide 
NMA   Methoxy-(1-naphthyl) acetic acid 
nm   nanometer 
NMR   Nuclear magnetic resonance 
3-NOBA  3-nitro benzyl alcohol 
PDGF   Platelet-derived growth factor  
PBS   Phosphate Buffered Saline 
Peg   Polyethylene glycol 
Ph   Phenyl 
pI   Isoelectric point 
ppm   Parts per million 
PTC   Phase transfer catalyst  
PTMs   Post-translational modifications 
PTSA   p-Toluenesulfonic acid 
RCM   Ring closing metathesis  
RNP   Ribonucleoprotein 
qNIRFABPs  Quenched near-infrared fluorescent activity based probes 
RCC   Renal cell carcinoma 
RNA   Ribonucleic acid 
 
 196 
Rf   Retention factor 
RT   Room temperature 
SAPK   Stress activated protein kinase 
SAR   Structure activity relationship 
SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SILAC   Stable isotope labelling by amino acids 
SPA   Solution phase analogue 
t-BuOH  tert-butanol 
TBDMSCl  Tert-Butyldimethylchlorosilane,  
TBTA   Tris-(1-benzyl-1H-[1,2,3]triazol-4-ylmethyl)-amine 
TEDOR  Transferred-echo double resonance 
TEMPO  2,2,6,6-Tetramethylpiperidin-1-yloxyl 
TFA   Trifluroacetic acid  
THF   Tetrahydrofuran 
THIOG  thioglycerol 
TLC   Thin layer chromatography 
UV   Ultra violet 
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